<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>peregrine_10k-043004.htm
<TEXT>
<HTML>
<HEAD>
<TITLE>Peregrine 10k 04-30-04</TITLE>
</HEAD>
<BODY>
<hr size="5" noshade  style="margin-top: -2px">
  <hr size="1" noshade style="margin-top: -10px">
<div align="center"><FONT size="4" face="Times New Roman, Times, Serif"><strong>UNITED STATES</strong></FONT><FONT face="Times New Roman, Times, Serif" size=4><B><br>
  SECURITIES AND EXCHANGE COMMISSION</B></FONT><FONT face="Times New Roman, Times, Serif" size=2><br>
  Washington, D.C. 20549</FONT>
</div><br>
<hr align="center" width="25%" size="1" noshade color="black">
<div align="center"><FONT face="Times New Roman, Times, Serif" size=4><B>FORM 10-K</B></FONT>
</div>

<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
  <TD vAlign=top>&nbsp;</TD>
  <TD vAlign=top>&nbsp;</TD>
</TR>
<TR>
  <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>(Mark One)</FONT></TD>
  <TD vAlign=top>&nbsp;</TD>
</TR>
<TR>
<TD vAlign=top width=66><font size="3" face="Wingdings">x</font></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>For the Fiscal Year Ended April 30, 2004</B></FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2>or</FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=66><font size="3" face="Wingdings">o</font></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B>Commission file number: 0-17085</B></FONT></P>
<div align="center"><FONT face="Times New Roman, Times, Serif" size=5><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT><FONT face="Times New Roman, Times, Serif" size=2><I><br>
  (Exact name of Registrant as specified in its charter)</I></FONT>
  <br>
  <br>
</div>
<table width="80%"  border="0" align="center" cellpadding="0" cellspacing="0">
  <tr>
    <td width="60%"><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;Delaware</B></FONT></td>
    <td width="5%">&nbsp;</td>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B>95-3698422</B></FONT></td>
  </tr>
  <tr>
    <td><font face="Times New Roman, Times, Serif" size=2><i>(State or other jurisdiction of&nbsp;<br>
    &nbsp;incorporation or organization)</i></font></td>
    <td>&nbsp;</td>
    <td><font face="Times New Roman, Times, Serif" size=2><i>(I.R.S. Employer <br>
    Identification No.)    </i></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font face="Times New Roman, Times, Serif" size=2><b>14272 Franklin Avenue, Suite 100, Tustin, California&nbsp;</b></font></td>
    <td>&nbsp;</td>
    <td><font face="Times New Roman, Times, Serif" size=2><b>92780-7017</b></font></td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><I>(Address of principal executive offices)</I></FONT></td>
    <td>&nbsp;</td>
    <td><font face="Times New Roman, Times, Serif" size=2><i>(Zip Code)&nbsp;</i></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr align="center">
    <td colspan="3"><FONT face="Times New Roman, Times, Serif" size=2><B>(714) 508-6000</B></FONT></td>
  </tr>
  <tr align="center">
    <td colspan="3"><font face="Times New Roman, Times, Serif" size=2><i>(Registrant&#146;s telephone number, including area code)</i></font></td>
  </tr>
  <tr align="left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr align="left">
    <td><font face="Times New Roman, Times, Serif" size=2>Securities registered pursuant to Section 12(b) of the Act:<b></b></font></td>
    <td>&nbsp;</td>
    <td><font face="Times New Roman, Times, Serif" size=2><b>None</b></font></td>
  </tr>
  <tr align="left">
    <td><font face="Times New Roman, Times, Serif" size=2>Securities registered pursuant to Section 12(g) of the Act:<b></b></font></td>
    <td>&nbsp;</td>
    <td><font face="Times New Roman, Times, Serif" size=2><b>Common Stock, $0.001 par value</b></font></td>
  </tr>
</table>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13
or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports); and (2) has been subject to such filing
requirements for the past 90 days. YES </FONT><FONT size=3 face="Wingdings">x</FONT><FONT face="Times New Roman, Times, Serif" size=2> &nbsp;&nbsp;NO </FONT><FONT size=3 face="Wingdings">o</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained
herein, and will not be contained, to the best of Registrant&#146;s knowledge, in definitive proxy
or information statements incorporated by reference in Part III of this Form 10-K. </FONT><FONT size=3 face="Wingdings">o</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate
by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act).
</FONT><FONT face="Times New Roman, Times, Serif" size=2>YES </FONT><FONT size=3 face="Wingdings">x</FONT><FONT face="Times New Roman, Times, Serif" size=2> &nbsp;&nbsp;NO </FONT><FONT size=3 face="Wingdings">o</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
approximate aggregate market value of voting stock held by non-affiliates of the registrant was&nbsp;$281,305,000&nbsp;as
of October 31 2003 based on the closing sale price of the Registrant&#146;s Common Stock as reported
on the Nasdaq Stock Market on October 31, 2003, the last business day of the Registrant&#146;s most
recently completed second fiscal quarter. Excludes 1,577,765 shares of common stock held by directors
and officers, and any stockholders whose ownership exceeds five percent of the shares outstanding,
at October 31, 2003.</FONT></P>
<P align=center><b><FONT face="Times New Roman, Times, Serif" size=2>141,268,182 <br>
</FONT></b><FONT face="Times New Roman, Times, Serif" size=2><I>(Number of shares of common stock outstanding as of July 9, 2004)</I></FONT></P>
<B> </B>

<hr size="1" noshade  style="margin-top: -2px">
  <hr size="5" noshade style="margin-top: -10px">
<P style="PAGE-BREAK-BEFORE: always">

<TABLE WIDTH=80% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2>&nbsp;</TH>
    <TH><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2>&nbsp;</TH>
    <TH><FONT face="Times New Roman, Times, Serif" size=2><B>ANNUAL REPORT ON FORM 10-K</B></FONT></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2>&nbsp;</TH>
    <TH><font face="Times New Roman, Times, Serif" size=2><b>FOR THE FISCAL YEAR ENDED APRIL 30, 2004</b></font></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2>&nbsp;</TH>
    <TH>&nbsp;</TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2>&nbsp;</TH>
    <TH>&nbsp;</TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2>&nbsp;</TH>
    <TH><font face="Times New Roman, Times, Serif" size=2><b>TABLE OF CONTENTS</b></font></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2>&nbsp;</TH>
    <TH>&nbsp;</TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=2>PART I </FONT></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
  </TR>
  <TR VALIGN=Bottom>
    <TD WIDTH=10% height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 1.</FONT></TD>
    <TD WIDTH=2% height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=75% height="20" ALIGN=LEFT><a href="#a1"><FONT FACE="Times New Roman, Times, serif" SIZE=2>Business</FONT></a></TD>
    <TD WIDTH=4% height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=4% height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 2.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><a href="#a2">Properties</a></FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>30</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 3.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><a href="#a3">Legal Proceedings</a></FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>31</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 4.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a4"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Submission of Matters to a Vote of Security Holders</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>31</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT>&nbsp;</TD>
    <TD height="20" ALIGN=LEFT>&nbsp;</TD>
    <TD height="20" ALIGN=center>&nbsp;</TD>
    <TD height="20" ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2><strong>PART II</strong></FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 5.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a5"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Market for Registrant&#146;s Common Equity and Related</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a5"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;Stockholders&#146; Matters</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>31</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 6.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a6"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Selected Financial Data</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>32</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 7.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a7"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Management&#146;s Discussion and Analysis of</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a7"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;Financial Condition and Results of Operations</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>33</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 7A.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quantitative and Qualitative Disclosures</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;About Market Risk</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>43</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 8.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a9"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Financial Statements and Supplementary Data</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>43</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 9.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a10"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Changes in and Disagreements with Accountants</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a10"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;on Accounting and Financial Disclosures</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>44</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 9A.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a11"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Controls and Procedures</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>44</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT>&nbsp;</TD>
    <TD height="20" ALIGN=LEFT>&nbsp;</TD>
    <TD height="20" ALIGN=center>&nbsp;</TD>
    <TD height="20" ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2><strong>PART III</strong></FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 10.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a12"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Directors and Executive Officers of the Registrant</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>44</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 11.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a13"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Executive Compensation</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>47</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 12.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a14"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Security Ownership of Certain Beneficial Owners</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a14"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;and Management</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>51</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 13.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a15"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Certain Relationships and Related Transactions</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>53</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT>&nbsp;</TD>
    <TD height="20" ALIGN=LEFT>&nbsp;</TD>
    <TD height="20" ALIGN=center>&nbsp;</TD>
    <TD height="20" ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2><strong>PART IV</strong></FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 14.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a16"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Principal Accountant Fees and Services</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>54</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 15.</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a17"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exhibits, Consolidated Financial Statement</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a17"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;Schedules, and Reports on Form 8-K</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>55</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=LEFT><a href="#a18"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Signatures</FONT></a></TD>
    <TD height="20" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD height="20" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>63</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
</TABLE>
<P align=center>&nbsp;</P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>The terms &#147;we&#148;, &#147;us&#148;, &#147;our&#148;, &#147;Company&#148; and &#147;Peregrine&#148;
as used in this report refers to Peregrine Pharmaceuticals, Inc., and its wholly-owned subsidiaries,
Avid Bioservices, Inc. and Vascular Targeting Technologies, Inc.</I></FONT></P>
<P align=center><font size="2" face="Times New Roman, Times, serif"><i>i</i></font></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><U>PART I</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a1"></a>Item 1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>BUSINESS</U></B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Forward Looking Statements</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> Except for historical information contained herein, this Annual Report on Form 10-K contains certain
forward-looking statements. The inclusion of forward-looking statements should not be regarded as
a representation by us or any other person that the objectives or plans will be achieved. The words
&#147;may,&#148; &#147;should,&#148; &#147;plans,&#148; &#147;believe,&#148; &#147;anticipate,&#148;
&#147;estimate,&#148; &#147;expect,&#148; their opposites and similar expressions are intended to
identify forward-looking statements. We caution readers that such statements are not guarantees of
future performance or events and are subject to a number of factors that may tend to influence the
accuracy of the statements, including but not limited to those risk factors outlined in the section
titled &#147;Risk Factors and Forward-Looking Statements&#148;. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
technical terms used in the following description of our business are defined in the &#147;Glossary
of Terms&#148;.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Company Overview</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>About Us.</I> &nbsp;Peregrine Pharmaceuticals, Inc., located in Tustin, California, is a biopharmaceutical company
primarily engaged in the research, development, manufacture and commercialization of cancer therapeutics
and cancer diagnostics through a series of proprietary platform technologies using monoclonal antibodies.
The Company was originally incorporated in California in June 1981 and was reincorporated in the
state of Delaware on September 25, 1996. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Our Location.</I> <B>&nbsp;&nbsp;</B> Our principal executive offices are located at 14272 Franklin Avenue, Suite 100, Tustin, California,
92780 and our telephone number is (714) 508-6000. Our internet website address is www.peregrineinc.com.
Information contained on our website does not constitute any part of this report.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Availability
of Our Reports and Other Information. </I>Our annual report on Form&nbsp;10-K, quarterly reports on Form&nbsp;10-Q, current reports on Form&nbsp;8-K,
and all amendments to those reports filed with or furnished to the SEC are available, free of charge,
through our website at <FONT style="TEXT-DECORATION: none">www.peregrineinc.com</FONT> as soon as reasonably practicable after such reports are electronically filed with or furnished to
the Securities and Exchange Commission. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Copies
of the following corporate governance documents are posted on our website: (1)&nbsp;Peregrine Pharmaceuticals,
Inc. Code of Business Conduct and Ethics (2)&nbsp;Peregrine Pharmaceuticals, Inc. Charter of the
Nominating Committee of the Board of Directors, (3) Peregrine Pharmaceuticals, Inc. Charter of the
Audit Committee of the Board of Directors, and (4)&nbsp;Peregrine Pharmaceuticals, Inc. Charter of
the Compensation Committee of the Board of Directors. If you would like a printed copy of any of
these corporate governance documents, please send your request to Peregrine Pharmaceuticals, Inc.,
Attention Corporate Secretary, 14272 Franklin Avenue, Suite 100, Tustin, California&nbsp;92780. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>1</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Our Development Focus.</I> &nbsp;We are primarily focused on developing therapeutic agents that
affect blood vessels and blood
flow in cancer and other diseases. Our vascular research programs fall under several different proprietary
platforms including Anti-Phospholipid Therapy (&quot;APT&quot;), Vascular Targeting Agents (&quot;VTAs&quot;), anti-Angiogenesis
and Vasopermeation Enhancement Agents (&quot;VEAs&quot;). Peregrine&#146;s first APT agent is scheduled to enter
into clinical trials during calendar year 2004. These therapeutic agents may have applications in
the treatment of cancer and other diseases such as viral infections, diabetes, arthritis, skin disorders
and eye diseases. Our most clinically advanced therapeutic program is based on a targeting platform
outside vascular biology. This technology platform is known as Tumor Necrosis Therapy (&quot;TNT&quot;) and targets
dead or dying tumor cells that are common to the majority of different tumor types and deliver therapeutic
agents that kill nearby living tumor cells. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Our Manufacturing Subsidiary.</I> &nbsp;In January 2002, we commenced operations of our wholly-owned subsidiary, Avid Bioservices, Inc.,
which was formed from the facilities and expertise of Peregrine. Avid produces clinical trial material
for monoclonal antibodies and recombinant proteins for Peregrine and other biotechnology companies
to support phase I through phase III clinical trials in stirred tank bioreactors.
In order to expand our current capacity and to meet our needs and the needs of
our customers, we have ordered
a 1,000 liter bioreactor we anticipate will be installed and operational before the end of calendar year 2004.
The 1,000 liter bioreator will augment our functioning 22.5 liter, 100 liter and 300 liter bioreactors.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Products in Research and Development.</I> &nbsp;Our product development efforts, including those of our collaborative partners, have been primarily
focused on cancer. During fiscal year 2004, we have expanded our preclinical research efforts into
viral infections and eye diseases. Below is a summary of products, with their respective current
stages of development and program status:</FONT></P>
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr valign="bottom">
    <th width="15%"><font size="1" face="Times New Roman, Times, serif">Technology</font></th>
    <th width="2%">&nbsp;</th>
    <th width="8%"><font size="1" face="Times New Roman, Times, serif">Product Name</font></th>
    <th width="2%">&nbsp;</th>
    <th width="10%"><font size="1" face="Times New Roman, Times, serif">Indication</font></th>
    <th width="2%">&nbsp;</th>
    <th><font size="1" face="Times New Roman, Times, serif">Current Stage of<br>
    Development</font></th>
    <th width="2%">&nbsp;</th>
    <th><font size="1" face="Times New Roman, Times, serif">Product Description and Program Status</font></th>
  </tr>
  <tr align="left" valign="top">
    <td><hr width="100%" color="black" size="1" ></td>
    <td>&nbsp;</td>
    <td><hr width="100%" color="black" size="1" ></td>
    <td>&nbsp;</td>
    <td><hr width="100%" color="black" size="1" ></td>
    <td>&nbsp;</td>
    <td><hr width="100%" color="black" size="1" ></td>
    <td>&nbsp;</td>
    <td><hr align="center" width="100%" size="1" noshade color="black"></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">Tumor Necrosis Therapy (TNT)</font></td>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">Cotara&#153;</font></td>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">Brain Cancer</font></td>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">Registration trial&nbsp;&nbsp;protocol was approved by the U.S. Food and Drug Administration (&#147;FDA&#148;) in February 2003</font></td>
    <td>&nbsp;</td>
    <td><p><font size="2"><strong> <font face="Times New Roman, Times, serif">Description.</font></strong><font face="Times New Roman, Times, serif"> TNT-based antibody product conjugated to a radioisotope, Iodine 131. Product is injected directly into the tumor region. <br>
                <br>
        </font><font size="2" face="Times New Roman, Times, serif"><B>Status.</B> &nbsp;&nbsp;We have been actively seeking a development or licensing partner since we received protocol approval. Due to the financial obligations of a large registration trial, we
    feel it is necessary to secure a partner before we could commence this registration trial.</font><font face="Times New Roman, Times, serif"><br>
    </font></font></p></td>
  </tr>
  <tr align="left" valign="top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">TNT</font></td>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">Cotara&#153;</font></td>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">Colon Cancer</font></td>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">Phase I</font></td>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif"><B>Description.</B> &nbsp;&nbsp;TNT-based antibody product conjugated to a radioisotope, Iodine 131. Product is administered into the blood stream (intravenous infusion).<br>
          <br>
          <B>Status. </B>&nbsp;Phase I enrollment expected to be completed during calendar year 2004. Clinical data will then be gathered and used for studies in other solid tumor indications, such as lung cancer. </font></td>
  </tr>
</table>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>2</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr valign="bottom">
    <th><font size="1" face="Times New Roman, Times, serif">Technology</font></th>
    <th>&nbsp;</th>
    <th><font size="1" face="Times New Roman, Times, serif">Product Name</font></th>
    <th>&nbsp;</th>
    <th><font size="1" face="Times New Roman, Times, serif">Indication</font></th>
    <th>&nbsp;</th>
    <th><font size="1" face="Times New Roman, Times, serif">Current Stage of<br>
    Development</font></th>
    <th>&nbsp;</th>
    <th><font size="1" face="Times New Roman, Times, serif">Product Description and Program Status</font></th>
  </tr>
  <tr align="left" valign="top">
    <td><hr width="100%" color="black" size="1" ></td>
    <td>&nbsp;</td>
    <td><hr width="100%" color="black" size="1" ></td>
    <td>&nbsp;</td>
    <td><hr width="100%" color="black" size="1" ></td>
    <td>&nbsp;</td>
    <td><hr width="100%" color="black" size="1" ></td>
    <td>&nbsp;</td>
    <td><hr align="center" width="100%" size="1" noshade color="black"></td>
  </tr>
  <tr align="left" valign="top">
    <td width="15%"><font size="2" face="Times New Roman, Times, serif">TNT</font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td width="8%" align="center"><font size="2" face="Times New Roman, Times, serif">&#150;</font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td width="10%"><font size="2" face="Times New Roman, Times, serif">Lung Cancer</font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td width="15%"><font size="2" face="Times New Roman, Times, serif">Product approved in China; pending manufacturing approval. </font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif"><B>Description.</B> &nbsp;&nbsp;TNT-based antibody product conjugated to a radioisotope, Iodine 131. Product is injected directly into the tumor region.<br>
          <br>
          <B>Status.</B> &nbsp;&nbsp;This product is being developed by Medipharm Biotech, through a license agreement with Cancer Therapeutics, Inc. We have not received any additional information regarding the approval in China and the status of the pending manufacturing approval. See &#147;Certain Relationships and Related Transactions&#148; included in Part III, Item 13 of this Form 10-K for additional information related to this collaboration. </font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">TNT</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">&#150;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Unknown</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Discovery</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif"><B>Description.</B> &nbsp;&nbsp;We licensed the TNT-based antibodies for producing immunocytokines (novel antibody-cytokine fusion proteins) for the treatment of various diseases to Merck KGaA of Darmstadt, Germany. <br>
      <br>
      <strong> Status. </strong> The development status has not been publicly disclosed by Merck KGaA.    </font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">Anti-
      Phospholipid <br>
      Therapy (APT)</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">Tarvacin&#153;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Various Cancers</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Preclinical</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif"><B>Description.</B> &nbsp;&nbsp;APT monoclonal antibody planned to be administered intravenously. <br>
          <br>
          <B>Status.</B> &nbsp;&nbsp;Tarvacin&#153; will be our first APT compound and is expected to enter clinical trials by the end of calendar year 2004. </font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">APT</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">&#150;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Eye Disease</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Discovery</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif"><B>Description.</B> &nbsp; APT monoclonal antibody. <br>
          <br>
          <B>Status.</B> &nbsp;&nbsp;We entered into a research collaboration with The Foundation Fighting Blindness to perform preclinical proof-of-principle studies. </font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">APT</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">&#150;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Viral Disease</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Discovery</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif"><B>Description.</B> &nbsp; APT monoclonal antibody. <br>
          <br>
          <B>Status</B>. &nbsp;We are working closely with the University of Texas Southwestern Medical Center at Dallas (&#147;UTSWMC&#148;) to research our APT antibodies for the potential treatment of viruses.
    Researchers at UTSWMC have received a $1.68 million grant from The National Institute of Allergy and Infectious Diseases (NIAID) for research in using our APT antibodies as a potential treatment for Lassa Fever. </font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">Anti-Angiogenesis</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">2C3</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Cancer</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Discovery</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif"><B>Description.</B> &nbsp;&nbsp;Monoclonal antibody that blocks VEGF binding to the key receptor involved in angiogenesis.<br>
      </font>
        <P><font size="2" face="Times New Roman, Times, serif"><B>Status.</B> &nbsp;&nbsp;We are working with outside collaborators to identify a clinical candidate. Once a clinical candidate is identified, we expect to initiate clinical studies within 12 to 18 months. </font></P></td>
  </tr>
</table>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>3</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr valign="bottom">
    <th><font size="1" face="Times New Roman, Times, serif">Technology</font></th>
    <th>&nbsp;</th>
    <th><font size="1" face="Times New Roman, Times, serif">Product Name</font></th>
    <th>&nbsp;</th>
    <th><font size="1" face="Times New Roman, Times, serif">Indication</font></th>
    <th>&nbsp;</th>
    <th><font size="1" face="Times New Roman, Times, serif">Current Stage of<br>
    Development</font></th>
    <th>&nbsp;</th>
    <th><font size="1" face="Times New Roman, Times, serif">Product Description and Program Status</font></th>
  </tr>
  <tr align="left" valign="top">
    <td><hr width="100%" color="black" size="1" ></td>
    <td>&nbsp;</td>
    <td><hr width="100%" color="black" size="1" ></td>
    <td>&nbsp;</td>
    <td><hr width="100%" color="black" size="1" ></td>
    <td>&nbsp;</td>
    <td><hr width="100%" color="black" size="1" ></td>
    <td>&nbsp;</td>
    <td><hr align="center" width="100%" size="1" noshade color="black"></td>
  </tr>
  <tr align="left" valign="top">
    <td width="15%"><font size="2" face="Times New Roman, Times, serif">Vascular Targeting Agents (VTA)</font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td width="8%" align="center"><font size="2" face="Times New Roman, Times, serif">&#150;</font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td width="10%"><font size="2" face="Times New Roman, Times, serif">Cancer</font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td width="15%"><font size="2" face="Times New Roman, Times, serif">Discovery</font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif"><B>Description. &nbsp;</B> Agents that bind to tumor blood vessels and stop blood flow to the tumor by damaging tumor blood vessels.<br>
          <br>
          <B>Status. &nbsp;</B> We have entered into a number of research collaborations to evaluate our proprietary targeting platforms combined with various therapeutic agents. </font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">VTA</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">&#150;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Cancer</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Discovery</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif"><B>Description. &nbsp;</B> In December 2002, we entered into an exclusive licensing agreement with Schering AG for the development of VTA-based imaging and diagnostic agents.<br>
          <br>
          <B>Status. </B>&nbsp;The development status has not been publicly disclosed by Schering AG.</font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">VTA</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">&#150;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Cancer</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Discovery</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><p><font size="2" face="Times New Roman, Times, serif"><B>Description. &nbsp;</B> In February 2001, we entered into an exclusive licensing agreement with SuperGen, Inc. for the development of VTAs using VEGF to target tumor blood vessels for cancer therapy. <br>
      </font></p>
        <font size="2" face="Times New Roman, Times, serif"><B>Status. </B>&nbsp;The development status has not been publicly disclosed by SuperGen, Inc.</font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
  </tr>
  <tr align="left" valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">Vasopermeation Enhancement Agents (VEA)</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Cancer</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Discovery</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif"><B>Description. &nbsp;</B> VEAs specifically localize to tumors and make the tumor blood vessels leaky allowing subsequently administered chemotherapy drugs to better reach the target tumor cells.<br>
          <br>
          <B>Status. &nbsp;</B> Our collaborator has generated a fully-human antibody for targeting tumor necrosis and we are currently generating a fusion protein containing the human antibody with a portion of IL-2, known as PEP, that induces blood vessel permeability.</font></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The following is a more in depth discussion on our technology platforms, TNT, APT, Anti-Angiogenesis,
VTAs, VEAs, Lymphoma Therapy, and our contract manufacturing subsidiary, Avid Bioservices, Inc.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tumor Necrosis
Therapy (&#147;TNT&#148;)</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Overview.</I> <B>&nbsp;&nbsp;</B> TNT, our most clinically advanced technology, acts by binding to dead and dying cells found primarily
at the necrotic core of the tumor. TNT antibodies are potentially capable of carrying a variety of
agents including radioisotopes, chemotherapeutic agents and cytokines to the interior of solid tumors.
Our first TNT-based product, Cotara&#153;, is a chimeric (an antibody which is part human and part
mouse) TNT antibody conjugated to a radioisotope, Iodine 131. We currently have one ongoing Phase
I clinical trial at Stanford University Medical Center accepting patients with colorectal cancer.
In February 2003, the Company received FDA approval to commence a single registration study for Cotara&#153;
in first recurrent glioblastoma multiforme, a particularly deadly form of brain cancer. We are actively
seeking a strategic partner for the Cotara&#153; program. We currently do not plan on initiating
the registration trial until a strategic transaction has been executed.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>4</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>The TNT Concept</I>. The concept behind TNT is that almost all solid tumors develop a core of dead or dying cells known
as necrosis or necrotic cells in the center of the tumor mass as it grows. The outer membrane of
necrotic cancer cells becomes leaky, thus exposing the DNA on the inside of the cell. Instead of
targeting living cancer cells, TNT targets the necrotic and dead cells, which can account for up
to 50% of the mass of a tumor found throughout the tumor mass but primarily at the tumor core. TNT
binds to Deoxyribonucleic Acid (&#147;DNA&#148;) or DNA-associated proteins, such as histones, found
within the nucleus of virtually every cell. TNT is only able to reach the DNA target in cells having
porous nuclear and cellular membranes, since porosity is a property uniquely associated with dead
and dying cells found within solid tumors. As such, DNA functions as a highly abundant but selective
target. This DNA target is not believed to modulate as is commonly seen with tumor-specific cell
surface antigens that are commonly used as targets with other antibody-based therapeutic modalities.
Thus, compared to a cell surface marker, the DNA target may be a more stable and reliable target.
Once concentrated in necrotic regions throughout the tumor, TNT can deliver a toxic payload to neighboring
viable cancer cells, resulting in death of the tumor cells surrounding the necrotic core.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Each successive treatment with TNT potentially kills more cancer cells, thereby increasing the necrotic
area of the tumor. Thus, TNT potentially becomes more effective upon subsequent doses, contrary to
conventional chemotherapy, which becomes less effective with subsequent doses due to increased drug
resistance. The TNT targeting mechanism could be the basis for a class of new products effective
across a wide-range of solid tumor types, including brain, lung, colon, breast, liver, prostate and
pancreatic cancers.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Cotara&#153; Registration Clinical Trial. </I>We filed a protocol with the Food &amp; Drug Administration (&#147;FDA&#148;) in February 2002 to commence
a single registration clinical trial using Cotara&#153; for the treatment of advanced brain cancer.
We reached an agreement with the FDA on a final registration protocol and we received notification
of FDA protocol approval in February 2003.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the protocol design that was approved by the FDA, the Cotara&#153; registration study for brain cancer
will begin with a group of approximately 60 patients treated with Cotara&#153;. Additional detailed
nuclear imaging data to support the product label will be collected and a preliminary evaluation
of the data will be performed to determine if the study will be continued or terminated. After the
initial approximate 60 patients, the remaining patients will be randomized to receive either Cotara&#153;
or temozolomide.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the anticipated number of patients to be treated and the anticipated cost of the study, we have
been actively seeking a strategic partner to fund the registration study since we received protocol
approval in February 2003. Due to the financial obligations and complexities of a large registration trial, we
feel it is necessary to secure assistance with running the registration trial
prior to initiating patient enrollment. We will continue to&nbsp;increase the commercial potential
of Cotara&#153;&nbsp; by continuing clinical studies in other solid tumor indications such as colorectal cancer. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Stanford Phase I Study.</I> &nbsp;In addition to brain cancer, Stanford University Medical Center is studying the safety, dosimetry,
and maximum tolerated dose (&#147;MTD&#148;) of Cotara&#153; using intravenous injection for patients
with colorectal cancer. This study is designed to treat three patients (referred to as a &#147;cohort&#148;)
at each dose level, calculate dosimetry, record side effects and monitor the patients for a minimum
of eight weeks between cohorts. If toxicities are not observed during these eight weeks, the next
cohort of three patients may be treated at the next higher dose. At the outset of the study, we did
not know the maximum tolerated dose for Cotara&#153;. Once the dose escalation is completed, additional
patients will be treated at the MTD (safe dose) to gain further experience with the drug and to provide
the basis of future studies. We expect the Phase I study to be completed during calendar year 2004
or early 2005. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>5</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Licensing Collaborations.</I> &nbsp;During October 2000, we entered into a licensing agreement with Merck KGaA of Darmstadt, Germany
to use our proprietary TNT antibodies for producing immunocytokines (novel antibody-cytokine fusion
proteins) for the treatment of various diseases. Within Merck, the international team of its affiliate
Lexigen, based in Lexington, MA, will develop these novel immunocytokines using our TNT targeting
technology. To our knowledge, Merck KGaA has not publicly disclosed the development status of the
project.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During September 1995, we entered into an agreement with Cancer Therapeutics, Inc. whereby we granted
to Cancer Therapeutics, Inc. the exclusive right to sublicense TNT to a major pharmaceutical company
solely in the People&#146;s Republic of China. See &quot;Certain Relationships and
Related Transactions&quot; included in Part III, Item 13 of this Form 10-K for
additional information related to this collaboration.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti-Phospholipid
Therapy (&#147;APT&#148;)</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Overview.</I> &nbsp;In August 2001, we exclusively licensed a new platform technology from the University of Texas
Southwestern Medical Center at Dallas which we have named Anti-Phospholipid Therapy. Tarvacin&#153;
will be our first APT compound expected to enter phase I clinical trials later this calendar year.
Over the past year, we have identified the final Tarvacin&#153; clinical candidate, developed cGMP
manufacturing processes, initiated manufacturing at Avid, recruited a scientific advisory board and
started formal toxicology studies to support our Investigational New Drug (IND) application to be
filed with the Food &amp; Drug Administration (FDA). We have also completed a number of preclinical
animal experiments using Tarvacin&#153; to study the safety and efficacy of the compound. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>Preclinical Studies.</I> &nbsp;In preclinical studies, 3G4, the parent antibody of Tarvacin&#153;, was shown to reduce the
growth of breast cancer tumors in animal models by 60% when given alone and by 93% when given in
combination with the commonly used chemotherapy drug docetaxel. These experiments clearly demonstrated
that the inclusion of 3G4 significantly improved the therapeutic value of the key breast cancer drug
docetaxel without any additional toxicity. This data in combination with other preclinical data has
increased our focus on the development of Tarvacin&#153;. We have worked with FDA, regulatory consultants
and our scientific advisory board to plan our preclinical program and to draft our phase I clinical
trial protocol. One of our major goals for fiscal year 2005 will be to file an IND and begin clinical
studies with Tarvacin&#153;. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>6</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
University of Texas Southwestern Medical Center at Dallas, with whom we have a sponsored research
agreement, has received a grant to study the use of APT agents for the treatment of viral infections
and other diseases. We have also started a collaboration with The Foundation Fighting Blindness to
study APT constructs as well as VTAs for the treatment of eye diseases.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>About Phospholipids.</I> &nbsp;Phospholipids are normal cellular structures that are present in all cells of the human body
and form the building blocks that make up the outer surface of cells responsible for maintaining
integrity and normal functions. The study of phospholipids as targets for therapeutic and diagnostic
intervention forms the basis of our Anti-Phospholipid Therapy (APT) technology platform. We and our
collaborators have been studying the characteristics of phospholipids in a variety of different diseases.
Phospholipids can be classified under several different subtypes including choline-containing phospholipids
and aminophospholipids. In normal healthy cells, there are a number of systems that are responsible
for keeping aminophospholipids facing the interior of the cell and choline-containing phospholipids
facing the exterior of the cell. Our scientists have demonstrated that tumor blood vessels differ
significantly from normal blood vessels with regard to the orientation of their phospholipids. Key
differences between the tumor environment and normal tissue environment include low oxygen levels
(hypoxia), high levels of various growth factors, reactive oxygen species and increased levels of various cytokines. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result of being exposed to the harsh environment within the tumor, the normal processes that keep
phospholipids in their correct orientation are inhibited resulting in the exposure of phospholipids
on the outside of tumor blood vessels that are not present in normal tissues. The group of phospholipids
known collectively as anionic phospholipids has emerged as particularly attractive targets for tumor
therapy. Peregrine has developed a lead anti-aminophospholipid monoclonal antibody (3G4) that preferentially
binds to the aminophospholipid. When injected into animals bearing various solid tumors, the antibody
binds to tumor vessels without binding to blood vessels in normal organs. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Peregrine is also evaluating 3G4 and antibodies against aminophospholipids as a targeting platform for
the development of Vascular Targeting Agents. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><B>Anti-Angiogenesis Technology</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Overview.</I> &nbsp;&nbsp;Our mouse derived antibody, 2C3, works by inhibiting a key tumor blood vessel growth factor
known as Vascular Endothelial Growth Factor (VEGF) from inducing the formation
of blood vessels in solid tumors. The 2C3 antibody is part of Peregrine&#146;s
anti-angiogenesis compound family under development for the treatment of cancer
and other diseases dependent on aberrant blood vessel formation. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>About VEGF.</I> &nbsp;VEGF is a potent growth factor that plays a role in a number of normal processes including blood
vessel formation (angiogenesis), bone formation and immune system regulation. The 2C3 antibody selectively
blocks VEGF binding to one of its two key receptors, VEGF receptor 2, without blocking binding to
VEGF receptor 1. VEGF binding to VEGF receptor 2 is believed to be the primary signal involved in
angiogenesis. VEGF binding to VEGF receptor 1 is believed to be involved in a number of normal VEGF-mediated
processes. Anti-angiogenesis agents that selectively block the blood vessel growth function of VEGF
without blocking other VEGF-mediated functions may have advantages over VEGF inhibition strategies
that block all VEGF functions.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>7</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Virtually
all detectable tumors are dependent upon a tumor vascular network to obtain oxygen and nutrients.
As the tumor increases in size, it produces angiogenic factors (formation of new blood vessels),
chief among them VEGF, to expand the vascular tree and increase the delivery of oxygen and nutrients
to the growing tumor. 2C3 is an anti-angiogenic agent that blocks VEGF-induced angiogenesis associated
with VEGF binding to VEGF receptor 2 but does not interfere with the VEGF activities associated with
binding to VEGF receptor 1. In preclinical studies presented this year at the American Association
of Cancer Research (AACR) annual meeting, the 2C3 antibody inhibited growth of blood vessels by up
to 85% in breast cancer tumor metastases. These results indicate that anti-VEGF agents that selectively
block the angiogenic functions of VEGF may be effective at treating cancer while potentially having
a better safety profile. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Preclinical Studies.</I> &nbsp;Preclinical research is currently being conducted by a number of investigators including Drs.
Rolf Brekken and Philip Thorpe at the University of Texas Southwestern Medical Center at Dallas.
VEGF-dependent angiogenesis is a key factor in pancreatic tumor growth, metastasis, and cancer-related
death. One of the studies presented evaluated the effect of 2C3 on the growth of tumors in various
preclinical models. Consistent with its anti-angiogenic activity, 2C3 decreased total blood vessel
density in these tumor models. 2C3 also controlled the growth of human pancreatic tumor cells injected
in the pancreas such that the 2C3 treated mice had primary tumors 50% smaller than tumors in mice
that received a control treatment. In addition, 2C3 therapy reduced the number and size of metastatic
colonies in the liver as well as the number of mice with metastatic disease. No therapy-related toxicity
was observed in any of these studies. Results of some of this research program were highlighted by
a presentation at the Third Annual Angiogenesis Conference in London, England. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Licensing Collaborations</I>. During August 2001, the Company entered into an exclusive worldwide license for a new preclinical
compound from the University of Texas Southwestern Medical Center. This new compound, named 2C3,
added to Peregrine&#146;s anti-cancer platform technologies in the anti-angiogenesis field. Under
this license agreement, the Company paid an up-front license fee, annual maintenance fees, and is
obligated to pay future milestone payments based on development progress, plus a royalty on net sales.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
June 2003, the Company entered into a research collaboration agreement with Affitech AS regarding
the production of human antibodies for the Company&#146;s anti-angiogenesis programs to be used as
possible future clinical candidates. Under the terms of the research collaboration agreement, the
Company will pay a non-refundable technology access fee and may either develop
identified antibodies as part of a joint venture program with Affitech AS or pay future milestone payments and
royalties on net sales. Affitech AS has achieved the first research milestone involving the identification
of an initial panel of fully human antibodies that bind to the blood vessel growth factor Vascular
Endothelial Growth Factor (VEGF) with a defined specificity. Once a final
clinical candidate (fully human antibody) is identified, we expect to initiate
clinical trials within 12 to 18 months. The anti-VEGF antibodies will also be
evaluated as targeting agents for the development of VTAs.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>8</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vascular
Targeting Agents (&#147;VTAs&#148;)</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Overview. &nbsp;</I> VTAs utilize monoclonal antibodies and other targeting agents that recognize markers found on tumor
blood vessels. VTAs act in a two-step process whereby the VTA first binds to the tumor blood vessels
and then induces a blood clot in the tumor blood vessels. The formation of the blood clot stops the
flow of oxygen and nutrients to the tumor cells, resulting in a wave of tumor cell death. VTAs have
the potential to be effective against a wide variety of solid tumors since: 1) the solid tumors studied
to date in excess of two millimeters in size forms a vascular network to enable the tumor to continue
to grow and, 2) tumor vasculature markers are believed to be consistent across various tumor types.
Another potential advantage of the VTA technology is that the cells targeted by VTAs (the vascular
endothelial cells) do not mutate to become drug resistant. Drug resistance caused by the instability
and mutability of cancer cells is a significant problem with conventional therapeutic agents that
must directly target the cancer cells of the tumor.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>The VTA Concept.</I> &nbsp;The Vascular Targeting Agent (&#147;VTA&#148;) technology is based on the concept that virtually
all detectable tumors rely on a tumor vascular network to obtain oxygen and nutrients. In preclinical
animal studies, VTAs have shown to be potent anti-cancer agents that act by cutting off the supply
of oxygen and nutrients to tumor cells by causing blood clots to form within the tumor&#146;s blood
supply network. VTAs localize within the tumor vasculature by selectively binding to the flat endothelial
cells that line tumor blood vessels. Once the VTA binds to its target, it initiates local blood clotting.
VTAs may be very potent anti-tumor agents because they create two amplified processes that have a
devastating effect on the tumor. The first process is the initiation of the coagulation cascade,
which is a highly amplified, self-sustaining chain reaction in which a huge number of blood clotting
molecules are generated, leading to complete clotting of the tumor blood vessels within a matter
of minutes. A second level of amplification occurs at the structural level where the blockage of
a single capillary can lead to the destruction of thousands of tumor cells. As a result, small quantities
of VTAs localized in the tumor&#146;s vascular system may cause an avalanche of tumor-cell death.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Vascular Targeting Agents versus Anti-Angiogenesis.</I> &nbsp;The VTA technology differs from conventional anti-angiogenesis therapy in that VTAs act by shutting
off the supply of oxygen and nutrients to tumor cells by inducing clot formation in existing tumor-blood
vessels. In contrast, anti-angiogenesis compounds typically work by inhibiting the growth of new
tumor blood vessels. In inhibiting the growth of new tumor blood vessels, tumor growth may be diminished,
but the existing tumor can maintain its bulk by utilizing the existing tumor blood vessels. The VTA
approach, therefore, is designed to provide a therapeutic effect for the destruction of existing tumors.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Preclinical Studies.</I> &nbsp;In preclinical animal studies, VTAs have been able to induce the formation of clots in tumor
blood vessels within 30 minutes leading to tumor cell death. Within days, large tumor masses have
been shown to disintegrate and have left nearby healthy tissue intact and fully functional. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Dr. Philip Thorpe and his scientific team at the University of Texas Southwestern Medical Center at
Dallas currently are conducting preclinical research under our sponsored research agreement. Some
of the results of this research program were highlighted by presentations at the 2003 American Association
for Cancer Research (&#147;AACR&#148;) annual meeting in Washington, D.C. and at the Angiogenesis
II Conference in Paris, France and published in a research article in the Proceedings of the National
Academy of Sciences in June of 2002. Dr. Philip Thorpe and his research collaborators have demonstrated
that these new compounds suppress the growth of a variety of human and mouse solid tumors growing
in mice and may be a promising anti-cancer candidate for clinical trials.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We have decided that in order to move our VTA program into human clinical studies, we will pursue chimeric
or fully human monoclonal antibodies in addition to the murine or mouse antibodies originally raised
at the University of Texas Southwestern Medical Center at Dallas. The Company is currently working
with a number of human antibody generation companies to develop fully human antibodies for its most
promising VTA targets. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>9</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>License Collaborations.</I> &nbsp;During December 2002, we granted the exclusive rights for the development of diagnostic and
imaging agents in the field of oncology to Schering A.G. under our Vascular Targeting Agent (&#147;VTA&#148;)
technology. Under the terms of the agreement, we received an up-front payment and could also receive
future milestone payments and a royalty on net sales, as defined in the agreement, based on development
success of each product candidate. Under the same agreement, we granted Schering an option to obtain
certain non-exclusive rights to the VTA technology with predetermined up-front fees and milestone
payments as defined in the agreement. To our knowledge, Schering A.G. has not publicly disclosed
the development status of the project.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During February 2001, we completed a licensing deal with SuperGen, Inc. (&#147;SuperGen&#148;) to license
a segment of our VTA technology, specifically related to Vascular Endothelial Growth Factor (&#147;VEGF&#148;)
in combination with certain toxins or killing agents. Under the terms of the licensing agreement,
we received an initial equity investment, continue to receive an annual license fee until an IND
is filed, and we could receive additional milestone payments based on the development success, plus
receive a royalty on net sales of all drugs commercialized by SuperGen utilizing the VEGF technology.
To our knowledge, SuperGen has not publicly disclosed the development status of the project.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vasopermeation
Enhancement Agents (&#147;VEAs&#148;)</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Overview.</I> &nbsp;&nbsp;VEAs are a new class of drugs, which are designed to increase the uptake of cancer therapeutics
and imaging agents into the tumor at the tumor site, potentially resulting in greater efficacy. VEAs
work by using monoclonal antibodies to deliver known vasoactive compounds (i.e., molecules that cause
tissues to become more permeable) selectively to solid tumors. VEAs currently use the same targeting
agent as TNT to deliver an agent that makes the blood vessels inside the tumor more permeable (leaky).
Once localized at the tumor site, VEAs alter the physiology and the permeability of the vessels and
capillaries that supply the tumor. In preclinical studies, drug uptake has been increased up to almost
400% in solid tumors when VEAs were administered several hours prior to the chemotherapeutic treatment.
VEAs are intended to be used as a pre-treatment for most existing cancer therapies and imaging agents. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increased permeability of the tumor blood vessels makes it possible to deliver an increased concentration
of killing agents into the tumor where they can potentially kill the living tumor cells. VEAs may
be effective across multiple tumor types. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Barriers to Existing Cancer Therapies.</I> &nbsp;Most traditional approaches to cancer therapy attempt to directly destroy individual cancer
cells. Drugs that target cancer cells must overcome a significant number of structural barriers within
the tumor in order to be effective. They must first exit the tumor blood vessels, migrate past the
support structures that underlie the vessels and eventually make their way to the cancer cells. As
a result of these structural barriers, very little drug injected into the blood stream of a patient
is able to reach and destroy cancer cells. One potential solution to this problem is to increase
the permeability of the blood vessels within the tumor which will permit more therapeutic drug to
reach and kill substantially more cancer cells. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>The VEA Concept.</I> &nbsp;Vasopermeation Enhancement Agents are designed to increase the uptake of existing and future
cancer therapeutics and imaging agents at the tumor site, potentially resulting in greater efficacy.
VEAs act by using monoclonal antibodies to deliver known vasoactive compounds (molecules that cause
tissues to become more permeable) selectively to solid tumors. Once localized at the tumor site,
VEAs alter the physiology and the permeability of the vessels and capillaries that supply the tumor.
VEAs are intended to be used as a pre-treatment for most existing cancer therapies and imaging agents
and may be effective across multiple tumor types.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>10</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Preclinical Studies.</I> &nbsp;VEAs are currently in preclinical development in collaboration with Dr. Alan Epstein and his
scientific team at the University of Southern California Medical Center. In preclinical studies,
drug uptake has been increased up to almost 400% in solid tumors when VEAs were administered several
hours prior to the therapeutic treatment. Recently published preclinical studies demonstrated the
ability of the VEA technology to significantly increase the anti-tumor activity of several leading
chemotherapy drugs including 5-FU, doxorubicin, vinblastine, BCNU, Taxol, or VP-16. In general, the
enhancement of chemotherapeutic drug effects from these studies could be divided into two categories:
(1) those tumors which normally respond to a given drug, such as human colon carcinoma treated with
doxorubicin, which were found to have a significant increase in anti-tumor response following VEA
pretreatment; (2) those tumors which normally do not respond to a given drug, such as lung carcinoma
treated with Taxol, which were found to have an increase in response following VEA pretreatment.
This data represents a major advancement in the VEA program and was presented at the American Society
of Clinical Oncology (&#147;ASCO&#148;) in 2002. Our researchers have met with top chemotherapy experts
to review the VEA preclinical data and received important advice on how to design a clinical study
for the lead VEA compound. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The Company has a fully human clinical candidate for the VEA technology. This candidate will be used
for cGMP manufacturing and completion of toxicology studies necessary for human clinical studies.
In order to complete toxicology studies, the Company must choose the chemotherapy drug(s) to be used,
the tumor type to be treated and the therapeutic regimen to be used in the Phase I study. Depending
on the Phase I trial design and the animal species used for preclinical work, the cost of the studies
can be significant depending on the complexity of the study. The Company is actively pursuing licensing
partners for this technology and may elect to have the potential partner finalize the clinical and
preclinical programs including the toxicology studies. In any case, the Company will continue with
manufacturing plans through Avid Bioservices, Inc. so that it should be in a position to begin the
preclinical toxicology studies as soon as the development plans are finalized. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lymphoma
Therapy</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>Overview.</I> &nbsp;The Lym-1 antibody is a murine monoclonal antibody that recognizes a protein on the </font><FONT face="symbol" size=2>b</FONT> <FONT face="Times New Roman, Times, Serif" size=2>-chain of HLA-DR, a cell surface marker present on over 80% of non-Hodgkin&#146;s Lymphomas. This
HLA-DR Lym-1 binding epitope is highly specific for non-Hodgkins Lymphomas. Lym-1 monoclonal antibody
selectively targets lymphoma cancer cells and spares the healthy B-cells necessary to fight infection.
</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>Non-Hodgkin&#146;s Lymphoma (&#147;NHL&#148;).</I> &nbsp;NHL is a malignant growth of cells in the lymph system. The lymph system is a connecting network
of glands and vessels, which produce and circulate lymph throughout the body. Under the Revised European-American
Classification of Lymphoid Neoplasms, NHL is sub-divided into two classes: indolent and aggressive.
Indolent lymphomas affect about 35% of the patients newly diagnosed with the disease. Indolent lymphoma
usually presents as a nodal (involving the lymph nodes) disease. Survival from the time of diagnosis
with indolent disease averages 5 to 7 years. Aggressive lymphoma affects some 65% of the newly diagnosed
cases of NHL and has average survival rates of 2-5 years in intermediate and six months to 2 years
in high-grade disease. Aggressive lymphomas are usually present with large extranodal (outside the lymph
nodes) bulky tumors.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>11</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>Oncolym.</I> &nbsp;Oncolym is the name for the radioimmunoconjugate formed when the Lym-1 antibody is combined
with the radioactive isotope, Iodine 131. Iodine 131 appears to have a number of advantages as a
therapeutic radionuclide. The primary potential advantage is that beta radiation emissions from the
isotope (the energy that kills the cancer cells) penetrate several millimeters through tissue killing
some 300 cells layers around the antibody. This makes the radioimmunoconjugate therapy potentially
effective against tumors, because it negates the need to target each and every cancer cell individually. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Clinical Trials.</I> &nbsp;To date, 137 patients were exposed in 7 IND clinical protocols, of which, 120 patients were
treated with a therapeutic dose of Oncolym. Data on 113 patients is currently available. In these
trials, some patients have achieved complete remissions (&#147;CR&#148;) where there is no detectable
tumor and some achieved partial remissions (&#147;PR&#148;) where there is at least a 50% shrinkage
of the tumor mass. To date, 47 patients with an indolent form of NHL have been treated, of which
28 were responders (60% response rate) with 8 CR&#146;s and 20 PR&#146;s. In addition, 66 patients
with an aggressive form of NHL were treated, of which, there were 17 responders (26% response rate)
with 6 CR&#146;s and 11 PR&#146;s. Radiation dosimetry demonstrates a tolerable safety index. Minor
side effects such as thrombocytopenia (low platelet count) and leukopenia (low white blood cell count)
have been observed. Clinical studies have revealed that the side effects appear to be reversible,
manageable and resolve without complications.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
suspended clinical studies during fiscal year 2002. We have been seeking a licensing or joint venture
partner for the Oncolym technology for a number of years. We do not anticipate continuing clinical
studies without a licensing or development partner for this technology. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contract
Manufacturing Facility</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During January 2002, we commenced the operations of our wholly-owned subsidiary, Avid Bioservices,
Inc., which was formed from the facilities and expertise of Peregrine. Avid provides an array of
contract manufacturing services, including contract manufacturing of antibodies and proteins, cell
culture development, process development, and testing of biologics for biopharmaceutical and biotechnology
companies under current Good Manufacturing Practices (&#147;cGMP&#148;).&nbsp;
In order to expand our current capacity and to meet our needs and the needs of
our customers, we have ordered a 1,000 liter
bioreactor we anticipate to be installed and operational before the end of calendar year 2004.
The 1,000 liter bioreactor will augment our functioning 22.5 liter, 100 liter and 300 liter bioreactors.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Operating a cGMP facility requires highly specialized personnel and equipment that must be maintained
on a continual basis. Prior to the formation of Avid, we manufactured our own antibodies for over
10 years and developed the manufacturing expertise and quality systems to provide the same service
to other biopharmaceutical and biotechnology companies. We believe Avid&#146;s existing facility
is well positioned to meet the growing needs of the industry. Avid is also well positioned to increase
its capacity in the future in order to become a significant supplier of contract manufacturing services.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>12</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Avid can provide an array of services to a variety of companies in the biotechnology and pharmaceutical
industries. Even though much of the process is very technical, knowledge of the process will help
investors understand the overall business. The manufacturing of monoclonal antibodies and recombinant
proteins under cGMP is a complex process and includes several phases before the finished drug product
is released to the client. The first phase of the manufacturing process is to receive the production
cell line (the cells that produce the desired protein) and any available process information from
the client. The cell line must be adequately tested according to FDA guidelines by an outside laboratory
to certify that it is suitable for cGMP manufacturing. This testing generally takes between one and
three months to complete, depending on the necessary testing. The cell line that is sent may either
be from a master cell bank (base cells from which all future cells will be grown), which is already
fully tested or may represent a research cell line. In the case of a research cell line, Avid can
use the research cell line to produce master and working cell banks. Clients often request further
development through media screening and adaptation followed by small scale bioreactor process development
in 1 to 5 liter bioreactor systems. In parallel to the production of the master and working cell
banks, the growth and productivity characteristics of the cell line may be evaluated in the research
and development labs and paper work to support the production plan and the IND filing may be continuously
drafted. The whole manufacturing process (master cell bank characterization, process development,
assay development, raw materials specifications, test methods, downstream processing methods, purification
methods, viral clearance and testing methods and final release specifications) must be developed
and documented prior to the commencement of manufacturing in the bioreactors. The second phase of
the process is in the manufacturing facility. Once the process is developed, pilot runs are performed
using smaller scale bioreactors, such as the 22.5 liter bioreactor in order to verify the process.
Once the process is set, a pilot run or runs at full scale will be performed to finalize batch record
development. Material produced during these runs is often used for toxicology studies. After the
pilot batch run(s) is completed, full-scale cGMP manufacturing is typically initiated. Once the cGMP
run(s) is completed, batch samples are sent to an outside lab for various required tests, including
sterility and viral testing. Once the test results verify the antibodies meet specifications, the product is released and shipped to the client. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Each contract is tailored to meet the specific needs of the client. Full process development from start
to cGMP product release can take ten months or longer. Research and development work can take from
two months to over six months. All stages of manufacturing can generally take between one to several
weeks depending on the manufacturing method and process. Product testing and release can take up
to three months to complete. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Given its inherent complexity, necessity for detail, and magnitude (contracts may be into the millions
of dollars), the contract negotiations and sales cycle for cGMP manufacturing services can take a
significant amount of time. The Company believes the sales cycle from client introduction to signing
an agreement will take anywhere from between three to six months to over one year. Introduction to
Avid&#146;s services will usually come from word of mouth, exposure from direct mailings, exposure
from attendance at conferences or from advertising in trade journals. The Company believes word of
mouth will be the most significant source of new clients once its reputation has been successfully
established by timely contract performances. The sales cycle consists of the introduction phase,
the proposal phase, the audit phase, the contract phase and the project initiation phase. The client
sets the speed at which the process moves.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
date, Avid has been audited and qualified by both large and small, domestic and foreign&nbsp;biotechnology
companies interested in the production of monoclonal antibodies for clinical trial use. Additionally,
Avid has been audited by the European Agency for the Evaluation of Medicinal Products (EMEA), the
United States Food and Drug Administration (FDA) and the California Department of Health. Since inception,
Avid has established six outside contract manufacturing agreements for the full or partial development
of nine (9) separate antibodies or recombinant proteins. The Company anticipates that additional
contracts will be signed during the ensuing year. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>13</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the past fiscal year, we have had discussions with several parties interested in either partnering
or acquiring Avid. Given our anticipated drug development plans over the next several years, we believe
maintaining our own facility will result in significant cost savings. Such savings must be considered
when reviewing a proposal to partner or sell Avid. Provided that the right opportunity and financial
terms are presented to us and further provided that the manufacturing needs of our customers and
Peregrine are not jeopardized, the Company would be open to a possible strategic transaction related
to Avid.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Government Regulation</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> Regulation by governmental authorities in the United States and other countries is a significant factor
in our ongoing research and development activities and in the production and marketing of our products
under development. All of our products will require regulatory approval by governmental agencies
prior to commercialization. In particular, in order to clinically test, manufacture, and market pharmaceutical
products for therapeutic use, the Company must satisfy mandatory procedures and safety and effectiveness
standards established by various regulatory bodies. In the United States, the Public Health Service
Act and the Federal Food, Drug, and Cosmetic Act, as amended, and the regulations promulgated there
under, and other federal and state statutes and regulations govern, among other things, the testing,
manufacture, labeling, storage, record keeping, approval, advertising, and promotion of the Company&#146;s
products on a product-by-product basis. In addition to regulating and auditing human clinical trials,
the FDA regulates and inspects equipment, facilities, and processes used in the manufacturing and
testing of such products prior to providing approval to market a product. The Company also must adhere
to current Good Manufacturing Practice (&#147;cGMP&#148;) and product-specific regulations enforced
by the FDA through its facilities inspection program. The FDA may withdraw product approval if compliance
with these regulatory standards, including labeling and advertising, is not maintained or if unforeseen
problems occur following initial product launch. Product development and approval within this regulatory
framework takes a number of years and involves the expenditure of substantial resources.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
activities required before a pharmaceutical product may be marketed in the United States, such as
Cotara&#153;, Tarvacin&#153;, a VTA or VEA candidate, or Oncolym, begins with preclinical testing,
including laboratory testing of those products in animals to determine safety, efficacy and potential
toxicity. Next, an investigational new drug application is filed with the FDA to begin human clinical
testing. The clinical testing program necessary for approval of a new drug or biologic typically
involves a three-phase process. In phase I, small clinical trials are conducted to determine the
safety of the product. In phase II, clinical trials are conducted to assess safety, acceptable dose,
and gain preliminary evidence of the efficacy of the product. In phase&nbsp;III, clinical trials
are conducted to provide sufficient data for the statistically valid proof of safety and efficacy.
A clinical trial&nbsp;designed to provide clinical evidence of&nbsp;a drug&#146;s effectiveness,
to support product license registration&nbsp;is termed a &#147;registration study&#148;. After completion
of clinical studies for a biologics product, a Biologics License Application (&#147;BLA&#148;) is
submitted to the FDA for product marketing approval. No action can be taken to market any new drug
or biologic product in the United States until the FDA had approved an appropriate marketing application.
Even after initial FDA approval has been obtained, further clinical trials may be required to provide
additional data on safety and effectiveness and are required to gain clearance for the use of a product
as a treatment for indications other than those initially approved. In addition, side effects or
adverse events that are reported during clinical trials can delay, impede, or prevent marketing approval.
Similarly, adverse events that are reported after marketing approval can result in additional limitations
being placed on the product&#146;s use and, potentially, withdrawal of the product from the market.
Any adverse event, either before or after marketing approval, can result in product liability claims against the Company. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>14</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are currently conducting phase I clinical studies using Cotara&#153; and we plan to file an investigation
new drug application for Tarvacin&#153; before the end of calendar year 2004. To date, we have not
filed a BLA for any of our product candidates.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition, we are subject to regulation under state, federal, and international laws and regulations
regarding occupational safety, laboratory practices, the use and handling of radioactive isotopes,
environmental protection and hazardous substance control, and other regulations. Our clinical trial
and research and development activities involve the controlled use of hazardous materials, chemicals
and radioactive compounds. Although we believe that our safety procedures for handling and disposing
of such materials comply with the standards prescribed by state and federal regulations, the risk
of accidental contamination or injury from these materials cannot be completely eliminated. In the
event of such an accident, we could be held liable for any damages that result and any such liability
could exceed the financial resources of the Company. In addition, disposal of radioactive materials
used in our clinical trials and research efforts may only be made at approved facilities. The Company
believes that it is in material compliance with all applicable laws and regulations including those
relating to the handling and disposal of hazardous and toxic waste.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Our product candidates, if approved, may also be subject to import laws in other countries, the food
and drug laws in various states in which the products are or may be sold and subject to the export
laws of agencies of the United States government. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During fiscal year 1999, the Office of Orphan Products Development of the FDA determined that Oncolym
and Cotara&#153; each qualified for orphan designation for the treatment of intermediate and high-grade
Non-Hodgkins B-cell Lymphoma and for the treatment of glioblastoma multiforme and anaplastic astrocytoma
(both brain cancers), respectively. The 1983 Orphan Drug Act (with amendments passed by Congress
in 1984, 1985, and 1988) includes various incentives that have stimulated interest in the development
of orphan drug and biologic products. These incentives include a seven-year period of marketing exclusivity
for approved orphan products, tax credits for clinical research, protocol assistance, and research
grants. Additionally, legislation re-authorizing FDA user fees also created an exemption for orphan
products from fees imposed when an application to approve the product for marketing is submitted. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Manufacturing and Raw Materials</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I> <I>Manufacturing</I>. Avid Bioservices, Inc., our wholly-owned subsidiary, manufactures the Company&#146;s products under
development and used in clinical trials. We have retained key development personnel, who are
to be responsible
for developing analytical methods and processes that will facilitate the manufacturing of our antibodies.
If the right opportunity presents itself and our Avid subsidiary is sold, we anticipate being able
to continue to use Avid&#146;s services under contract to meet our immediate manufacturing needs. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I> Once the Cotara&#153; antibodies have been manufactured at Avid, the antibodies are shipped to a third
party facility for radiolabeling (the process of attaching the radioactive agent, Iodine 131, to
the antibody). From the radiolabeling facility, the radiolabeled Cotara&#153; antibodies are shipped
directly to the clinical site for use in clinical trials.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>15</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is currently evaluating other options for commercial radiolabeling, including the development
of a product kit that will enable hospitals to combine the antibody and radioactive isotope locally
at each site. Any commercial radiolabeling supply arrangement will require the investment of significant
funds by the Company in order for a radiolabeling vendor to develop the expanded facilities necessary
to support the Company&#146;s products. There can be no assurance that material produced by this
radiolabeling facility will be suitable for human use in clinical trials or that commercial supply
will be available to meet the demand for radiolabeled product. In addition, we have been working
with Paul Scherer Institut in Switzerland for a number of years on the process development and formulation
work for the Cotara&#153; radiolabeled product currently under clinical development. The Company
will continue with its research in radiolabeling scale-up, but believes this research will be eventually
supported by a potential licensing or marketing partner for Cotara&#153;.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Raw Materials.</I> &nbsp;&nbsp;Various common raw materials are used in the manufacture of our products and in the development
of our technologies. These raw materials are generally available from several alternate distributors
of laboratory chemicals and supplies. The Company has not experienced any significant difficulty
in obtaining these raw materials and does not consider raw material availability to be a significant
factor in its business. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Patents and Trade Secrets</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Peregrine
continues to seek patents on inventions originating from ongoing research and development activities
within the Company and in collaboration with other companies and university researchers. Patents,
issued or applied for, cover inventions relating in general to cancer therapy and in particular to
different antibodies and conjugates, methods and devices for labeling antibodies, and therapeutic
uses of the antibodies and conjugates. We intend to pursue opportunities to license these technologies
and any advancements or enhancements, as well as to pursue the incorporation of our technologies
in the development of our own products.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Our issued patents extend for varying periods according to the date of patent application filing or
grant and the legal term of patents in the various countries where patent protection is obtained.
The actual protection afforded by a patent, which can vary from country to country, depends upon
the type of patent, the scope of its coverage and the availability of legal remedies in the country.
We have either been issued patents or have patent applications pending that relate to a number of
current and potential products including products licensed to others. We consider that in the aggregate
our patent applications, patents and licenses under patents owned by third-parties are of material
importance to our operations. In general, we have obtained licenses from various parties that we
deem to be necessary or desirable for the manufacture, use or sale of our products. These licenses
(both exclusive and non-exclusive) generally require us to pay royalties to the parties. The terms
of the licenses, obtained and expected to be obtained, are not expected to significantly impact the
cost structure or marketability of the Company&#146;s products.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In general, the patent position of a biotechnology firm is highly uncertain and no consistent policy
regarding the breadth of allowed claims has emerged from the actions of the U.S. Patent Office with
respect to biotechnology patents. Accordingly, there can be no assurance that the Company&#146;s
patents, including those issued and those pending, will provide protection against competitors with
similar technology, nor can there be any assurance that such patents will not be legally challenged,
infringed upon or designed around by others.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>International patents relating to biologics are numerous and there can be no assurance that current
and potential competitors have not filed or in the future will not file patent applications or receive
patents relating to products or processes utilized or proposed to be used by the Company. In addition,
there is certain subject matter which is patentable in the United States but which may not generally
be patentable outside of the United States. Statutory differences in patentable subject matter may
limit the protection the Company can obtain on some of its products outside of the United States.
These and other issues may prevent the Company from obtaining patent protection outside of the United
States. Failure to obtain patent protection outside the United States may have a material adverse
effect on the Company&#146;s business, financial condition and results of operations.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>16</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>No one has sued the Company for infringement and no third party has asserted their patents against
us that we believe are of any merit. However, there can be no assurances that such lawsuits have
not been or will not be filed and, if so filed, that we will prevail or be able to reach a mutually
beneficial settlement. We also intend to continue to rely upon trade secrets and improvements, unpatented
proprietary know-how, and continuing technological innovation to develop and maintain our competitive
position in research and diagnostic products. We typically place restrictions in our agreements with
third parties, which contractually restricts their right to use and disclose any of the Company&#146;s
proprietary technology with which they may be involved. In addition, we have internal non-disclosure
safeguards, including confidentiality agreements, with our employees. There can be no assurance,
however, that others may not independently develop similar technology or that the Company&#146;s
secrecy will not be breached. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Customer Concentration and Geographic Area Financial Information </B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Peregrine
is currently in the research and development phase for all of its products and has not generated
any product sales from any of its technologies under development. For financial information concerning
Avid&#146;s customer concentration and geographic areas of its customers, see Note&nbsp;12, &#147;Segment
Reporting&#148; to the consolidated financial statements. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Marketing Our Potential Products</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We intend to sell our products, if approved, in the United States and internationally in collaboration
with marketing partners or through an internal sales force. If the FDA approves Cotara&#153; or our
other product candidates under development, the marketing of these product candidates will be contingent
upon the Company entering into an agreement with a company to market our products or upon the Company
recruiting, training and deploying its own sales force. We do not presently possess the resources
or experience necessary to market TNT or our other product candidates and we currently have no arrangements
for the distribution of our product candidates. Development of an effective sales force requires
significant financial resources, time, and expertise. There can be no assurance that the Company
will be able to obtain the financing necessary to establish such a sales force in a timely or cost
effective manner or that such a sales force will be capable of generating demand for the Company&#146;s
product candidates. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Competition</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The

biotechnology industry is intensely competitive. We face competition from pharmaceutical companies,

pharmaceutical divisions of chemical companies, and biotechnology companies of various sizes. Some

or all of these companies may have greater financial resources, larger technical staffs, and larger

research budgets than we have, as well as greater experience in developing products and running
clinical
trials. We expect to continue to experience significant and increasing levels of competition
in the
future. In addition, there may be other companies which are currently developing competitive
technologies
and products or which may in the future develop technologies and products which are
comparable or
superior to our technologies and products. The FDA has approved our Cotara&#153;
registration protocol
for the treatment of brain cancer, for which we are seeking a partner or
grant support prior to commencing
the study. Companies conducting late stage clinical trials in
brain cancer that may compete with
us include, among others, Xenova&#146;s, Allos Therapeutics,
Inc. and NeoPharm. Xenova Group plc
has begun patient dosing in a phase III clinical trial of TransMID&#153;
for the treatment of progressive
or recurrent non-operable glioblastoma multiforme. Allos Therapeutics,
Inc. is developing RSR13 (efaproxiral)
for the treatment of patients with brain metastases originating
from breast cancer in a phase III
study. NeoPharm is developing IL13-PE38QQR for the treatment
of recurrent glioblastoma multiforme
in a Phase III study. Most of our other products are in early
stages of development or clinical trials,
including Tarvacin&#153;. We anticipate Tarvacin&#153;
will enter clinical trials later this calendar
year for the treatment of various solid tumor cancers.
As for Tarvacin&#153;, there are a number
of possible competitors with approved products or developing
targeted agents in combination with
standard chemotherapy,&nbsp;including but not limited to, Avastin&#153;
by Genentech, Iressa&#174;
by AstraZeneca, Gleevec&#174; by Novartis, Tarceva&#153; by OSI Pharmaceuticals
and Genetech, Erbitux&#153;
by ImClone, and panitumumab by Abgenix. Due to the significant number
of companies attempting to
develop cancer therapeutics combined with the fact that our other products
are generally in early
stages of development, we cannot provide an accurate listing of all possible competitors at this stage of development.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>17</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Research and Development</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A major
portion of our operating expenses to date is related to research and development. Research and development
expenses primarily include (i) payroll and related costs associated with research and development
personnel, (ii) costs related to clinical and pre-clinical testing of the Company&#146;s technologies
under development, (iii) the costs to manufacture the product candidates, including raw materials
and supplies, (iv) patent filing fees, (v) expenses for research and services rendered under outside
contracts, including sponsored research funding, and (vi) facility expenses. Research and development
expenses were $9,673,000 in fiscal year 2004, $8,744,000 in fiscal year 2003, and $11,494,000 in
fiscal year 2002. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Human Resources</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>As of April 30, 2004, we employed 59 full-time employees and 3 part-time employees. Our employees are
not represented by a collective bargaining organization and we have not experienced a work stoppage.
</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>18</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B>GLOSSARY OF TERMS</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>2C3 ANTIBODY - </B>Peregrine&#146;s mouse derived antibody that inhibits a key tumor blood vessel growth factor known
as Vascular Endothelial Growth Factor (VEGF) from inducing the formation of blood vessels in solid
tumors based on preclinical studies. The 2C3 antibody is part of Peregrine&#146;s anti-angiogenesis
compound family under development for the treatment of cancer and other diseases dependent on aberrant
blood vessel formation.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>3G4 ANTIBODY</B> &nbsp;&#150; Peregrine&#146;s mouse derived antibody that preferentially binds to the aminophospholipids. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>ANGIOGENESIS - </B> The formation of new blood vessels.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>ANTI-PHOSPHOLIPID THERAPY (&#147;APT&#148;) -</B>  The study of phospholipids as targets for therapeutic and diagnostic intervention forms the
basis of our Anti-Phospholipid Therapy (APT) technology platform. We and our collaborators have been
studying the characteristics of phospholipids in a variety of different diseases.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>ANTIBODY - </B>Protein formed by the body to help defend against infection and disease. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>ANTIGEN - </B>Any substance that antagonizes or stimulates the immune system to produce antibodies.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>CELL LINES - </B>Specific cell types artificially maintained in the laboratory (in-vitro) for scientific purposes.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>CHEMOTHERAPY -</B> Treatment&nbsp;of disease by means of chemical substances or drugs.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>CHIMERIC - </B> &nbsp;A type of antibody which is mostly human and partially mouse.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>cGMP -</B>  current Good Manufacturing Practices; regulations established by the FDA for the manufacture, processing,
packing, or holding of a drug to assure that such drug meets the requirements of the Federal Food,
Drug and Cosmetic Act as to safety, and has the identity and strength and meets the quality and purity
characteristics that it purports or is represented to possess.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>COLORECTAL - </B>Relating to the colon (large intestine) and rectum.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>CYTOKINE - </B>A chemical messenger protein released by certain white blood cells. The cytokines include the interferons,
the interleukins, Tumor necrosis factor, and many others. Cytokines produced by lymphatic cells are
also called &#147;Lymphokines.&#148;</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>DATABASE - </B>A collection of data files that are organized in a specified manner, and used in analysis of trials.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>DNA (DEOXYRIBONUCLEIC ACID) - </B>A complex protein that is the carrier of genetic information.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>DOSIMETRY -</B> The process or method of calculating the level of radiation exposure due to radioactive isotopes,
such as Iodine 131.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>EFFECTOR -</B> &nbsp;A substance, such as a hormone, that increases or decreases the activity of an enzyme.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>ENDOTHELIAL CELLS -</STRONG> A layer of flat cells that line blood vessels.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>19</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>ENDPOINT - </B>A primary or secondary outcome variable used to judge the effectiveness of a treatment.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>EPITOPE - </B>A unique shape or marker carried on an antigen&#146;s surface which triggers a corresponding antibody
response.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>FDA -</STRONG> U.S. Food and Drug Administration; the government agency responsible for regulating the food,&nbsp;drug
and cosmetic industries, including the commercial approval of pharmaceuticals in the United States.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>GLIOMA -</STRONG>  A tumor derived from cells that form the glial cells of the brain.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>GLIOBLASTOMA MULTIFORME -</B>  A type of brain tumor that forms from glial (supportive) tissue of the brain. Also called
grade IV astrocytoma. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>IN VIVO - </B>Studies conducted within a living organism, such as animal or human studies. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>IN VITRO - </B>An artificial environment created outside a living organism, such as a test tube or culture plate,
used in experimental research to study a disease or process.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>IND -</STRONG>  Investigational New Drug Application; the application submitted to the FDA requesting permission
to conduct human clinical trials.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>KAPLAN-MEIER CURVE - </B>A way of graphing patient progress (e.g., how many are still alive or free of disease) against time.
</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>LYM-1 (Oncolym) -</STRONG>  A radiolabeled antibody designed to treat patients with intermediate and high-grade non-Hodgkin&#146;s
B-cell Lymphoma.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>LYMPH </B>- The almost colorless fluid that travels through the lymphatic system and carries cells that help
fight infection and disease. Also called lymphatic fluid. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>LYMPH NODE -</B> A rounded mass of lymphatic tissue that is surrounded by a capsule of connective tissue. Lymph
nodes are spread out along lymphatic vessels and contain many lymphocytes, which filter the lymphatic
fluid (lymph). </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>LYMPHOMA - </B>Cancers of the lymphatic system. There are many categories of lymphoma, such as lymphoblastic, cleaved,
non-cleaved, Burkitt&#146;s, and Hodgkin&#146;s disease.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>MAXIMUM TOLERATED DOSE -</B> The highest nontoxic dose that can be reasonably given to patients.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>MEDIAN - </B>The middle value such that for a series of numbers, one half are above the median, and one half are
below.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>MEDIAN SURVIVAL TIME - </B> The time at which half of the patients with a given disease are found to be, or expected to be, alive.
In a clinical trial, the median survival time is a way to measure the effectiveness of a product.
</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>MEDIAN TIME TO PROGRESSION - </B>The time in which half of the patients with a given disease show evidence of disease progression. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>MURINE -</STRONG>  Derived from a mouse.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>MOLECULE -</B> The <FONT style="TEXT-DECORATION: none">result</FONT> of two or more <FONT style="TEXT-DECORATION: none">atoms</FONT> combining by <FONT style="TEXT-DECORATION: none">chemical </FONT><FONT style="TEXT-DECORATION: none">bonding</FONT>, such as, a molecule of water consists of two atoms of hydrogen and one of oxygen.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>20</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>MONOCLONAL ANTIBODY -</B> An antibody derived from a single clone of cells. Monoclonal antibodies bind to one unique epitope.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>NECROSIS&nbsp; or NECROTIC  - </STRONG> The death and degradation of cells within a tissue. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>ONCOLOGY -</STRONG>  The study and treatment of cancer.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PHARMACOKINETIC - </B>Concerning the study of how a drug is processed by the body, with emphasis on the time required for
absorption, distribution in the body metabolism and excretion.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PHOSPHOLIPIDS -</B>  Phospholipids are normal cellular structures that are present in all cells of the human body
and form the building blocks that make-up the outer surface of cells responsible for maintaining
integrity and normal functions.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PRECLINICAL - </B>Generally refers to research that is performed in animals or tissues in the laboratory.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PROTOCOL - </B>A detailed plan for studying a treatment for a specific condition.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>RANDOMIZED - </B>Having been assigned to a treatment via a random process. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>RADIOLABELING  or RADIOLABELED  -  </STRONG>Process of attaching a radioactive isotope, such as Iodine 131. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG></STRONG></FONT><FONT face="Times New Roman, Times, Serif" size=2><STRONG>RADIOIMMUNOTHERAPY -</STRONG>   Therapy with a radiolabeled monoclonal antibody.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>RECURRENCE - </B>The return or flare up of a condition thought to be cured or in remission.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>REGISTRATION TRIAL -</B>  A clinical trial&nbsp;designed to provide clinical evidence of&nbsp;a drug&#146;s effectiveness,
to support product license registration.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>SOLID TUMORS -</STRONG> Cancer cells which grow as a solid mass. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>TARVACIN&#153; -</B> The tradename of Peregrine&#146;s first APT clinical compound expected to enter clinical trials
during calendar year 2004. Tarvacin&#153; is a chimeric version of 3G4 in which most of the mouse
portion of the antibody has been replaced with a human antibody. This was performed in order to reduce
the likelihood of the human body recognizing the antibody as foreign and developing an immune response
to 3G4. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>TEMOZOLOMIDE -</B>  A chemotherapy drug that is given as a treatment for some types of cancer, including brain tumors.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>TIME TO PROGRESSION - </B>The time from either diagnosis or treatment to the date that the disease shows progression. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>TOXICITY - </B>The extent, quality, or degree of being poisonous or harmful to the body.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>TOXICOLOGY STUDIES  -</B> The study of a drug in animals designed to characterize possible toxic effects. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>TUMOR -</STRONG> An abnormal overgrowth of cells. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>21</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>TUMOR NECROSIS THERAPY (&#147;TNT&#148;) -</STRONG> Therapeutic agents that target dead and dying cells found primarily at the core of a tumor.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>VASCULATURE -</STRONG> Tubelike structures that deliver blood to tissues.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>VASCULAR TARGETING AGENTS (&#147;VTAs&#148;) -</STRONG>  Monoclonal antibodies and other targeting agents that recognize markers found on tumor blood
vessels. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>VASOPERMEATION ENHANCEMENT AGENTS (&#147;VEAs&#148;) -</STRONG> &nbsp; A new generation of drugs which increase the uptake of therapeutic agents to solid tumors.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>VASCULAR ENDOTHELIAL GROWTH FACTOR (&#147;VEGF&#148;)  -</STRONG> <B>A</B> &nbsp;growth factor that plays a role in a number of normal processes including blood vessel formation
(angiogenesis) and immune system regulation.</FONT></P><B><U></U></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>22</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>RISK FACTORS AND FORWARD-LOOKING STATEMENTS</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following discussion outlines certain factors that could affect our financial statements for fiscal
2004 and beyond and could cause them to differ materially from those that may be set forth in forward-looking
statements made by or on behalf of the Company.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>If We Cannot Obtain Additional Funding, Our Product Development and Commercialization Efforts May Be
Reduced or Discontinued.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>At April 30, 2004, we had approximately $14.9 million in cash and cash equivalents and trade and other
receivables of $1.5 million. We have expended substantial funds on (i) the research, development
and clinical trials of our product candidates, and (ii) funding the initial operations of our wholly-owned
subsidiary, Avid Bioservices, Inc. As a result, we have historically experienced negative cash flows
from operations since our inception and we expect the negative cash flows from operations to continue
for the foreseeable future, unless and until we are able to generate sufficient revenues from Avid&#146;s
contract manufacturing services and/or from the sale and/or licensing of our products under development.
While we expect Avid to generate revenues in the foreseeable future, we expect our monthly negative
cash flow to continue for the foreseeable future, due to our anticipated clinical trial activities
using Cotara&#153; and Tarvacin&#153;, our anticipated development costs associated with Anti-Phospholipid
Therapy (&#147;APT&#148;), Vasopermeation Enhancement Agents (&#147;VEA&#146;s&#148;) and Vascular
Targeting Agents (&#147;VTA&#146;s&#148;), and expansion of our manufacturing capabilities. We believe
we have sufficient cash on hand to meet our obligations on a timely basis through at least fiscal year 2005. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition to the operations of Avid, we plan to obtain any necessary financing through one or more
methods including either equity or debt financing and/or negotiating additional licensing or collaboration
agreements for our platform technologies. There can be no assurances that we will be successful in
raising such funds on terms acceptable to us, or at all, or that sufficient additional capital will
be raised to complete the research, development, and clinical testing of our product candidates.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>We Have Had Significant Losses And We Anticipate Future Losses.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>All of our products are currently in development, pre-clinical studies or clinical trials, and no sales
have been generated from commercial product sales. We have incurred net losses in most fiscal years
since we began operations in 1981. The following table represents net losses incurred during the
past three fiscal years:</FONT></P>
<TABLE WIDTH=40% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=Bottom>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
     <TH><font size="1" face="Times New Roman, Times, serif">Net Loss</font></TH>
     <TH>&nbsp;</TH>
</TR>
<TR VALIGN=Bottom>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><hr width="100%" color="black" size="1" ></TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
</TR>
<TR VALIGN=Bottom bgcolor="#eaf9e8">
     <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Fiscal Year 2004</FONT></TD>
     <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
     <TD WIDTH=16% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 14,345,000</FONT></TD>
        <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Fiscal Year 2003</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 11,559,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom bgcolor="#eaf9e8">
     <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Fiscal Year 2002</FONT></TD>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 11,718,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>As of April 30, 2004, we had an accumulated deficit of $154,351,000. While we expect to generate revenues
from Avid&#146;s contract manufacturing services, in order to achieve and sustain profitable operations,
we must successfully develop and obtain regulatory approval for our products, either alone or with
others, and must also manufacture, introduce, market and sell our products. The costs associated
with clinical trials and product manufacturing are very expensive and the time frame necessary to
achieve market success for our products is long and uncertain. We do not expect to generate product
or royalty revenues for at least the next 2 years, and we may never generate product revenues sufficient
to become profitable or to sustain profitability.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>23</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>Our Product Development Efforts May Not Be Successful.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Since inception, we have been engaged in the development of drugs and related therapies for the treatment
of people with cancer. Our product candidates have not received regulatory approval and are generally
in research, clinical and pre-clinical stages of development. If the results from any of the clinical
trials are poor, those results may adversely affect our ability to raise additional capital, which
will affect our ability to continue full-scale research and development for our antibody technologies.
In addition, our product candidates may take longer than anticipated to progress through clinical
trials or patient enrollment in the clinical trials may be delayed or prolonged significantly, thus
delaying the clinical trials. Patient enrollment is a function of many factors, including the size
of the patient population, the nature of the protocol, the proximity of patients to the clinical
sites, the eligibility criteria for the study, and the availability of insurance coverage. In addition,
because our Cotara&#153; product currently in clinical trials represents a departure from more commonly
used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional
therapies, such as chemotherapy, rather than enroll patients in our clinical study. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>If We Cannot License Or Sell Our Cotara&#153; and Oncolym Products, Those Products May Be Delayed or
Never Be Further Developed.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we have continued to conduct the Phase I study with Cotara&#153; for colorectal cancer, we continue
to seek a partner or grant support for our FDA approved registration trial with Cotara&#153; for
brain cancer. The Cotara&#153; registration study for brain cancer is at the stage in development
where substantial financial resources are needed to complete clinical studies necessary for potential
product approval. We do not presently have the financial resources internally to complete such clinical
study and we have been seeking a licensing or funding partner for our Cotara&#153; brain cancer project
since February 2003 when we obtained protocol acceptance from the FDA. In addition, we continue to
seek a partner for our Oncolym clinical trial for lymphoma therapy. If licensing partners are not
found for these two technologies, we may not be able to advance these projects past their current
state of development. Because there are a limited number of companies which have the financial resources,
the internal infrastructure, the technical capability and the marketing infrastructure to develop
and market a radiopharmaceutical based anti-cancer drug, we may not find a suitable partnering candidate
for either technology. If we are not successful in licensing either of our technologies, we may explore
the possibility of a spin-off of the technology into a separate entity whereby the Company will contribute
the technology and the other entity will fund future clinical development in exchange for a percentage
ownership of the new entity. We cannot assure you that we will be able to find a suitable licensing
partner for these technologies. Furthermore, we cannot assure you that if we do find a suitable licensing
partner, the financial terms that they propose will be acceptable to the Company.</FONT></P><B><I></I></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>24</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>Our Dependency On One Radiolabeling Supplier May Negatively Impact Our Ability To Complete Clinical
Trials And Market Our Products.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We have procured our antibody radioactive isotope combination services (&#147;radiolabeling&#148;)
with Iso-tex Diagnostics, Inc. for all clinical trials using Cotara&#153; and Oncolym. If this supplier
is unable to continue to qualify its facility or label and supply our antibody in a timely manner,
our current clinical trial or potential licensing partner clinical trials using radiolabeling technology
could be adversely affected and delayed. While there are other suppliers for radioactive isotope
combination services, our clinical trial would be delayed for up to 12 to 18 months because it may
take that amount of time to certify a new facility under current Good Manufacturing Practices and
qualify the product, plus we would incur significant costs to transfer our technology to another
vendor. Prior to commercial distribution of any of our products, if approved, we will be required
to identify and contract with a company for commercial antibody manufacturing and radioactive isotope
combination services. An antibody that has been combined with a radioactive isotope, such as Iodine
131, cannot be stored for long periods of time as it must be used within one week of being radiolabeled
to be effective. Accordingly, any change in our existing or future contractual relationships with,
or an interruption in supply from, any such third-party service provider or antibody supplier could
negatively impact our ability to complete ongoing clinical trials conducted by us or a potential licensing partner. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>We May Not be Able to Manufacture Our Products in Commercial Quantities, Which Would Prevent Us From
Marketing Our Products, if Approved.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the clinical trial process, drug candidates are generally manufactured in small quantities. If the
FDA approves one of our product candidates for commercial sale, we may need to manufacture these
products in larger quantities to support commercial quantities. If necessary, we cannot assure you
that we will be able to successfully increase the manufacturing capacity, whether on our own or in
collaboration with third party manufacturers, for any of our product candidates in a timely or economic
manner, or at all. Significant scale-up of manufacturing may require certain additional validation
studies, which the FDA must review and approve. Currently, we manufacture all pre-clinical and clinical
material through Avid Bioservices, our wholly-owned subsidiary. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>We May Have Significant Product Liability Exposure Because We Maintain Only Limited Product Liability
Insurance.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We face an inherent business risk of exposure to product liability claims in the event that the administration
of one of our drugs during a clinical trial adversely affects or causes the death of a patient. Although
we maintain product liability insurance for clinical studies in the amount of $5,000,000 per occurrence
or $5,000,000 in the aggregate on a claims-made basis, this coverage may not be adequate. Product
liability insurance is expensive, difficult to obtain and may not be available in the future on acceptable
terms, if at all. Our inability to obtain sufficient insurance coverage on reasonable terms or to
otherwise protect against potential product liability claims in excess of our insurance coverage,
if any, or a product recall, could negatively impact our financial position and results of operations.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition, the contract manufacturing services that we offer through Avid expose us to an inherent
risk of liability as the antibodies or other substances manufactured by Avid, at the request and
to the specifications of our customers, could possibly cause adverse effects or have product defects.
We obtain agreements from our customers indemnifying and defending us from any potential liability
arising from such risk. There can be no assurance that such indemnification agreements will adequately
protect us against potential claims relating to such contract manufacturing services or protect us
from being named in a possible lawsuit. Although Avid has procured insurance coverage, there is no
guarantee that we will be able to maintain our existing coverage or obtain additional coverage on
commercially reasonable terms, or at all, or that such insurance will provide adequate coverage against
all potential claims to which we might be exposed. A successful partially or completely uninsured
claim against Avid would have a material adverse effect on our consolidated operations<I>.</I></FONT></P><I></I>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>25</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>The Liquidity Of Our Common Stock Will Be Adversely Affected If Our Common Stock Is Delisted from The
Nasdaq SmallCap Market.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Our common stock is presently traded on The Nasdaq SmallCap Market. To maintain inclusion on The Nasdaq
SmallCap Market, we must continue to meet the following six listing requirements:</FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="666" border="0">

<TR>
<TD vAlign=top width=76></TD>
<TD vAlign=top width=34><FONT face="Times New Roman, Times, Serif" size=2>1.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD vAlign=top width="556"><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Net tangible assets of at least $2,000,000 or market capitalization of at least $35,000,000 or net
income of at least $500,000 in either our latest fiscal year or in two of our last three fiscal years;</FONT></TD></TR>
<TR>
<TD vAlign=top width="76"></TD>
<TD vAlign=top width="34"></TD>
<TD vAlign=top width="556">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=76></TD>
<TD vAlign=top width=34><FONT face="Times New Roman, Times, Serif" size=2>2.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD vAlign=top width="556"><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Public float of at least 500,000 shares;</FONT></TD></TR>
<TR>
<TD vAlign=top width="76"></TD>
<TD vAlign=top width="34"></TD>
<TD vAlign=top width="556">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=76></TD>
<TD vAlign=top width=34><FONT face="Times New Roman, Times, Serif" size=2>3.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD vAlign=top width="556"><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Market value of our public float of at least $1,000,000;</FONT></TD></TR>
<TR>
<TD vAlign=top width="76"></TD>
<TD vAlign=top width="34"></TD>
<TD vAlign=top width="556">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=76></TD>
<TD vAlign=top width=34><FONT face="Times New Roman, Times, Serif" size=2>4.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD vAlign=top width="556"><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>A minimum closing bid price of $1.00 per share of common stock, without falling below this minimum
bid price for a period of 30 consecutive trading days; </FONT></TD></TR>
<TR>
<TD vAlign=top width="76"></TD>
<TD vAlign=top width="34"></TD>
<TD vAlign=top width="556">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=76></TD>
<TD vAlign=top width=34><FONT face="Times New Roman, Times, Serif" size=2>5.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD vAlign=top width="556"><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>At least two market makers; and</FONT></TD></TR>
<TR>
<TD vAlign=top width="76"></TD>
<TD vAlign=top width="34"></TD>
<TD vAlign=top width="556">&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=76></TD>
<TD vAlign=top width=34><FONT face="Times New Roman, Times, Serif" size=2>6.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD vAlign=top width="556"><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>At least 300 stockholders, each holding at least 100 shares of common stock. </FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We cannot guarantee that we will be able to maintain the minimum bid price requirement or maintain
any of the other requirements in the future. The market price of our common stock has generally been
highly volatile. During fiscal year 2004, the trading price of our common stock on the Nasdaq SmallCap
Market ranged from $0.60 per share to $3.14 per share. If we fail to meet any of the Nasdaq SmallCap
Market listing requirements, the market value of our common stock could fall and holders of common
stock would likely find it more difficult to dispose of the common stock.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our common stock is delisted, we would apply to have our common stock quoted on the over-the-counter
electronic bulletin board. Upon being delisted, however, our common stock will become subject to
the regulations of the Securities and Exchange Commission relating to the market for penny stocks.
Penny stock, as defined by the Penny Stock Reform Act, is any equity security not traded on a national
securities exchange or quoted on the NASDAQ National or SmallCap Market, that has a market price
of less than $5.00 per share. The penny stock regulations generally require that a disclosure schedule
explaining the penny stock market and the risks associated therewith be delivered to purchasers of
penny stocks and impose various sales practice requirements on broker-dealers who sell penny stocks
to persons other than established customers and accredited investors. The broker-dealer must make
a suitability determination for each purchaser and receive the purchaser&#146;s written agreement
prior to the sale. In addition, the broker-dealer must make certain mandated disclosures, including
the actual sale or purchase price and actual bid offer quotations, as well as the compensation to
be received by the broker-dealer and certain associated persons. The regulations applicable to penny
stocks may severely affect the market liquidity for our common stock and could limit your ability
to sell your securities in the secondary market. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>The Sale Of Substantial Shares Of Our Common Stock May Depress Our Stock Price.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of April 30, 2004, we had 141,268,182 shares of common stock outstanding, and the last reported sales
price of our common stock was $1.67 per share on April 30, 2004. We could also issue up to approximately
&shy;&shy;&shy;&shy;&shy;27,716,000 additional shares of common stock upon the exercise of outstanding
options and warrants as further described in the following table:</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>26</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<TABLE WIDTH=75% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH align="left"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Description of instrument</FONT></TH>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Number of<br>
      Shares <br>
      Outstanding</FONT></TH>
    <TH>&nbsp;</TH>
    <TH>&nbsp;</TH>
    <TH><font face="Times New Roman, Times, Serif" size=1>Weighted Average Per<br>
      Share Exercise Price</font></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH><hr align="left" width="120" size="1" noshade  color="black"></TH>
    <TH><hr width="100%" color="black" size="1" ></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><hr width="100%" color="black" size="1" ></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Common shares issuable upon exercise of</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD width="21%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>outstanding stock options</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11,704,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.48</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>

  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Common shares issuable upon exercise of outstanding warrants</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>16,012,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.60</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD ALIGN=RIGHT><HR NOSHADE color="black" SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE color="black" SIZE=1></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>27,716,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.55</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD ALIGN=RIGHT><HR NOSHADE color="black" SIZE=2></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE color="black" SIZE=2></TD>
    <TD></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of
the total warrants and options outstanding as of April 30, 2004, approximately 17,309,000 option
and warrants would be considered dilutive to stockholders because we would receive an amount per
share which is less than the market price of our common stock at April 30, 2004. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>Our Highly Volatile Stock Price And Trading Volume May Adversely Affect The Liquidity Of Our Common
Stock.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
market price of our common stock and the market prices of securities of companies in the biotechnology
sector have generally been highly volatile and are likely to continue to be highly volatile.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows the high and low sales price and trading volume of our common stock for each
quarter in the three years ended April 30, 2004: </FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Common Stock</FONT><FONT FACE="Times New Roman, Times, Serif" SIZE=1><br>
      Sales Price </FONT></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Common Stock</FONT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> Daily<br>
      Trading Volume<br>
      (000&#146;s omitted)</FONT></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=5><hr width="100%" color="black" size="1" ></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=3><hr width="100%" color="black" size="1" ></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>High</FONT></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Low</FONT></TH>
    <TH>&nbsp;</TH>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1>High</FONT></TH>
    <TH>&nbsp;</TH>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Low</FONT></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=2><hr width="100%" color="black" size="1" ></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><hr width="100%" color="black" size="1" ></TH>
    <TH>&nbsp;</TH>
    <TH><hr width="100%" color="black" size="1" ></TH>
    <TH>&nbsp;</TH>
    <TH><hr width="100%" color="black" size="1" ></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><strong>Fiscal Year 2004</strong></FONT></TD>
    <TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended April 30, 2004</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.85</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.56</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,550</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>320</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended January 31, 2004</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3.14</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.01</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6,062</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>201</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended October 31, 2003</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.44</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.25</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>18,060</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>314</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended July 31, 2003</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.19</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.60</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12,249</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>255</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><strong>Fiscal Year 2003</strong></FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended April 30, 2003</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.85</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.44</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,239</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>94</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended January 31, 2003</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.20</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.50</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,619</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>59</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended October 31, 2002</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.93</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.35</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,696</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>104</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended July 31, 2002</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.29</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.66</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,686</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>113</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><strong>Fiscal Year 2002</strong></FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD></TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended April 30, 2002</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.90</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.50</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>751</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>135</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended January 31, 2002</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4.00</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.32</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,525</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>73</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended October 31, 2001</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.23</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.81</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,265</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>117</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended July 31, 2001</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3.50</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.21</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,127</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>127</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;The market price of our common stock may be significantly impacted by many factors, including,
but not limited to:</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>27</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=42></TD>
<TD width=24 align="center" vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Announcements of technological innovations or new commercial products by us or our competitors;</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD align="center" vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=42></TD>
<TD width=24 align="center" vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Publicity regarding actual or potential clinical trial results relating to products under development
by us or our competitors;</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD align="center" vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=42></TD>
<TD width=24 align="center" vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Our financial results or that of our competitors;</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD align="center" vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=42></TD>
<TD width=24 align="center" vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Announcements of licensing agreements, joint ventures, strategic alliances, and any other transaction
that involves the sale or use of our technologies or competitive technologies;</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD align="center" vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=42></TD>
<TD width=24 align="center" vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Developments and/or disputes concerning our patent or proprietary rights;</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD align="center" vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=42></TD>
<TD width=24 align="center" vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Regulatory developments and product safety concerns;</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD align="center" vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=42></TD>
<TD width=24 align="center" vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>General stock trends in the biotechnology and pharmaceutical industry sectors;</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD align="center" vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=42></TD>
<TD width=24 align="center" vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Economic trends and other external factors, including but not limited to, interest rate fluctuations,
economic recession, inflation, foreign market trends, national crisis, and disasters; and</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD align="center" vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=42></TD>
<TD width=24 align="center" vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Health care reimbursement reform and cost-containment measures implemented by government agencies.
</FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
and other external factors have caused and may continue to cause the market price and demand for
our common stock to fluctuate substantially, which may limit or prevent investors from readily selling
their shares of common stock and may otherwise negatively affect the liquidity of our common stock.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>We May Become Involved in Lawsuits to Protect or Enforce Our Patents That Would Be Expensive and Time
Consuming.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to protect or enforce our patent rights, we may initiate patent litigation against third parties.
In addition, we may become subject to interference or opposition proceedings conducted in patent
and trademark offices to determine the priority of inventions. The defense of intellectual property
rights, including patent rights through lawsuits, interference or opposition proceedings, and other
legal and administrative proceedings, would be costly and divert our technical and management personnel
from their normal responsibilities. An adverse determination of any litigation or defense proceedings
could put our patent application at risk of not issuing.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
because of the substantial amount of discovery required in connection with intellectual property
litigation, there is a risk that some of our confidential information could be compromised by disclosure
during this type of litigation. For example, during the course of this kind of litigation, confidential
information may be inadvertently disclosed in the form of documents or testimony in connection with
discovery requests, depositions or trial testimony. This disclosure could materially adversely affect
our business and financial results.</FONT></P><B><I></I></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>28</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>We May Not Be Able To Compete With Our Competitors In The Biotechnology Industry Because Many Of Them
Have Greater Resources Than We Do And They Are Further Along In Their Development Efforts.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The

biotechnology industry is intensely competitive. We face competition from pharmaceutical companies,

pharmaceutical divisions of chemical companies, and biotechnology companies of various sizes. Some

or all of these companies may have greater financial resources, larger technical staffs, and larger

research budgets than we have, as well as greater experience in developing products and running
clinical
trials. We expect to continue to experience significant and increasing levels of competition
in the
future. In addition, there may be other companies which are currently developing competitive
technologies
and products or which may in the future develop technologies and products which are
comparable or
superior to our technologies and products. The FDA has approved our Cotara&#153;
registration protocol
for the treatment of brain cancer, for which we are seeking a partner or
grant support prior to commencing
the study. Companies conducting late stage clinical trials in
brain cancer that may complete with
us include, among others, Xenova&#146;s, Allos Therapeutics,
Inc. and NeoPharm. Xenova Group plc
has begun patient dosing in a phase III clinical trial of TransMID&#153;
for the treatment of progressive
or recurrent non-operable glioblastoma multiforme. Allos Therapeutics,
Inc. is developing RSR13 (efaproxiral)
for the treatment of patients with brain metastases originating
from breast cancer in a phase III
study. NeoPharm is developing IL13-PE38QQR for the treatment
of recurrent glioblastoma multiforme
in a Phase III study. Most of our other products are in early
stages of development or clinical trials,
including Tarvacin&#153;. We anticipate Tarvacin&#153;
will enter clinical trials later this calendar
year for the treatment of various solid tumor cancers.
As for Tarvacin&#153;, there are a number
of possible competitors with approved products or developing
targeted agents in combination with
standard chemotherapy,&nbsp;including but not limited to, Avastin&#153;
by Genentech, Iressa&#174;
by AstraZeneca, Gleevec&#174; by Novartis, Tarceva&#153; by OSI Pharmaceuticals
and Genetech, Erbitux&#153;
by ImClone, and panitumumab by Abgenix. Due to the significant number
of companies attempting to
develop cancer therapeutics combined with the fact that our other products
are generally in early
stages of development, we cannot provide an accurate listing of all possible competitors at this stage of development.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>New and Potential New Accounting Pronouncements May Impact Our Future Financial Position and Results
of Operations</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
may be potential new accounting pronouncements or regulatory rulings, which may have an impact on
our future financial position and results of operations. In particular, there are a number of rule
changes and proposed legislative initiatives following the recent corporate bankruptcies and failures
which could result in changes in accounting rules, including the accounting for employee stock options
as an expense. These and other potential changes could materially impact our assets and liabilities,
and the expenses we report under generally accepted accounting principles, and could adversely affect
our operating results or financial condition. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>If We Lose Qualified Management and Scientific Personnel or Are Unable to Attract and Retain Such Personnel,
We May Be Unable to Successfully Develop our Products or We May be Significantly Delayed in Developing
Our Products. </I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></B> Our success is dependent, in part, upon a limited number of key executive officers, each of whom is
an at-will employee, and our scientific researchers. For example, because of his extensive understanding
of our technologies and product development programs, the loss of Mr. Steven King, our President
and Chief Executive Officer, would adversely affect our development efforts and clinical trial programs
during the 6 to 12 month period we estimate it would take to find and train a qualified replacement. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also believe that our future success will depend largely upon our ability to attract and retain highly-skilled
research and development and technical personnel. We face intense competition in our recruiting activities,
including competition from larger companies with greater resources. We do not know if we will be
successful in attracting or retaining skilled personnel. The loss of certain key employees or our
inability to attract and retain other qualified employees could negatively affect our operations
and financial performance.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>29</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>The Manufacture of Our Products and the Products of Avid&#146;s Customers is Subject to Government
Regulation</I></B> &nbsp;</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Avid
is generally required to maintain compliance with current Good Manufacturing Practice, or cGMP, and
is subject to inspections by the FDA or comparable agencies in other jurisdictions to confirm this
compliance. Any changes of suppliers or modifications of methods of manufacturing require amending
our application to the FDA. Our inability to demonstrate ongoing cGMP compliance could require us
to suspend or terminate the manufacture of our products or those of Avid&#146;s third party customers.
Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or
storage of our products or those of Avid&#146;s third party customers as a result of a failure of
our facilities to pass any regulatory agency inspection could significantly impair (i) our ability
to advance our products through clinical trials, and (ii) Avid&#146;s ability to generate revenue.
This could increase our costs, cause us to lose revenue or market share and damage our reputation.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>If We Sell Avid Bioservices, We Could Experience Difficulties or Delays in Product Manufacturing Which
Could Harm Our Business</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the past fiscal year, we have had discussions with several parties interested in either partnering
or acquiring Avid. Given our anticipated drug development plans over the next several years, we believe
maintaining our own facility may result in significant cost savings. Such savings must be considered
when reviewing a proposal to partner or sell Avid. If the right opportunity and acceptable terms
are presented to us, we may enter into a transaction for the sale or Avid. Our wholly-owned subsidiary,
Avid, currently produces all of our products at our manufacturing facilities located in Tustin, California.
If we sell all or a portion of Avid, we would become dependent on the buyer of Avid, and possibly
other third party manufacturers, for all of our manufacturing needs. Even though we would require
certain clauses in any agreement to protect our rights and continued manufacturing needs, problems
or interruptions with any such manufacturer&#146;s processes could result in failure to produce adequate
clinical product supplies, which could require us to delay preclinical development and clinical trials.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A number
of factors could cause interruptions, including the inability of a supplier to provide raw materials
used for manufacture of our products, equipment malfunctions or failures, damage to a facility due
to natural disasters, including earthquakes as Avid&#146;s facilities are located in an area where
earthquakes could occur, changes in FDA regulatory requirements or standards that require modifications
to our manufacturing processes, action by the FDA or by the Company that results in the halting or
slowdown of production of one or more of our products due to regulatory issues, a contract manufacturer
going out of business or failing to produce product as contractually required or other similar factors.
Because our manufacturing processes and those of our contractors are highly complex and are subject
to a lengthy FDA approval process, alternative qualified production capacity may not be available
on a timely basis. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a2"></a>ITEM 2. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U></U> <U>PROPERTIES</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The Company&#146;s corporate, research and development, and clinical trial operations are located in
two Company-leased office and laboratory buildings with aggregate square footage of approximately
47,770 feet. The facilities are adjacent to one another and are located at 14272 and 14282 Franklin
Avenue, Tustin, California 92780-7017. The Company currently makes combined monthly lease payments
of approximately $60,000 for these facilities with a 3.35% rental increase every two years. The next
rental increase is scheduled for December 2004. The lease, which commenced in December 1998, has
an initial twelve-year term with two five-year term extensions. The Company believes its facilities
are adequate for its current needs and that suitable additional substitute space would be available
if needed.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>30</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a3"></a>ITEM 3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U></U><U>LEGAL PROCEEDINGS</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
the Company is not a party to any legal proceedings as of April 30, 2004, the Company is currently
investigating whether certain technologies discovered and developed at the University of Southern
California (&#147;USC&#148;) and subsequently licensed to&nbsp;a private company, Pivotal BioSciences,
Inc., an entity we believe is partially owned by the principal investigator and others at USC, were
developed&nbsp;using&nbsp;resources under the Company&#146;s sponsored research agreement with USC
and/or funding provided from another source for which the Company has geographic technology rights.
The Company is in active discussions with Pivotal BioSciences, Inc. to resolve
the matter in an amicable manner. The current investigation does not affect the Company&#146;s current rights to its technologies under
development nor should it have any effect, regardless of the outcome of the investigation, on the
development of any of the Company&#146;s existing technologies. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a4"></a>ITEM 4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U></U><U>SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS</U></B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
were no matters submitted to a vote of security holders during the quarter ended April 30, 2004. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><U>PART II</U></B></FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top width=96><b><font size="2" face="Times New Roman, Times, serif"><a name="a5"></a>ITEM 5.</font></b></TD>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B><U>MARKET FOR REGISTRANT&#146;S COMMON EQUITY AND RELATED STOCKHOLDERS&#146; MATTERS</U></B></FONT></TD>
  </TR>
</TABLE>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>(a)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> <I>Market Information.</I> &nbsp;The Company is listed on the SmallCap market of the Nasdaq Stock Market under the trading symbol
&#147;PPHM&#148;. The following table shows the high and low sales price of the Company&#146;s common
stock for each quarter in the two years ended April 30, 2004: </FONT></P>
<TABLE WIDTH=600 BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TH>
    <TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Common Stock Sales Price </FONT>    </TH>
    <td><font size="1">&nbsp;</font></td>
  </TR>
  <TR VALIGN=Bottom>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>High</FONT>
        <HR color="#000000" SIZE=1></TH>
    <td>&nbsp;</td>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Low</FONT>
        <HR color=black SIZE=1></TH>
    <td><font size="1">&nbsp;</font></td>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD WIDTH=62% ALIGN=LEFT><b><i><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Fiscal Year 2004</FONT></i></b></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended April 30, 2004</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.85</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.56</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended January 31, 2004</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3.14</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.01</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended October 31, 2003</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.44</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.25</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended July 31, 2003</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.19</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.60</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8" >
    <TD colspan=7 ALIGN=LEFT><b><i><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Fiscal Year 2003</FONT></i></b></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended April 30, 2003</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.85</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.44</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended January 31, 2003</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.20</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.50</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended October 31, 2002</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.93</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.35</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Quarter Ended July 31, 2002</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.29</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.66</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>(b)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> <I>Holders.</I> &nbsp;As of June 30, 2004, the number of stockholders of record of the Company&#146;s common stock
was 5,884.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>(c)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> <I>Dividends.</I> &nbsp;No dividends on common stock have been declared or paid by the Company. The Company intends
to employ all available funds for the development of its business and, accordingly, does not intend
to pay any cash dividends in the foreseeable future.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recent sales of unregistered securities.</I> &nbsp;None.</FONT></P>
<B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>31</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a6"></a>ITEM 6.  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U></U><U>SELECTED FINANCIAL DATA</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> The following selected financial data has been derived from audited consolidated financial statements
of the Company for each of the five years in the period ended April 30, 2004. These selected financial
summaries should be read in conjunction with the financial information contained for each of the
three years in the period ended April 30, 2004, included in the consolidated financial statements
and notes thereto, Management&#146;s Discussion and Analysis of Results of Operations and Financial
Condition, and other information provided elsewhere herein.</FONT></P>
<TABLE WIDTH=100% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TD colspan="15" ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2><strong>CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
    </strong></FONT><strong><font size="2">FIVE YEARS ENDED APRIL 30, </font></strong></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="15" ALIGN=LEFT><hr size="1" color="black"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2002</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2001</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2000</FONT></strong></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr size="1" color="black"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr size="1" color="black"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr size="1" color="black"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr size="1" color="black"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr size="1" color="black"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Revenues</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3,314,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3,921,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3,766,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 979,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 50,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net loss</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (14,345,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (11,559,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (11,718,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (9,535,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (14,514,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#EAF9E8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net loss attributable to common stockholders</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (14,345,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (11,559,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (11,718,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (9,535,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (14,516,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Basic and diluted loss per share</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.11</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.10</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.11</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.10</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.18</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Weighted average number of shares of common stock</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>134,299,407</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>116,468,353</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>104,540,204</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>95,212,423</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>81,195,049</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
</TABLE>
<br>
<TABLE WIDTH=100% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH>&nbsp;</TH>
    <TH COLSPAN=14>&nbsp;</TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH colspan="15"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CONSOLIDATED BALANCE SHEET DATA<BR>
AS OF APRIL 30, </FONT></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH colspan="15">
    <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2002</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2001</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2000</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cash and cash equivalents</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 14,884,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3,137,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 6,072,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 6,327,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,131,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Working capital (deficit)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 13,631,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,949,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,007,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,446,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (3,668,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total assets</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 19,137,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5,399,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 7,866,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 7,900,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5,953,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Long-term debt</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 760,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 89,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Accumulated deficit</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (154,351,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (140,006,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (128,447,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (116,729,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (107,194,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Stockholders&#146; equity (deficit)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 14,759,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,131,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5,083,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,686,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (2,721,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
</TABLE>
<B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>32</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
<TR>
<TD vAlign=top width=96><b><font size="2" face="Times New Roman, Times, serif"><a name="a7"></a>ITEM 7.</font></b></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B><U>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</U></B></FONT></TD>
</TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The following discussion is included to describe the Company&#146;s financial position and results
of operations for each of the three years in the period ended April 30, 2004. The consolidated financial
statements and notes thereto contain detailed information that should be referred to in conjunction
with this discussion.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Overview</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Peregrine Pharmaceuticals, Inc., (&#147;Peregrine&#148;) located in Tustin, California, is a biotechnology
company engaged in the research, development and manufacturing of biotechnology products. We are
organized into two reportable operating segments: (i) Peregrine, the parent company, is engaged in
the research and development of novel therapeutics and (ii) Avid Bioservices, Inc., (&#147;Avid&#148;)
a wholly-owned subsidiary, is engaged in providing contract manufacturing and development of biologics
for biopharmaceutical and biotechnology companies. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Results of Operations</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table compares the statement of operations for the fiscal years ended April 30, 2004, April
30, 2003 and April 30, 2002. This table provides you with an overview of the changes in the statement
of operations for the comparative periods, which changes are further discussed below. </FONT></P>
<table width=100% border=0 align="center" cellpadding=0 cellspacing=0>
  <tr valign=Bottom>
    <th><font face="Times New Roman, Times, Serif" size=1></font></th>
    <th colspan=8><font face="Times New Roman, Times, Serif" size=1>Years Ended<br>
      April 30, </font>
        <hr color=black size=1>
    </th>
    <th>&nbsp;</th>
    <th colspan=8><font face="Times New Roman, Times, Serif" size=1>Years Ended<br>
      April 30, </font>
        <hr color=black size=1>
    </th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom>
    <th><font face="Times New Roman, Times, Serif" size=1></font></th>
    <th colspan="2"><font face="Times New Roman, Times, Serif" size=1>2004</font>
        <hr color=black size=1></th>
    <th>&nbsp;</th>
    <th colspan="2"><font face="Times New Roman, Times, Serif" size=1>2003</font>
        <hr color=black size=1></th>
    <th>&nbsp;</th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>$ Change</font>
        <hr color=black size=1></th>
    <th>&nbsp;</th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>2003</font>
        <hr color=black size=1></th>
    <th>&nbsp;</th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>2002</font>
        <hr color=black size=1></th>
    <th>&nbsp;</th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>$ Change</font>
        <hr color=black size=1></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom>
    <th><font face="Times New Roman, Times, Serif" size=1></font></th>
    <th colspan=8 valign="top"><font face="Times New Roman, Times, Serif" size=1><b><i>(in thousands)</i></b></font>
    </th>
    <th valign="top">&nbsp;</th>
    <th colspan=8 valign="top"><font face="Times New Roman, Times, Serif" size=1><b><i>(in thousands)</i></b></font>
    </th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT bgcolor="#eaf9e8"><b><font face="Times New Roman, Times, Serif" size=2>REVENUES:</font></b></td>
    <td width=1% align=RIGHT>&nbsp;</td>
    <td width=8% align=RIGHT><font face="Times New Roman, Times, Serif" size=2></font></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=8% align=RIGHT><font face="Times New Roman, Times, Serif" size=2></font></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=8% align=RIGHT><font face="Times New Roman, Times, Serif" size=2></font></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=8% align=RIGHT><font face="Times New Roman, Times, Serif" size=2></font></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=8% align=RIGHT><font face="Times New Roman, Times, Serif" size=2></font></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=8% align=RIGHT><font face="Times New Roman, Times, Serif" size=2></font></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Contract manufacturing</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 3,039</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 3,346</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (307</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 3,346</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 46</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 3,300</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>License revenue</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>275</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>575</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(300</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>575</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>3,720</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT bgcolor="#eaf9e8"><font face="Times New Roman, Times, Serif" size=2>(3,145</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan="2" align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;Total revenues</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>3,314</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>3,921</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(607</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>3,921</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>3,766</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>155</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td colspan=19 align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT colspan=19><b><font face="Times New Roman, Times, Serif" size=2>COST AND EXPENSES:</font></b></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Cost of contract manufacturing</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>2,212</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>2,860</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(648</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>2,860</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>12</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>2,848</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Research and development</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>9,673</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>8,744</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>929</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>8,744</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>11,494</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(2,750</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Selling, general and administrative</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>4,225</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>2,987</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>1,238</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>2,987</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>2,478</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>509</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Purchased in-process research</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;and development</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>2,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(2,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan="2" align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;Total cost and expenses</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>16,110</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>14,591</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>1,519</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>14,591</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>15,984</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(1,393</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><b><font face="Times New Roman, Times, Serif" size=2>LOSS FROM OPERATIONS</font></b></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(12,796</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(10,670</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(2,126</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(10,670</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(12,218</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>1,548</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td colspan=19 align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT colspan=19><b><font face="Times New Roman, Times, Serif" size=2>OTHER INCOME</font></b></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Interest and other income</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>291</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>291</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>291</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>512</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(221</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Interest and other expense</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(1,840</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(1,180</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(660</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(1,180</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(12</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(1,168</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan="2" align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><HR COLOR=Black SIZE=1></td>
    <td></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><b><font face="Times New Roman, Times, Serif" size=2>NET LOSS</font></b></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (14,345</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (11,559</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (2,786</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (11,559</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (11,718</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 159</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan="2" align=RIGHT><hr noshade color=Black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr noshade color=Black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr noshade color=Black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr noshade color=Black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr noshade color=Black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr noshade color=Black size=2></td>
    <td></td>
  </tr>
</table>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>33</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Total Revenues</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2004 Compared to the Year Ended April 30, 2003:</I> &nbsp;</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The decrease in revenues of $607,000 during the year ended April 30, 2004 compared to the prior year
was primarily due to a reduction in contract manufacturing revenue of $307,000 combined with a decrease
in license revenue of $300,000. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The current year decrease in contract manufacturing revenue was primarily due to fewer equivalent manufacturing
days billed in fiscal year 2004. During fiscal year 2004, we actively worked primarily on six antibody
projects compared to primarily two projects in the prior year for unrelated entities. The majority
of our current year projects were in the process development stage which is performed prior to actual
manufacturing in the bioreactors. We expect to complete the manufacturing of four of the six current
antibodies in development during fiscal year 2005. We expect contract manufacturing revenue to increase
during fiscal year 2005 based on the anticipated completion of projects under our current contract
manufacturing agreements and the anticipated demand for Avid&#146;s services. In addition, we will
double Avid&#146;s production capacity in fiscal year 2005 through the addition of a 1,000 liter
bioreactor. Although Avid currently has a number of active projects and outstanding project proposals
with various potential customers, we cannot estimate nor can we determine the likelihood that we
will be successful in completing these ongoing projects or converting any of these proposals into
definitive agreements during fiscal year 2005.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The current year decrease in license revenue was primarily due to the prior year recognition of $350,000
in license revenue associated with certain TNT rights licensed to Merck KGaA while we had no corresponding
revenue recognized during the current year. We cannot estimate nor can we determine the likelihood
that we will be successful in entering into any additional definitive license agreements during the
next fiscal year. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2003 Compared to the Year Ended April 30, 2002:</I> &nbsp;</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increase in total revenues of $155,000 during the year ended April 30, 2003 compared to the prior
year was primarily due to a $3,300,000 increase in contract manufacturing revenue offset by a $3,145,000
decrease in license revenue. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increase in contract manufacturing revenue was due to services provided by our wholly-owned subsidiary,
Avid, which we announced its formation and start-up in January 2002. Avid signed its initial two
contracts in March 2002 and minimal revenues were generated during fiscal year ended April 30, 2002.
During our first full year of operations, Avid completed its initial contracts and delivered clinical
product to its two primary customers for the development of two antibodies projects.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The decrease in license revenue was primarily due to the recognition of a $3,000,000 up-front license
fee during fiscal year 2002 when we assumed the Oncolym licensing rights from Schering A.G. and met
all obligations under the agreement. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>34</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Cost of Contract Manufacturing</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2004 Compared to the Year Ended April 30, 2003:&nbsp;</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The decrease in cost of contract manufacturing of $648,000 during the year ended April 30, 2004 compared
to the prior year was primarily due to Peregrine&#146;s increased use of the manufacturing facility
for its products under development and the related costs being allocated to research and development
expenses. During the current year, we increased our antibody process development efforts associated
with the Anti-Phospholipid Therapy program and manufactured the Tarvacin&#153; antibody for research
and toxicology studies required for the anticipated commencement of Phase I clinical studies during
calendar year 2004. The decrease in cost of contract manufacturing was further supplemented by a
decrease in the cost of raw materials for projects completed during the current fiscal year.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2003 Compared to the Year Ended April 30, 2002:</I> &nbsp;</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increase in cost of contract manufacturing of $2,848,000 during the year ended April 30, 2003 compared
to the prior year is primarily due to the increase in contract manufacturing revenue and the additional
personnel costs required to operate a current Good Manufacturing Practices (&#147;cGMP&#148;) facility.
Prior to the formation of Avid, these costs were charged to research and development expense since
the manufacturing facility was fully utilized for Peregrine&#146;s product development efforts.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Research and Development Expenses</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2004 Compared to the Year Ended April 30, 2003:&nbsp;</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increase in research and development expenses of $929,000 during the year ended April 30, 2004
compared to the prior year was primarily due to an increase in, i) Anti-Phospholipid Therapy pre-clinical
development expenses, ii) manufacturing expenses, and iii) patent filing and maintenance fees. These
amounts were primarily offset by a decrease in clinical trial expenses. During the current year,
we expended an aggregate of $1,557,000 for antibody license and development fees and toxicology studies
associated with our Tarvacin&#153; preclinical program, which amount was not incurred in the prior
year. Manufacturing expenses increased $599,000 to $2,825,000 in fiscal year 2004 compared to $2,226,000
in fiscal year 2003 primarily due to our increased use of Avid&#146;s manufacturing facility to manufacture
material for our planned Phase I clinical study using Tarvacin&#153;, which study we plan to initiate
during the current calendar year. In addition, patent filing and maintenance fees increased $403,000
to $1,335,000 in fiscal year 2004 compared to $933,000 in fiscal year 2003 primarily due to increase
filing fees related to the Vascular Targeting Agent technology and the Anti-Phospholipid Therapy technology. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>These increases in research and development expenses were offset by a current year decrease in clinical
trial program expenses and stock-based compensation expense. During fiscal year 2004, clinical trial
program expenses decreased $1,394,000 to $476,000 compared to $1,871,000 in fiscal year 2003. This
current year decrease was primarily due to costs incurred in the prior year of $762,000 related to
clinical trial start-up activities associated with seeking protocol approval for the Cotara&#153;
registration trial which amount was not incurrent in the current year. This was supplemented by a
decrease in patient fees of $245,000 due to the treatment of fewer patients in the current year since
we only enrolled patients in our Phase I Cotara&#153; study at Stanford during fiscal year 2004.
Moreover, stock-based compensation expense decreased $330,000 to $199,000 in fiscal year 2004 compared
to $529,000 in fiscal year 2003 due to a decrease in amortization expenses associated with the fair
value of options granted to non-employee consultants performing research and development activities
that were fully amortized in the prior year period. The options were valued using the Black-Scholes
valuation model and are being amortized over the estimated period of service or related vesting period.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>35</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We expect research and development expenses to increase over the near term primarily under the following
ongoing research and development programs:</FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="666" border="0">

<TR>
<TD width=73></TD>
<TD vAlign=top width=29><FONT face="Times New Roman, Times, Serif" size=2>1.</FONT></TD>
<TD vAlign=top width="564"><FONT face="Times New Roman, Times, Serif" size=2>Cotara&#153; clinical program at Stanford University for the treatment of colorectal cancer; </FONT></TD></TR>
<TR>
<TD width="73"></TD>
<TD width="29"></TD>
<TD width="564">&nbsp;</TD></TR>
<TR>
<TD width=73></TD>
<TD vAlign=top width=29><FONT face="Times New Roman, Times, Serif" size=2>2.</FONT></TD>
<TD vAlign=top width="564"><FONT face="Times New Roman, Times, Serif" size=2>Anti-Phospholipid Therapy pre-clinical and clinical programs for the anticipated commencement of Phase
I clinical trials during calendar year 2004; </FONT></TD></TR>
<TR>
<TD width="73"></TD>
<TD width="29"></TD>
<TD width="564">&nbsp;</TD></TR>
<TR>
<TD width=73></TD>
<TD vAlign=top width=29><FONT face="Times New Roman, Times, Serif" size=2>3.</FONT></TD>
<TD vAlign=top width="564"><FONT face="Times New Roman, Times, Serif" size=2>2C3 (anti-angiogenesis antibody) research and development program; </FONT></TD></TR>
<TR>
<TD width="73"></TD>
<TD width="29"></TD>
<TD width="564">&nbsp;</TD></TR>
<TR>
<TD width=73></TD>
<TD vAlign=top width=29><FONT face="Times New Roman, Times, Serif" size=2>4.</FONT></TD>
<TD vAlign=top width="564"><FONT face="Times New Roman, Times, Serif" size=2>Vascular Targeting Agent research and development program; and </FONT></TD></TR>
<TR>
<TD width="73"></TD>
<TD width="29"></TD>
<TD width="564">&nbsp;</TD></TR>
<TR>
<TD width=73></TD>
<TD vAlign=top width=29><FONT face="Times New Roman, Times, Serif" size=2>5.</FONT></TD>
<TD vAlign=top width="564"><FONT face="Times New Roman, Times, Serif" size=2>Vasopermeation Enhancement Agent research and development program. </FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Due to the number of ongoing research programs, if we fail to obtain additional funding during fiscal
year 2005, we may be forced to scale back our product development efforts, or our operations in a
manner that will ensure we can pay our obligations as they come due in the ordinary course of business
through at least April 30, 2005.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2003 Compared to the Year Ended April 30, 2002:&nbsp;</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The decrease in research and development expenses of $2,750,000 during the year ended April 30, 2003
compared to the prior year is primarily due to a decrease in clinical trial program expenses and
stock-based compensation expense combined with the allocation of labor and overhead expenses to cost
of contract manufacturing and inventories in relation to contract manufacturing services provided
by Avid to outside customers. During fiscal year 2003, clinical trial program expenses decreased
$1,166,000 to $1,871,000 compared to $3,037,000 in fiscal year 2002 primarily due to suspending all
clinical trial patient enrollments other than our ongoing trial at Stanford University Medical Center
during fiscal year 2003, in order to focus our efforts on licensing our technologies. This decrease
in clinical trial program expenses was offset by an increase in expenses of $762,000 incurred in
the first quarter of fiscal year 2003 associated with seeking protocol approval from the Food and
Drug Administration and start-up activities to support a previously planned registration clinical
trial for the treatment of brain cancer using Cotara&#153;. Stock-based compensation expense decreased
$169,000 to $529,000 in fiscal year 2003 compared to $698,000 in fiscal year 2002 due to a decrease
in amortization expenses associated with the fair value of options granted to non-employee consultants
performing research and development activities that were fully amortized in the prior year period.
The options were valued using the Black-Scholes valuation model and are being amortized over the
estimated period of service or related vesting period. In addition, the decrease in research and
development expenses was further supplemented by the allocation of labor and overhead expenses that
were allocated to cost of contract manufacturing and inventories in relation to contract manufacturing
services provided by Avid to outside customers in the amount of $2,237,000. The above decreases in
research and development expenses were offset by an increase in manufacturing expenses primarily
associated with the increase in our supply of Cotara&#153; during the first quarter of fiscal year
2003 for use in the planned registration clinical trial for the treatment of brain cancer in the amount of $53,000. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>36</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The following represents the research and development expenses (&#147;R&amp;D Expenses&#148;) we have
incurred by each major platform technology under development:</FONT></P>
<TABLE WIDTH=100% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1><i>Platform Technology<BR>
      under Development </i></FONT>
    <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1><i>R&amp;D Expenses-<BR>
      Year Ended<BR>
      April 30, 2002 </i></FONT>
    <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1><i>R&amp;D Expenses-<BR>
      Year Ended<BR>
      April 30, 2003 </i></FONT>
    <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1><i>R&amp;D Expenses-<BR>
      Year Ended<BR>
      April 30, 2004 </i></FONT>
    <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1><i>R&amp;D Expenses-<br>
      May 1, 1998 to <br>
      April 30, 2004 </i></FONT>
    <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>TNT (Cotara&#153;)</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 7,352,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,913,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,350,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 25,633,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>APT (Tarvacin&#153;)</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,077,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,077,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>VTA and Anti-Angiogenesis</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,523,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,325,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,819,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8,153,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>VEA</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,392,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,187,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,191,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,801,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>LYM (Oncolym)</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,227,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>319,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>236,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13,434,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=2></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total research and development</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 11,494,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 8,744,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 9,673,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 55,098,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=2></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=Black SIZE=2></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=Black SIZE=2></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=Black SIZE=2></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=Black SIZE=2></TD>
    <TD></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>From inception to April 1998, we expensed $20,898,000 on research and development of our product candidates,
with the costs primarily being closely split between the TNT and Oncolym technologies. In addition
to the above costs, we expensed an aggregate of $32,004,000 for the acquisition of our TNT and VTA
technologies, which were acquired during fiscal years 1995 and 1997, respectively. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Looking beyond the next twelve months, it is extremely difficult for us to reasonably estimate all
future research and development costs associated with each of our technologies due to the number
of unknowns and uncertainties associated with pre-clinical and clinical trial development. These
unknown variables and uncertainties include, but are not limited to:</FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=48></TD>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>The uncertainty of our capital resources to fund research, development and clinical studies beyond
the current fiscal year; </FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=48></TD>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>The uncertainty of future costs associated with our pre-clinical candidates, Anti-Phospholipid Therapy,
Vasopermeation Enhancement Agents and Vascular Targeting Agents, which costs are dependent on the
success of pre-clinical development. We are uncertain whether or not these product candidates will
be successful and we are uncertain whether or not we will incur any additional costs beyond pre-clinical
development; </FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=48></TD>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>The uncertainty of future clinical trial results; </FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=48></TD>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>The uncertainty of the number of patients to be treated in any clinical trial;</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=48></TD>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>The uncertainty of the Food and Drug Administration allowing our studies to move forward from Phase
I clinical studies to Phase II and Phase III clinical studies; </FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=48></TD>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>The uncertainty of the rate at which patients are enrolled into any current or future study. Any delays
in clinical trials could significantly increase the cost of the study and would extend the estimated
completion dates.</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=48></TD>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>The uncertainty of terms related to potential future partnering or licensing arrangements; and</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=48></TD>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>The uncertainty of protocol changes and modifications in the design of our clinical trial studies,
which may increase or decrease our future costs.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>37</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We or our potential partners will need to do additional development and clinical testing prior to seeking
any regulatory approval for commercialization of our product candidates as all of our products are
in discovery, pre-clinical or clinical development. Testing, manufacturing, commercialization, advertising,
promotion, exporting and marketing, among other things, of our proposed products are subject to extensive
regulation by governmental authorities in the United States and other countries. The testing and
approval process requires substantial time, effort and financial resources, and we cannot guarantee
that any approval will be granted on a timely basis, if at all. Companies in the pharmaceutical and
biotechnology industries have suffered significant setbacks in conducting advanced human clinical
trials, even after obtaining promising results in earlier trials. Furthermore, the United States
Food and Drug Administration may suspend clinical trials at any time on various grounds, including
a finding that the subjects or patients are being exposed to an unacceptable health risk. Even if
regulatory approval of a product is granted, such approval may entail limitations on the indicated
uses for which it may be marketed. Accordingly, we or our potential partners may experience difficulties
and delays in obtaining necessary governmental clearances and approvals to market our products, and
we or our potential partners may not be able to obtain all necessary governmental clearances and
approvals to market our products.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Selling, General and Administrative Expenses</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2004 Compared to the Year Ended April 30, 2003: </I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Selling, general and administrative expenses consist primarily of compensation, board fees, facility,
travel, legal and accounting fees, insurance, and other expenses relating to our general management,
financial, administrative and business development activities. The increase in selling, general and
administrative expenses of $1,238,000 during the year ended April 30, 2004 compared to the prior
year is primarily due to an increase in i) compensation and related expenses, ii) director fees,
and iii) legal fees. During fiscal year 2004, compensation and related expenses increased $584,000
to $2,184,000 compared to $1,600,000 in fiscal year 2003 primarily due to business development efforts
of Avid (to generate new customers and business) and Peregrine (to license our technologies under
development). We incurred aggregate director fees of $464,000 in the current year associated with
increased oversight responsibilities mandated by the Sarbanes-Oxley Act of 2002. These fees were
not incurred in the prior year as directors did not receive any cash compensation other than the
reimbursement of expenses. In addition during fiscal year 2004, legal fees increased $120,000 to
$196,000 compared to $76,000 in fiscal year 2003 primarily due to an increase in corporate activities
associated with generating new business for Avid and our increased focus to license our technologies under development.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2003 Compared to the Year Ended April 30, 2002:</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increase in selling, general and administrative expenses of $509,000 during the year ended April
30, 2003 compared to the prior year is primarily due to an increase in compensation and related expenses.
During fiscal year 2003, compensation and related expenses increased $456,000 to $1,600,000 compared
to $1,144,000 in fiscal year 2002 primarily due to business development activities associated with
the formation and start-up of Avid combined with our efforts to license our technologies under development.
</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Purchased In-process Research and Development</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2003 Compared to the Year Ended April 30, 2002:&nbsp;</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The decrease in purchased in-process research and development expense of $2,000,000 during the year
ended April 30, 2003 compared to the prior year is due to a charge in fiscal year 2002 of $2,000,000
related to the dissolution of the joint venture with Oxigene, Inc. whereby we re-acquired all rights
to our intellectual property around our Vascular Targeting Agent technology for a cash fee of $2,000,000.</FONT></P><B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>38</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Interest and Other Income</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2003 Compared to the Year Ended April 30, 2002:&nbsp;</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The decrease in interest and other income of $221,000 during the year ended April 30, 2003 compared
to the prior year is primarily due to a decrease in interest income as a result of a lower average
cash balance on hand and lower prevailing interest rates during the fiscal year 2003 compared to
the prior fiscal year. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Interest and Other Expense</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2004 Compared to the Year Ended April 30, 2003:&nbsp;</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increase in interest and other expense of $660,000 during the year ended April 30, 2004 compared
to the prior year is primarily due to an increase in non-cash interest expense associated with the
amortization of the convertible debt discount and debt issuance costs related to an increase in convertible
debt conversions in the current year compared to the prior year. As of April 30, 2004, all outstanding
convertible debt was converted into common stock and the associated discount and debt issuance costs
were fully amortized (see Note 8-Convertible Debt to the consolidated financial statements). </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2003 Compared to the Year Ended April 30, 2002:&nbsp;</I></FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
increase in interest and other expense of $1,168,000 during the year ended April 30, 2003 compared
to the prior year is primarily due to an increase in interest expense associated with the issuance
of $3,750,000 in convertible debt during August 2002 combined with an increase in non-cash interest
expense of $1,017,000 resulting from the amortization of the convertible debt discount and related
debt issuance costs.</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following non-cash interest expense was included in Interest and other expense in the accompanying
consolidated statements of operations for fiscal years 2004, 2003 and 2002:</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
</TR></TABLE>
<br>
<TABLE WIDTH=70% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2002</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Interest and other expense, as reported</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,840,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,180,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 12,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Less interest and other expenses paid in cash</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(29,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(163,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(12,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black SIZE=1></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black SIZE=1></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black SIZE=1></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Interest, non-cash expense</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,811,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,017,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black SIZE=2></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black SIZE=2></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black SIZE=2></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
</TABLE>
<B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>39</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Critical Accounting Policies</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The methods, estimates and judgments we use in applying our most critical accounting policies have
a significant impact on the results we report in our consolidated financial statements. We evaluate
our estimates and judgments on an on-going basis. We base our estimates on historical experience
and on assumptions that we believe to be reasonable under the circumstances. Our experience and assumptions
form the basis for our judgments about the carrying value of assets and liabilities that are not
readily apparent from other sources. Actual results may vary from what we anticipate and different
assumptions or estimates about the future could change our reported results. We believe the following
accounting policies are the most critical to us, in that they are important to the portrayal of our
financial statements and they require our most difficult, subjective or complex judgments in the
preparation of our consolidated financial statements:&nbsp;</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Revenue Recognition</I>. We currently derive revenues primarily from licensing agreements associated with Peregrine&#146;s
technologies under development and from contract manufacturing services provided by Avid. We recognize
revenues pursuant to Staff Accounting Bulletin No. 101, <I>Revenue Recognition in Financial Statements</I>, as well as the recently issued Staff Accounting Bulletin No. 104, <I>Revenue Recognition</I>. These bulletins draw on existing accounting rules and provides specific guidance on how those accounting
rules should be applied. Revenue is generally realized or realizable and earned when (i) persuasive
evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii)
the seller&#146;s price to the buyer is fixed or determinable, and (iv) collectibility is reasonably
assured. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Revenues associated with licensing agreements primarily consist of nonrefundable up-front license fees
and milestones payments. Revenues under licensing agreements are recognized based on the performance
requirements of the agreement. Nonrefundable up-front license fees received under license agreements,
whereby continued performance or future obligations are considered inconsequential to the relevant
licensed technology, are generally recognized as revenue upon delivery of the technology. Milestone
payments are generally recognized as revenue upon completion of the milestone assuming there are
no other continuing obligations. Nonrefundable up-front license fees, whereby we have an ongoing
involvement or performance obligation, are generally recorded as deferred revenue and generally recognized
as revenue over the term of the performance obligation or relevant agreement. Under some license
agreements, the obligation period may not be contractually defined. Under these circumstances, we
must exercise judgment in estimating the period of time over which certain deliverables will be provided
to enable the licensee to practice the license. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;Contract manufacturing revenues are generally recognized once the service has been provided
and/or upon shipment of the product to the customer. We also record a provision for estimated contract
losses, if any, in the period in which they are determined. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In July 2000, the Emerging Issues Task Force (&#147;EITF&#148;) released Issue 99-19 (&#147;EITF 99-19&#148;),
<I>Reporting Revenue Gross as a Principal versus Net as an Agent</I>. EITF 99-19 summarized the EITF&#146;s views on when revenue should be recorded at the gross amount

billed to a customer because it has earned revenue from the sale of goods or services, or the net

amount retained (the amount billed to the customer less the amount paid to a supplier) because
it
has earned a fee or commission. In addition, the EITF released Issue 00-10 (&#147;EITF 00-10&#148;),
<I>Accounting for Shipping and Handling Fees and Costs</I>, and Issue 01-14 (&#147;EITF 01-14&#148;), <I>Income Statement Characterization of Reimbursements Received for &#147;Out-of-Pocket&#148; Expenses

Incurred</I>. EITF 00-10 summarized the EITF&#146;s views on how the seller of goods should classify in the income
statement amounts billed to a customer for shipping and handling and the costs associated with shipping
and handling. EITF 01-14 summarized the EITF&#146;s views on when the reimbursement of out-of-pocket
expenses should be characterized as revenue or as a reduction of expenses incurred. Our revenue recognition
policies are in compliance with EITF 99-19, EITF 00-10 and EITF 01-14 whereby we record revenue for
the gross amount billed to customers (the cost of raw materials, supplies, and shipping, plus the
related handling mark-up fee) and record the cost of the amounts billed as cost of sales as we act
as a principal in these transactions. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>40</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allowance
for Doubtful Receivables</I>. We continually monitor our allowance for all receivables. A considerable amount of judgment is required
in assessing the ultimate realization of these receivables and we estimate an allowance for doubtful
accounts based on factors that appear reasonable under the circumstances.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Liquidity and Capital Resources</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Our cash and cash equivalents totaled $14,884,000 at April 30, 2004 compared to $3,137,000 at April
30, 2003. During the year ended April 30, 2004, we raised $23,659,000 in net proceeds under various
equity transactions (as further explained in our notes to the consolidated financial statements in
Item 8 of this report). Since inception, we have generally financed our operations primarily through
the sale of our common stock and issuance of convertible debt, which has been supplemented with payments
received from various licensing collaborations and through the revenues generated by Avid. We plan
to raise additional capital through the registered offer and sale of shares of our common stock from
our current shelf registration statement on Form S-3, File No. 333-109982, which as of June 30, 2004,
had approximately 8,757,000 shares available for possible future transactions, or through private
placements. However, given uncertain market conditions and the volatility of our stock price, we
may not be able to sell our securities in public offerings or private placements at prices and on
terms that are favorable to us, if at all.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the year ended April 30, 2004, cash used in operating activities increased $946,000 to $11,251,000
compared to $10,305,000 for the year ended April 30, 2003. Net cash used in investing activities
increased $488,000 to $661,000 for the year ended April 30, 2004 compared to $173,000 for the year
ended April 30, 2003. The increase in cash used in investing activities is primarily due to added
laboratory equipment combined with installment payments made on the planned 1,000-liter bioreactor
to be installed during calendar year 2004. Net cash provided by financing activities increased $16,116,000
to $23,659,000 for the year ended April 30, 2004 compared to net cash provided of $7,543,000 for
the year ended April 30, 2003. The increase in net cash provided by financing activities was due
to $23,659,000 in net proceeds received from the sale of our common stock and the exercise of options
and warrants during the year ended April 30, 2004. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We have expended substantial funds on the development of our product candidates and for clinical trials
and we have incurred negative cash flows from operations for the majority of our years since inception.
We expect negative cash flows from operations to continue until we are able to generate sufficient
revenue from the contract manufacturing services provided by Avid and/or from the licensing of Peregrine&#146;s
products under development. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>41</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Revenues earned by Avid during the year ended April 30, 2004 amounted to $3,039,000. We expect that
Avid will continue to generate revenues which should lower consolidated cash flows used in operations,
although we expect those near term revenues will be insufficient to cover consolidated cash flows
used in operations. As such, we will continue to need to raise additional capital to provide for
our operations, including the anticipated development and clinical trial costs of Tarvacin&#153;
and Cotara&#153;, the anticipated development costs associated with Anti-Phospholipid Therapy, Vasopermeation
Enhancement Agents (&#147;VEA&#146;s&#148;) and Vascular Targeting Agents (&#147;VTA&#146;s&#148;),
and the potential expansion of Avid&#146;s manufacturing capabilities. Our goal is to maintain sufficient
cash on hand at all times to fund operations for at least one year. If we fail to obtain additional
funding during fiscal year 2005, we may be forced to scale back our product development efforts,
or our operations in a manner that will ensure we can pay our obligations as they come due in the
ordinary course of business through at least April 30, 2005. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Assuming we do not raise any additional capital from financing activities or from the sale or licensing
of our technologies, and further assuming that Avid does not generate any additional revenues beyond
our current active contracts, we believe we have sufficient cash on hand to meet our obligations
on a timely basis through fiscal year 2005. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition to equity financing, we are always actively exploring various other sources of cash by
utilizing our many assets. We believe we have a broad intellectual property portfolio that allows
us to develop products in-house while at the same time we can out-license certain areas of the technology
we cannot focus on developing internally. In addition, for the products that we do develop internally,
we may seek a licensing or development partner after we have generated clinical proof of efficacy,
which we believe will generate the most value to the Company. We are also seeking to out-license
or partner products we do not have sufficient financial resources to develop internally, such as
the registration trial using Cotara&#153; for the treatment of brain cancer, which final stage trial
would require significant financial resources to complete. Such licensing or partnering arrangements
may require us to relinquish our rights to our technologies, products or marketing territories, or
to grant licenses on terms that are not favorable to us.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We also have the facilities of Avid that we may utilize for non-dilutive financing. During the past
fiscal year, we have had discussions with several parties interested in either partnering or acquiring
Avid. Provided that the right opportunity and financial terms are presented to us and further provided
that the manufacturing needs of our customers and Peregrine are not jeopardized,
we would
be open to a possible strategic transaction related to Avid. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>There can be no assurances that we will be successful in raising additional funds on terms acceptable
to us, or at all, or that sufficient additional capital will be raised to complete the research,
development, and clinical testing of our product candidates beyond fiscal year 2005.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Contractual Obligations</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> Contractual obligations represent future cash commitments and liabilities under agreements with third
parties, and exclude contingent liabilities for which we cannot reasonably predict future payments.
The following chart represents our contractual obligations as of April 30, 2004, aggregated by type
(in thousands):</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>42</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<TABLE WIDTH=90% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=14><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Payments Due by Period
    (in thousands)</FONT>
        <HR color=black SIZE=1>
    </TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Total</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&#139; 1 year</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>1-3 years</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>4-5 years</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>After 5 years</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Operating leases, net (1)</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5,079</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 702</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,257</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,589 </FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><font face="Times New Roman, Times, Serif" size=2>531</font></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Purchase obligations (2)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>153</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>153</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD colspan=16 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other
    long-term liabilities -</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT bgcolor="#EAF9E8">
    <font face="Times New Roman, Times, Serif" size="2">minimum license
    obligations(3)</font></TD>
    <TD ALIGN=RIGHT bgcolor="#EAF9E8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#EAF9E8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>650</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#EAF9E8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#EAF9E8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#EAF9E8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>650</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#EAF9E8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#EAF9E8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#EAF9E8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#EAF9E8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#EAF9E8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#EAF9E8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#EAF9E8">&nbsp;</TD>
    <TD ALIGN=RIGHT bgcolor="#EAF9E8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#EAF9E8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#EAF9E8">&nbsp;</TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total contractual obligations</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5,882</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,505</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,257</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,589 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><font face="Times New Roman, Times, Serif" size=2>531</font></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD colspan="2"><HR NOSHADE COLOR=Black SIZE=2></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=Black SIZE=2></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=Black SIZE=2></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=Black SIZE=2></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=Black SIZE=2></TD>
    <TD></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>_______________</B></FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=48></TD>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>(1)</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Represents our facility operating lease, net of sublease income of $157,000, under non-cancelable lease
and sublease agreements. In addition to our facility operating lease, we have various office equipment
leases, which have five year lease terms and aggregate annual minimum lease payments of $29,000.</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=48></TD>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>(2)</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Represents remaining purchase obligation for the acquisition of equipment, which equipment is planned
to be delivered and installed during fiscal year 2005. </FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=48></TD>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>(3)</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>We periodically enter into licensing agreements with third parties to obtain exclusive or non-exclusive
licenses for certain technologies. The terms of certain of these agreements require us to pay future
milestone payments based on product development success. We anticipate we will make milestone payments
in the amount of $650,000 during fiscal year 2005 under various licensing agreements primarily related
to the anticipated filing of the Investigational New Drug application for Tarvacin&#153; before the
end of calendar year 2004. Other milestones fees under these licensing agreements cannot be predicted
due to the uncertainty of future clinical trial results and development milestones and therefore,
cannot be reasonably predicted or estimated at the present time. </FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a8"></a>ITEM 7A. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Changes in United States interest rates would affect the interest earned on our cash and cash equivalents.
Based on our overall interest rate exposure at April 30, 2004, a near-term change in interest rates,
based on historical movements, would not materially affect the fair value of interest rate sensitive
instruments. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a9"></a>ITEM 8. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINANCIAL STATEMENT AND SUPPLEMENTARY DATA</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Reference is made to the financial statements included in this Report at pages F-1 through&nbsp;F-35.</FONT></P><B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>43</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=96><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a10"></a>ITEM 9. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B><U>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</U></B></FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Not applicable.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a11"></a>ITEM 9A.</B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B><U>CONTROLS AND PROCEDURES</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains disclosure controls
and procedures (as defined in Rules&nbsp;13a-15(e) and 15d-15(e)) under the Securities Exchange Act
of 1934, as amended (the &#147;Exchange Act&#148;), that are designed to ensure that information
required to be disclosed in its reports filed under the Securities Exchange Act of 1934, as amended,
is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s
rules and forms, and that such information is accumulated and communicated to our management, including
its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions
regarding required disclosure. In designing and evaluating the disclosure controls and procedures,
management recognized that any controls and procedures, no matter how well designed and operated,
can provide only reasonable assurance of achieving the desired control objectives, and management
necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible
controls and procedures. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company carried out an evaluation,
under the supervision and with the participation of management, including its Chief Executive Officer
and Chief Financial Officer, of the effectiveness of the design and operation of its disclosure controls
and procedures as of April 30, 2004, the end of the period covered by this Annual Report. Based on
that evaluation, the Company&#146;s Chief Executive Officer and Chief Financial Officer concluded
that its disclosure controls and procedures were effective at the reasonable assurance level as of
April 30, 2004.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There have been no changes in the Company&#146;s
internal control over financial reporting subsequent to the date of the Company&#146;s evaluation
that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal
controls over financial reporting. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><U>PART III</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a12"></a>ITEM 10. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT</U></B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Directors of the Registrant </B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> The members of our Board of Directors (the &#147;Board&#148;) and nominees to the Board as of July
9, 2004 are as follows: </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Carlton
M. Johnson, age 44, was appointed a director on November 3, 1999. Mr. Johnson currently serves as
legal counsel for Roswell Capital Partners, LLC and has served as legal counsel
for Equiplace Securities, LLC (formerly Swartz Investments, LLC) since 1996. Mr. Johnson has been
an active member of the Alabama State Bar since 1986, the Florida Bar since 1988, and the State Bar
of Georgia since 1997. He has been a shareholder in the Florida AV rated, Bar registered firm of
Smith, Sauer, DeMaria &amp; Johnson and Vice President and President-Elect of the 600 member Escambia-Santa
Rosa Bar Association. He also served on the Florida Bar Young Lawyers Division Board of Governors.
Mr. Johnson earned his degree in History/Political Science at Auburn University and his Juris Doctor
at Samford University &#150; Cumberland School of Law. Mr. Johnson also serves on the board of Patriot
Scientific Corporation, a publicly traded company.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>44</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Steven W. King, age 40, was elected a director on October
14, 2003. Mr. King also serves as the President
and Chief Executive Officer since March 19, 2003 after performing in positions of increased responsibility
at the Company. From August 2002 to such date, Mr. King served as Chief Operating Officer of Peregrine.

From February 2000 to August 2002, Mr. King served as our Vice President of Technology and Product
Development. Mr. King joined Peregrine in 1997 in the capacity of Director of Research and Development.
Mr. King was responsible for planning and launching our wholly-owned contract manufacturing subsidiary,
Avid Bioservices, Inc., in 2002. Mr. King has served as the President and Chief Executive Officer
of Avid since its inception. Mr. King was previously employed at Vascular Targeting Technologies,
Inc., (formerly known as Peregrine Pharmaceuticals, Inc.) a company we acquired in 1997, which held
the rights to the Vascular Targeting Agent technology. Mr. King previously worked with Dr. Phillip
Thorpe, inventor of the Company&#146;s VTA technology, at the University of Texas Southwestern Medical
Center at Dallas and is a co-inventor on over 25 U.S. and foreign patents and patent applications
in the Vascular Targeting Agent field. Mr. King received his Bachelors and Masters degrees from Texas
Tech. University in Cell and Molecular Biology.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eric
S. Swartz, age 48, was appointed a director on November 3, 1999. Mr. Swartz is the founder and President
of Roswell Capital Partners, LLC and previous founder and President of Equiplace Securities, LLC (formerly Swartz Investments, LLC),
which he started in 1993. Prior to 1993, Mr. Swartz was a Vice President at Bear Stearns &amp; Co. specializing
in foreign institutional equity investments in U.S. securities. Prior to that, Mr. Swartz was a Vice
President with Oppenheimer &amp; Co., where he was involved in overseas placements of equity and
debt for institutions in Germany, Austria, Switzerland, France, Australia, and New Zealand. Mr. Swartz
has approximately 20 years of experience in the securities business.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clive
R. Taylor, M.D., Ph.D., age 60, has served as a director of the Company since November 2, 1988. He
is professor of pathology at the University of Southern California, Chairman of the Department of
Pathology and Dean of Educational Affairs. Currently, Dr. Taylor serves as a director of Laboratories
for the Los Angeles County Medical Center and is on the attending staff of the Kenneth Norris, Jr.
Cancer Hospital and Research Institute. Dr. Taylor also serves as director on four privately held
companies. He received his M.D. degree from Cambridge University and his Ph.D. from Oxford University
and is board certified by the American Board of Pathology in Anatomic and Clinical Pathology.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Executive Officers of the Registrant </B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our executive officers as of July&nbsp;9, 2004 are as follows:</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Steven
W. King, age 40, is a director and was appointed our President and Chief Executive Officer on March
19, 2003. Mr. King&#146;s biography is described above under &#147;Directors of the Registrant&#148;.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;K.A.
Ajit-Simh, age 51, started with Peregrine on January 2, 2002 as our Vice President of Quality Assurance.
Mr. Ajit-Simh also serves as the Vice President of Quality Systems &amp; Regulatory Affairs of Avid
Bioservices, Inc. Since 1994, he has been affiliated as an instructor in the department of BioScience
at the University of California, San Diego teaching courses in Quality Control / Assurance and Regulatory
Compliance. In 1999 he was appointed as an Adjunct Professor in the Department of Pharmaceutical
Sciences and BioDevice Development which offers a Graduate Degree in Regulatory Affairs. Mr. Ajit-Simh
has been working in the Pharmaceutical and Biotechnology industry for more than twenty years. He
began his career at Mallinckrodt Medical and subsequently worked in increasingly senior positions
at Cambridge Medical, Baxter Health Care Corporation, Abbott Biotech and Cytel Corporation in operations,
manufacturing, quality and regulatory compliance. Mr. Ajit-Simh received his undergraduate degree
in Biology and Chemistry and a graduate degree in Cell Biology from St. Louis University, St. Louis,
Missouri. Mr. Ajit-Simh has lectured nationally and internationally in the areas of quality and compliance
and has taught at the PDA, an international association for pharmaceutical science and technology.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>45</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paul
J. Lytle, age 36, was appointed our Chief Financial Officer on August 28, 2002 and appointed Corporate
Secretary on June 19, 2000. Mr. Lytle served as our Vice President of Finance and Accounting from
February 2000 until August 2002. Mr. Lytle started with the Company in March 1997 as the Company&#146;s
Corporate Controller. Mr. Lytle currently oversees the Finance &amp; Accounting Department, SEC Reporting,
Human Resources and Information Technology. Mr. Lytle also serves as the Chief Financial Officer
and Corporate Secretary of Avid Bioservices, Inc. Prior to joining Peregrine, Mr. Lytle worked for
Deloitte &amp; Touche LLP, an accounting firm, from 1992 to 1997. Mr. Lytle holds a Bachelor of Science
in Business Administration from the California State University at Long Beach. Mr. Lytle is a certified
public accountant in the State of California and a member of the American Institute of Certified
Public Accountants. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Richard
A. Richieri, age 39, was appointed our Vice President of Manufacturing of Avid Bioservices, Inc.
on January 7, 2002. Mr. Richieri started with Peregrine in October 1996 as a Senior Process Engineer.
Mr. Richieri is currently responsible for all aspects of manufacturing including process development
and scale-up activities for the products produced by Avid Bioservices, Inc. Prior to joining Peregrine,
Mr. Richieri worked in the Fermentation Department at Xoma Corporation where he was responsible for
large-scale manufacturing and cell culture process development. Mr. Richieri received his M.S. degree
from the University of California, San Diego studying the dependency of antibody production on cell
cycle kinetics and holds a B.S. degree from the University of California, Los Angeles in Chemical
Engineering. Mr. Richieri is published in the field of antibody production, is an active member of
ISPE, and is licensed in the State of California to manufacture pharmaceutical products.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;William
Jay Treat, Ph.D., age 48, was appointed our Chief Operations Officer of Avid Bioservices, Inc. on
January 2, 2004. Dr. Treat started with Avid Bioservices in January 2002 as a consultant to head
up business development, and subsequently hired as the Vice President of Business Development in
May 2003. Dr. Treat is currently responsible for all aspects of the Avid operations with direct reports
representing regulatory affairs, quality systems and validations, quality control and analytical
methods, process sciences, cGMP manufacturing, business development and project management. Prior
to joining Avid Bioservices, Dr. Treat was Vice President of Research and Development at Irvine Scientific,
joining them after 9 years at BioWhittaker/Cambrex where he served in several capacities including
Technical Director and Director of Manufacturing. Dr. Treat received his B.S. and M.S. degree in
Microbiology from Texas A&amp;M University followed by his Ph.D. in Agricultural and Biochemical
Engineering from Texas A&amp;M University in 1988. He serves as a member of the Texas A&amp;M Chemical
Engineering Scientific Advisory Board.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>46</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Audit Committee Financial Expert </B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee of our Board of Directors has determined that Mr. Carlton M. Johnson is an &#147;audit
committee financial expert&#148; as defined by the Securities and Exchange Commission (&#147;SEC&#148;)
and is independent under the revised listing standards of NASDAQ. According to outside counsel and
the Audit Committee, Mr. Johnson qualifies as an audit committee financial expert and has acquired
the relevant experience and expertise as being required for an audit committee financial expert,
as defined by the applicable rules of the Exchange Act, pursuant to the fact that, among other things,
Mr. Johnson has been on the audit committee of Patriot Scientific Corporation, a publicly traded
company, since August 2001, is a registered Series 7 representative of the National Association of
Securities Dealers, has completed a number of accounting courses in college and law school, and has
been a practicing attorney since 1986 working complex commercial litigation and transactions requiring
financial due diligence, including analysis and verification of financial statements of publicly
traded companies as well as successfully working with the National Association of Securities Dealers
and the Securities and Exchange Commission in various audits on no less than five occasions.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a)
of the Exchange Act requires our executive officers and directors, and persons who own more than
10% of a registered class of our equity securities (&#147;Reporting Persons&#148;), to file reports
of ownership and changes in ownership with the SEC and with The Nasdaq Stock Market. Reporting Persons
are required by SEC regulations to furnish us with copies of all forms they file pursuant to Section&nbsp;16(a).
Based solely on its review of the copies of such reports received by it, and written representations
from certain Reporting Persons that no other reports were required for those persons, we believe
that, during the year ended April 30, 2004, the Reporting Persons met all applicable Section&nbsp;16(a)
filing requirements, except for Mr. Swartz who, on October 23, 2003 filed a late Form 4 covering
an option granted on October 14, 2003. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Code of Ethics</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> We maintain a code of business conduct and ethics applicable to all employees and directors, including
our principal executive officer, principal financial officer, principal accounting
officer or controller, and other persons performing similar functions including consultants. To view
this code of ethics and business conduct free of charge, please visit our website at
<font color="#0000FF"> <I>www.peregrineinc.com</I></font> (This website address is not intended to function as a hyperlink, and the information contained in
our website is not intended to be a part of this filing). We intend to satisfy
the disclosure requirements under Item&nbsp;10 of Form&nbsp;8-K regarding an amendment to, or waiver
from, a provision of this code of ethics and business conduct, if any, by posting such information
on our website. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a13"></a>ITEM 11. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>EXECUTIVE COMPENSATION</U></B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Compensation of Directors </B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>Board Fees.</I> &nbsp;Our members of the Board of Directors who are also employees of the Company are not separately
compensated for their services as directors. Our non-employee&nbsp;Directors did not receive any
cash consideration for attending meetings or meetings of Committees of the Board of Directors on
which such director serves prior to May 2003. Effective May 2003, non-employee Directors receive
an annual retainer of $60,000 (payable monthly) and meeting fees of $2,000 for each regular Board
meeting attended either in person or telephonically. In addition, as a result of the non-employee
directors having foregone any form of cash compensation for their services as directors since 1999,
each non-employee director received a one-time cash payment of $45,000 in August 2003. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>47</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>Other Fees.</I> &nbsp;Mr. Johnson received $4,917 per month during fiscal year 2004 for consulting services provided
to us beyond his duties as a non-employee Director. In addition, Dr. Taylor received $2,000 per month
during fiscal year 2004 for scientific professional fees unrelated to his services as a non-employee
Director. The consulting fees payable to Mr. Johnson and Dr. Taylor will both terminate in September
2004 prior to our annual meeting of stockholders planned to be held on October 25, 2004.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>Equity Compensation.</I> &nbsp;The Compensation Committee of the Board of Directors makes periodic stock option grants to all
non-employee directors. During fiscal year 2003, the Compensation Committee granted each non-employee
Board member an option to purchase up to 350,000 shares of our common stock at $2.20
per share. In addition, on August 20, 2003, Mr. Swartz voluntarily cancelled an option to purchase
150,000 shares of our common stock in order to increase the number of options available for grant
to our new employees. On October 14, 2003, Mr. Swartz was granted a replacement option to purchase
150,000 shares of our common stock at the same exercise price as the original option.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Compensation of Executive Officers</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary
Compensation Table</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table contains information concerning the compensation of (i) all individuals serving as
the Chief Executive Officer during fiscal year 2004, (ii) up to four other most highly compensated
executive officers (based on salary plus bonus for fiscal year 2004) who were serving as executive
officers at the end of fiscal 2004 and (iii) up to two individuals who would have been included in
this table under clause (ii) above except for the fact that they were not serving as executive officers
at the end of fiscal year 2004. All the individuals named in the table will hereinafter be referred
to as the &#147;Named Executive Officers&#148;.</FONT></P>
<TABLE WIDTH=100% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2>&nbsp;</TH>
    <TH COLSPAN=8><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Annual Compensation </FONT>
        <HR color=black SIZE=1>
    </TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Long-Term<BR>
      Compensation <br>
      Award </FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH align="center"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Name and Principal Position </FONT>
        <HR color=black SIZE=1></TH>
    <TH width="2%">&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Fiscal<BR>
      Year </FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Salary (1) </FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Bonus </FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Securities<BR>
      Underlying<br>
      Options </FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Other<br>
      Compensation </FONT>
        <HR color=black SIZE=1></TH>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD colspan="2" ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Steven W. King</FONT></TD>
    <TD WIDTH=1% ALIGN=center bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=center bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2004</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 294,548</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;(3)</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 115,000</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>350,000</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;&nbsp;&nbsp;&nbsp;(2)</FONT></TD>
    <TD WIDTH=3% ALIGN=left bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="2" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;President and</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2003</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 232,490</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>200,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;&nbsp;&nbsp;&nbsp;(2)</FONT></TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD colspan="2" ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Chief Executive Officer</FONT></TD>
    <TD ALIGN=center bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2002</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 206,827</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 152,500</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>150,000</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;&nbsp;&nbsp;&nbsp;(2)</FONT></TD>
    <TD ALIGN=left bgcolor="#eaf9e8">&nbsp;</TD>
  </TR>
  <TR>
    <TD COLSPAN=2></TD>
    <TD COLSPAN=2 align="center"><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=center><HR COLOR=Black SIZE=1></TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="2" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>K.A. Ajit-Simh</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2004</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 184,616</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 50,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>66,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;&nbsp;&nbsp;&nbsp;(2)</FONT></TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD colspan="2" ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Vice President,</FONT></TD>
    <TD ALIGN=center bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2003</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 200,000</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;&nbsp;&nbsp;&nbsp;(2)</FONT></TD>
    <TD ALIGN=left bgcolor="#eaf9e8">&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="2" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Quality Assurance</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2002</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 64,423</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;(4)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>150,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;&nbsp;&nbsp;&nbsp;(2)</FONT></TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
  <TR bgcolor="#eaf9e8">
    <TD COLSPAN=2 bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Avid Bioservices, Inc.</FONT></TD>
    <TD COLSPAN=2 align="center" bgcolor="#eaf9e8">&nbsp;</TD>
    <TD bgcolor="#eaf9e8"></TD>
    <TD COLSPAN=2 ALIGN=RIGHT bgcolor="#eaf9e8">&nbsp;</TD>
    <TD bgcolor="#eaf9e8"></TD>
    <TD COLSPAN=2 ALIGN=RIGHT bgcolor="#eaf9e8">&nbsp;</TD>
    <TD bgcolor="#eaf9e8"></TD>
    <TD COLSPAN=2 ALIGN=RIGHT bgcolor="#eaf9e8">&nbsp;</TD>
    <TD bgcolor="#eaf9e8"></TD>
    <TD COLSPAN=2 ALIGN=center>&nbsp;</TD>
    <TD ALIGN=left bgcolor="#eaf9e8">&nbsp;</TD>
  </TR>
  <TR>
    <TD COLSPAN=2></TD>
    <TD COLSPAN=2 align="center"><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=center><HR COLOR=Black SIZE=1></TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="2" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Paul J. Lytle</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2004</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 239,124</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;(5)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 81,176</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>300,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;&nbsp;&nbsp;&nbsp;(2)</FONT></TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD colspan="2" ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer,</FONT></TD>
    <TD ALIGN=center bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2003</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 217,582</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 133,000</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>135,000</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;&nbsp;&nbsp;&nbsp;(2)</FONT></TD>
    <TD ALIGN=left bgcolor="#eaf9e8">&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="2" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Corporate Secretary</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2002</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 188,115</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;&nbsp;&nbsp;&nbsp;(2)</FONT></TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD COLSPAN=2></TD>
    <TD COLSPAN=2 align="center"><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=center><HR COLOR=Black SIZE=1></TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD COLSPAN=2></TD>
    <TD COLSPAN=3 align="center"></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=2 align="center"></TD>
    <TD align="left"></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD colspan="2" ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Richard A. Richieri</FONT></TD>
    <TD ALIGN=center bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2004</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 173,558</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 50,000</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>57,750</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;&nbsp;&nbsp;&nbsp;(2)</FONT></TD>
    <TD ALIGN=left bgcolor="#eaf9e8">&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="2" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vice President, Manufacturing,</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2003</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 149,231</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;&nbsp;&nbsp;&nbsp;(2)</FONT></TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD colspan="2" ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp; Avid Bioservices, Inc.</FONT></TD>
    <TD ALIGN=center bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2002</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 105,192</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 29,500</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>65,000</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;&nbsp;&nbsp;&nbsp;(2)</FONT></TD>
    <TD ALIGN=left bgcolor="#eaf9e8">&nbsp;</TD>
  </TR>
  <TR>
    <TD COLSPAN=2></TD>
    <TD COLSPAN=2 align="center"><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=center><HR COLOR=Black SIZE=1></TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD colspan="2" ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>William Jay Treat</FONT></TD>
    <TD ALIGN=center bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2004</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 174,135</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;(6)</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 25,000</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>207,750</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;&nbsp;&nbsp;&nbsp;(2)</FONT></TD>
    <TD ALIGN=left bgcolor="#eaf9e8">&nbsp;</TD>
  </TR>
  <TR>
    <TD COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Chief Operating Officer,</FONT></TD>
    <TD COLSPAN=2 align="center">&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=center>&nbsp;</TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
  <TR bgcolor="#eaf9e8">
    <TD COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Avid Bioservices, Inc.</FONT></TD>
    <TD COLSPAN=2>&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD COLSPAN=2></TD>
    <TD COLSPAN=2><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=Black SIZE=1></TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
</TABLE>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2>__________________</FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>(1)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Salary information is reported as of the last payroll paid prior to or immediately after April 30th
of each fiscal year.</FONT></TD></TR>
<TR>
  <TD vAlign=top>&nbsp;</TD>
  <TD vAlign=top>&nbsp;</TD>
</TR>
<TR>
  <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>(2)<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
  <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2> Amounts were not significant enough to meet the disclosure requirements.</FONT></TD>
</TR>
</TABLE>

<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
  <TD vAlign=top>&nbsp;</TD>
  <TD vAlign=top>&nbsp;</TD>
</TR>
<TR>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>(3)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Includes a one-time retroactive pay adjustment of $24,548 related to a previous year when Mr. King
accepted a pay decrease when we were focused on reducing expenses.</FONT></TD></TR>
<TR>
  <TD vAlign=top>&nbsp;</TD>
  <TD vAlign=top>&nbsp;</TD>
</TR>
<TR>
  <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>(4)</FONT></TD>
  <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2> Represents salary from January 2, 2002 through April 30, 2002.</FONT></TD>
</TR>
<TR>
  <TD vAlign=top>&nbsp;</TD>
  <TD vAlign=top>&nbsp;</TD>
</TR>
</TABLE>

<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>(5)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Includes a one-time retroactive pay adjustment of $23,893 related to a previous year when Mr. Lytle
accepted a pay decrease when we were focused on reducing expenses.</FONT></TD></TR>
<TR>
  <TD vAlign=top>&nbsp;</TD>
  <TD vAlign=top>&nbsp;</TD>
</TR>
<TR>
  <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>(6)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></FONT></TD>
  <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Represents salary from May 19, 2003 to April 30, 2004.</FONT></TD>
</TR>
</TABLE>

<P align=center><FONT face="Times New Roman, Times, serif" size=2>48</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Option
Grants</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth information concerning individual grants of stock options approved by
our Compensation Committee during the fiscal year ended April 30, 2004, to each of the Named Executive
Officers: </FONT></P>
<TABLE WIDTH=100% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH rowspan="2"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Named Executive<BR>
      Officer </FONT>
        <HR color=black SIZE=1>      </TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2 rowspan="2"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Grant <BR>
      Date </FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2 rowspan="2"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Number of<BR>
      Securities<BR>
      Underlying<BR>
      Options <BR>
      Granted </FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2 rowspan="2"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Percent<BR>
      Total Options<BR>
      Granted to<BR>
      All Employees in<BR>
      Fiscal Year (1) </FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2 rowspan="2"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Exercise<BR>
      Price<BR>
      (per share)<BR>
      (2) </FONT>
        <HR color=black SIZE=1>      </TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2 rowspan="2"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Expiration<BR>
      Date </FONT>
        <HR color=black SIZE=1>      </TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Potential Realizable<BR>
      Value at Assumed<BR>
      Annual Rates of Stock<BR>
      Appreciation for<BR>
      Option Term (3) </FONT>
      <HR COLOR=Black SIZE=1>
    </TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH>&nbsp;</TH>
    <TH>&nbsp;</TH>
    <TH>&nbsp;</TH>
    <TH>&nbsp;</TH>
    <TH>&nbsp;</TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>5%</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>10%</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Steven W. King</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT>&nbsp;</TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10/21/2003</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>350,000</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(4)</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=12% ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.36%</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.20</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10/21/2013</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 484,249</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,227,182</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="2" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>K.A. Ajit-Simh</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10/21/2003</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>66,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(5)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.58%</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.20</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10/21/2013</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 91,315</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 231,411</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD colspan="2" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Paul J. Lytle</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10/21/2003</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>300,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(4)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7.16%</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.20</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10/21/2013</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 415,070</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,051,870</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="2" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Richard A. Richieri</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10/21/2003</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>57,750</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(5)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.38%</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.20</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10/21/2013</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 79,901</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 202,485</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD colspan="2" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>William Jay Treat</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5/19/2003</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>150,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(6)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3.58%</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.74</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5/19/2013</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 69,807</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 176,905</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="2" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10/21/2003</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>57,750</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(5)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.38%</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.20</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10/21/2013</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 79,901</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 202,485</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>__________________</FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=48><FONT face="Times New Roman, Times, Serif" size=2>(1)</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Options to purchase an aggregate of 4,187,947 shares were granted to all employees, directors and consultants
during the fiscal year ended April&nbsp;30, 2004, including the Named Executive Officers, under our
1996 Stock Incentive Plan and our 2003 Stock Incentive Plan. Other than the above grants, no other
options were granted to the Named Executive Officer during fiscal year 2004.</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=48><FONT face="Times New Roman, Times, Serif" size=2>(2)</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>All options were granted at an exercise price at least equal to the fair market value of our common
stock on the date of grant. Fair market value is the closing price of our common stock on the date
of grant.</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=48><FONT face="Times New Roman, Times, Serif" size=2>(3)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>These columns show the possible gains the Named Executive Officer could realize if our common stock
on the date of grant appreciates at a rate of 5% or 10% over the ten-year term of the option. The
assumed 5% and 10% annual rates of appreciation over the term of the options are set forth in accordance
with the rules and regulations of the Securities and Exchange Commission and are not our predictions.
The potential realizable value is calculated by assuming that the stock price on the date of grant
appreciates at the indicated rate, compounded annually, for the entire term of the option and that
the option is exercised and the stock sold on the last day of its term at this appreciated stock
price. No valuation method can accurately predict future stock prices or option values because there
are too many unknown factors. No gain to the optionee is possible unless the stock price increases
over the option term. If the stock price appreciates, then such a gain in stock price would benefit
all stockholders. </FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR></TABLE>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=48><FONT face="Times New Roman, Times, Serif" size=2>(4)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Option vests one-third on date of grant and one-third on the second and third anniversary dates from
the date of grant.</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=42><FONT face="Times New Roman, Times, Serif" size=2>(5)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Option vests entirely on October 21, 2004.</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=42><FONT face="Times New Roman, Times, Serif" size=2>(6)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Option vests twenty-five percent annually on each anniversary date from the date of grant.</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR></TABLE>
<B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>49</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B>Aggregated Option Exercises </B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth information (on an aggregated basis) concerning each exercise of stock
options during the year ended April 30, 2004, by each of the Named Executive Officers and the final
year-end value of unexercised options: </FONT></P>
<TABLE WIDTH=100% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH rowspan="2"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Named Executive<BR>
      Officer </FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2 rowspan="2"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>No. of Shares<BR>
      Acquired on<BR>
      Exercise </FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2 rowspan="2"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Value<BR>
      Realized (1) </FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Number of<BR>
      Securities Underlying<BR>
      Unexercised Options<BR>
      at April 30, 2004 </FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Value of Unexercised<BR>
      In-the-Money Options at<BR>
      April 30, 2004 (2) </FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH>&nbsp;</TH>
    <TH>&nbsp;</TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Exercisable</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Unexercisable</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Exercisable</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Unexercisable</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Steven W. King</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>815,833</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>325,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 636,291</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 102,667</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>K.A. Ajit-Simh</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>50,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 51,875</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>35,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>131,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 6,300</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 11,700</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Paul J. Lytle</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>550,833</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>200,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 342,858</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Richard A. Richieri</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>288,083</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>57,750</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 255,033</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>William Jay Treat</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>20,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 37,992</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>187,750</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 120,900</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>__________________</FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2><FONT style="TEXT-DECORATION: none">(1)</FONT></FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>The value realized upon the exercise of stock options represents the difference between the exercise
price of the stock option and the fair market value of the shares, multiplied by the number of options
exercised on the date of exercise. </FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>(2)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>The value of &#147;In-the-Money Options&#148; represents the positive spread between the exercise price
of the option and the fair market value of the underlying shares based on the closing stock price
of our common stock on April 30, 2004, which was $1.67 per share. &#147;In-the-Money Options&#148;
include only those options where the fair market value of the stock is higher than the exercise price
of the option on the date specified. The actual value, if any, a Named Executive Officer realizes
on the exercise of options will depend on the fair market value of our common stock at the time of
exercise.</FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employment
Agreement and Change-in-Control Arrangements</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Steven
W. King is subject to an employment agreement with us dated March 19, 2003, pursuant to which he
was employed as our President and Chief Executive Officer. The Agreement provides for an initial
annual base salary of $270,000 and a stock option to purchase up to 200,000 shares of common stock,
which option vests monthly over 24 monthly periods. The Agreement provides that Mr. King shall serve
as President and Chief Executive Officer for a minimum of six months. Thereafter, Mr. King may terminate
his employment upon 90 days notice. Upon such termination, Mr. King shall receive six months&#146;
base salary as severance. We may terminate Mr. King&#146;s employment at any time for &#147;cause&#148;
(as defined in the Agreement). If Mr. King&#146;s employment is terminated by us for any
reason other than &#147;cause&#148;, or within 90 days following a &#147;Change in Control&#148;
(as defined in the Agreement), Mr. King shall receive six months&#146; base salary as severance,
benefit continuation for six months, and two years to exercise any vested options. Mr. King&#146;s
annual salary has not been changed since March 19, 2003.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation
Committee Interlocks and Insider Participation</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following non-employee directors serve on the Compensation Committee of the Board of Directors:&nbsp;Carlton
Johnson and Clive R. Taylor, M.D., Ph.D. There are no interlocks of executive officers or directors
of the Company serving on the compensation committee or equivalent committee of another entity, which
has any director or executive officer serving on the Compensation Committee, other committees or
the Board of Directors of the Company.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>50</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a14"></a>ITEM 12. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</U></B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Equity Compensation Plan Information</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We currently maintain three equity compensation plans, as more fully described below: the 1996 Plan,
the 2002 Plan, and the 2003 Plan. The 1996 and 2003 Plans were approved by the stockholders while
the 2002 Plan was not submitted for stockholder approval. The Compensation committee is responsible
for granting options under all option plans.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Equity Compensation Plan Approved by Stockholders</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We have two incentive stock option plans with outstanding options as of April 30, 2004: the 1996 Plan
and the 2003 Plan. The plans provide for the granting of options to purchase shares of our common
stock at prices not less than the fair market value of the stock at the date of grant and generally
expire ten years after the date of grant. The 1996 and 2003 Plans were approved by our stockholders.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The 1996 Plan originally provided for the issuance of options to purchase up to 4,000,000 shares of
our common stock. The number of shares for which options may be granted under the 1996 Plan automatically
increases for all subsequent common stock issuances by us in an amount equal to 20% of such subsequent
issuances up to a maximum of 10,000,000 shares as long as the total shares allocated to the 1996
Plan do not exceed 20% of the our authorized stock. As a result of issuances of common stock by us
subsequent to the adoption of the 1996 Plan, the number of shares for which options may be granted
has increased to 10,000,000. Options granted generally vest over a period of four years with a maximum
term of ten years. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During October 2003, the stockholders approved our 2003 Plan for the grant of options to purchase up
to 5,000,000 shares of common stock. The 2003 Plan provides for the granting of options to purchase
shares of the our common stock at prices not less than the fair market value of the stock at the
date of grant and generally expire ten years after the date of grant.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>Equity Compensation Plans Not Approved by Stockholders </I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> During June 2002, the Company adopted a broad-based non-qualified stock option plan (&#147;2002 Plan&#148;)
for the grant of options to purchase up to 3,000,000 shares of common stock. The 2002 Plan is intended
to provide incentives to key employees, officers, directors, consultants and others expected to provide
significant services to the Company, to encourage proprietary interest in the Company, to encourage
such key employees to remain in the employ of the Company, to attract new employees with outstanding
qualifications, and to afford additional incentives to others to increase their efforts in providing
significant services to the Company. The 2002 Plan provides for the granting of options to purchase
shares of our common stock at prices not less than the fair market value of the stock at the date
of grant and generally expire ten years after the date of grant. In the event of a merger or consolidation
in which the Company is not the surviving corporation, the date of exercisability of each outstanding
option grant shall be accelerated to a date prior to such merger or consolidation.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition to the 2002 Plan, during 1999, we made a one-time grant of non-qualified options to purchase
up to an aggregate of 1,500,000 shares of the our common stock. As of April 30, 2004, options to
purchase 921,664 shares of the our common stock were outstanding. The resale of the underlying shares
of common stock is registered on a registration statement on Form S-3. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>51</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth certain information as of April 30, 2004 concerning our common stock that
may be issued upon the exercise of options or pursuant to purchases of stock under all of our equity
compensation plans approved by stockholders and equity compensation plans not approved by stockholders
in effect as of April 30, 2004:</FONT></P>
<TABLE WIDTH=100% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH nowrap><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Plan Category</FONT>
    <HR color=black SIZE=1></TH>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=2 nowrap><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(a)<BR>
      Number&nbsp;of&nbsp;Securities to<BR>
      be Issued Upon the<BR>
      Exercise of Outstanding<BR>
      Options </FONT>
    <HR color=black SIZE=1></TH>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=2 nowrap><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(b)<BR>
      Weighted-Average<BR>
      Exercise Price of<BR>
      Outstanding Options </FONT>
    <HR color=black SIZE=1></TH>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=2 nowrap><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(c)<BR>
      Available for Future<BR>
      Issuance Under Equity<BR>
      Compensation Plans<BR>
      (Excluding Securities<BR>
      Reflected in Column (a)) </FONT>
    <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Equity compensation plans</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=14% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;approved by stockholders</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8,096,792</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.63</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,022, 278</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Equity compensation plans</FONT></TD>
    <TD colspan=10 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;not approved by</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;stockholders</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,607,413</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.15</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>231,202</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>

  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2"><HR COLOR=Black SIZE=1></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2"><HR COLOR=Black SIZE=1></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2"><HR COLOR=Black SIZE=1></TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11,704,205</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.48</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,253,480</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2"><hr noshade color=Black size=2></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2"><hr noshade color=Black size=2></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2"><hr noshade color=Black size=2></TD>
    <TD>&nbsp;</TD>
  </TR>
</TABLE>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Common Stock </B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth certain information regarding the beneficial ownership of the our common
stock as of June&nbsp;30, 2004, by: (i)&nbsp;each entity or person whom we know to own beneficially
more than five percent (5%) of our common stock (ii) each director and director nominee; (iii)&nbsp;our
Chief Executive Officer and President, and each of our remaining Named Executive Officers for the
year ended April 30, 2004; and (iv)&nbsp;all directors, director nominees, and Named Executive Officers
of the Company as a group. Unless otherwise noted below, the persons named in the table have sole
voting and investment power with respect to all shares of common stock shown as beneficially owned
by them, subject to community property laws where applicable. </FONT></P>
<TABLE WIDTH=80% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=6><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Beneficial Ownership of<BR>
      Common Stock </FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH align="left"><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Name of Beneficial Owner</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Number of Shares</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Percent (A)</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Carlton M. Johnson</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>666,667 </FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;(B)</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT>&nbsp;</TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>*</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><font size="2" face="Times New Roman, Times, serif">Steven W. King </font></TD>
    <TD ALIGN=LEFT><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2" face="Times New Roman, Times, serif">851,166</font></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;&nbsp;(B)</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2" face="Times New Roman, Times, serif">*</font></TD>
    <TD ALIGN=LEFT><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Eric S. Swartz</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,995,010</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &nbsp;&nbsp;(C)</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.10</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Clive R. Taylor, M.D., Ph.D.</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,757,667</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &nbsp;&nbsp;(B)</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1.23</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>K.A. Ajit-Simh</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>35,000 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;(B)</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>*</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Paul J. Lytle</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>550,833 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;(B)</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>*</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Richard A. Richieri</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>288,083 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;(B)</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>*</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>William Jay Treat, Ph.D.</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>32,500</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;(B)</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>*</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Barclays Global Investors, NA</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11,945,220</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.46</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3"><HR COLOR=Black SIZE=1></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2"><HR COLOR=Black SIZE=1></TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>All directors, director nominees and executive</FONT></TD>
    <TD colspan=8 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>officers as a group (8&nbsp;persons)</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7,176,926</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &nbsp;&nbsp;(C)</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.89</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>__________________</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><FONT style="TEXT-DECORATION: none">&nbsp;</FONT><FONT style="TEXT-DECORATION: none">* Less than 1% of the outstanding shares of our common stock.</FONT></FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=48><FONT face="Times New Roman, Times, Serif" size=2><FONT style="TEXT-DECORATION: none">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Percent of common stock computed on the basis of 141,268,182 shares outstanding at June 30, 2004, plus
shares that could be acquired through the exercise of stock options and warrants that will become
exercisable within 60 days of June 30, 2004.</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=48><FONT face="Times New Roman, Times, Serif" size=2>(B)</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Includes shares which the individuals shown above have the right to acquire as of June&nbsp;30, 2004,
or within 60&nbsp;days thereafter, pursuant to outstanding stock options as follows: Mr. Johnson
- 666,667 shares; Mr. King - 849,166 shares; Dr. Taylor - 1,738,667 shares; Mr. Ajit-Simh - 35,000
shares; Mr. Lytle - 550,833 shares; Mr. Richieri - 288,083 shares; Dr. Treat - 32,500 shares. Such
shares are deemed to be outstanding in calculating the percentage ownership of such individual (and
the group), but are not deemed to be outstanding as to any other person.</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR>
<TR>
<TD vAlign=top width=48><FONT face="Times New Roman, Times, Serif" size=2>(C)</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Includes (i) 1,018,495 shares of common stock issuable upon the exercise of outstanding stock options
and warrants owned by Mr. Swartz (ii) 236,000 shares of common stock owned by Swartz Ventures, Inc.
and (iii) 419,750 shares of common stock issuable upon the exercise of warrants owned by Swartz Ventures,
Inc. Mr. Swartz has sole control over Swartz Ventures, Inc.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>52</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a15"></a>ITEM 13. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During September 1995, we entered into an agreement with Cancer Therapeutics, Inc. whereby we granted
to Cancer Therapeutics, Inc. the exclusive right to sublicense TNT solely to a major pharmaceutical
company located in the Peoples Republic of China for a period of 10 years, subject to the major pharmaceutical
company obtaining product approval within 36 months. In exchange for this right, the major pharmaceutical
company would be required to fund not less than $3,000,000 for research and development expenses
of Cancer Therapeutics related to TNT and we would retain exclusive rights to all research, product
development and data outside of the Peoples Republic of China. The technology was then sublicensed
to Brilliance Shanghai Pharmaceuticals, Inc. (&#147;Brilliance&#148;) and later assigned to Medipharm
Biotech. In addition, we are entitled to receive 50% of all revenues received by Cancer Therapeutics
with respect to its sublicensing of TNT to Brilliance/Medipharm Biotech. During March 2001, we extended
the exclusive licensing period granted to Cancer Therapeutics, which now expires on December 31,
2016. In exchange for this extension, Cancer Therapeutics, Inc. agreed to pay us ten percent (10%)
of all other consideration received by Cancer Therapeutics, Inc., excluding research funding. Dr.
Clive Taylor, a member of our Board of Directors, owns 26% of Cancer Therapeutics and is an officer
and director of Cancer Therapeutics. Dr. Taylor has abstained from voting at meetings of our board
of directors on any matters relating to Cancer Therapeutics or Brilliance/Medipharm Biotech. Through
fiscal year ended April 30, 2004, Cancer Therapeutics has not derived any revenues from its agreement
with Brilliance/Medipharm Biotech.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the fiscal year 2004, we paid to Equiplace Securities, LLC (&#147;Equiplace&#148;) a total of $72,000
for Avid business development services provided by employees of Equiplace under a Finder&#146;s Fee
Agreement. Under the Finder&#146;s Fee Agreement, Equiplace is given a call list of potential customers
which is provided by Avid. Equiplace employees then call each contact and present Avid&#146;s manufacturing
services. All contacts that show an interest in Avid&#146;s services are then turned over to Avid&#146;s
in-house Business Development Department for continued discussions. In addition, Equiplace may receive
a commission ranging from 2% to 4% of revenues generated by Avid Bioservices, Inc. on new customers
referred to Avid by Equiplace. The commissions due Equiplace can be reduced in half if another third-party
finder is jointly responsible for new customer contracts. Mr. Swartz, a director, owns fifty percent
(50%) of Equiplace. The Finder&#146;s Fee Agreement was canceled on June 30, 2004. To date, the Company
has not paid any commissions under the agreement. Mr. Swartz has referred one of Avid&#146;s largest
customers to date without receiving any commission or fee.</FONT></P><B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>53</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a16"></a>Item 14. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>PRINCIPAL ACCOUNTING FEES AND SERVICES</U></B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following summarizes the fees paid to Ernst &amp; Young LLP for the fiscal years ended April 30,
2004 and 2003: </FONT></P>
<TABLE WIDTH=50% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT>
        <HR color=black SIZE=1></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Audit Fees</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=11% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 131,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=11% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 136,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Tax Fees</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>25,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>All Other Fees</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD colspan="2"><HR color=black SIZE=1></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2"><HR color=black SIZE=1></TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;Total Fees</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 157,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 151,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD colspan="2"><HR NOSHADE COLOR=Black SIZE=2></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2"><HR NOSHADE COLOR=Black SIZE=2></TD>
    <TD>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> Audit Fees pertain to the audit of our annual consolidated financial statements for fiscal year 2004
and 2003 and quarterly reviews of the consolidated financial statements included in our Form 10-Q&#146;s
for fiscal year 2004 and 2003. Tax Fees relate to tax compliance services involving the preparation
of the Company&#146;s tax returns for fiscal year 2004 and 2003. All Other Fees are attributable
to the Company&#146;s subscription to an Ernst &amp; Young LLP online service used for accounting
research purposes for fiscal year 2004. The Company paid no audit related fees in fiscal year 2004
and 2003. Ernst &amp; Young LLP did not perform any professional services with respect to information
systems design and implementation for the years ended April 30, 2004 and 2003. The Audit Committee
has considered whether the Audit, Tax and All Other services provided by Ernst &amp; Young LLP are
compatible with maintaining that firm&#146;s independence. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>54</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">

<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><U>PART IV</U></B></FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=96><FONT face="Times New Roman, Times, Serif" size=2><B><a name="a17"></a>ITEM 15. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B><U>EXHIBITS, CONSOLIDATED FINANCIAL STATEMENTS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K</U></B></FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consolidated Financial Statements</U></FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=90>&nbsp;</TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Index to consolidated financial statements:</FONT></TD></TR></TABLE>

<br>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center"><FONT face="Times New Roman, Times, Serif" size=2><strong>Page</strong></FONT></TD>
  </TR>
  <TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center"><HR COLOR=Black SIZE=1></TD>
  </TR>
  <TR valign="bottom">
    <TD width=144>&nbsp;</TD>
    <TD><a href="#b1"><FONT face="Times New Roman, Times, Serif" size=2>Report of Independent Registered Public Accounting Firm</FONT></a></TD>
    <TD width="45" align="right"><FONT face="Times New Roman, Times, Serif" size=2>F-1&nbsp;</FONT></TD>
  </TR>
  <TR valign="bottom">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
  </TR>
  <TR valign="bottom">
    <TD width=144>&nbsp;</TD>
    <TD><a href="#b2"><FONT face="Times New Roman, Times, Serif" size=2>Consolidated Balance Sheets as of April 30, 2004 and 2003</FONT></a></TD>
    <TD align="right"><FONT face="Times New Roman, Times, Serif" size=2> F-2&nbsp;</FONT></TD>
  </TR>
  <TR valign="bottom">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
  </TR>
  <TR valign="bottom">
    <TD width=144>&nbsp;</TD>
    <TD><a href="#b3"><FONT face="Times New Roman, Times, Serif" size=2>Consolidated Statements of Operations&nbsp;for each of the three years in the period ended April 30, 2004</FONT></a></TD>
    <TD align="right"><FONT face="Times New Roman, Times, Serif" size=2>F-4&nbsp;</FONT></TD>
  </TR>
  <TR valign="bottom">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
  </TR>
  <TR valign="bottom">
    <TD width=144>&nbsp;</TD>
    <TD><a href="#b4"><FONT face="Times New Roman, Times, Serif" size=2>Consolidated Statements of Stockholders&#146; Equity for each of the three years in the period ended April 30, 2004</FONT></a></TD>
    <TD align="right"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;F-5&nbsp;</FONT></TD>
  </TR>
  <TR valign="bottom">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
  </TR>
  <TR valign="bottom">
    <TD width=144>&nbsp;</TD>
    <TD><a href="#b5"><FONT face="Times New Roman, Times, Serif" size=2>Consolidated Statements of Cash Flows&nbsp;for each of the three years in the period ended April 30, 2004</FONT></a></TD>
    <TD align="right"><FONT face="Times New Roman, Times, Serif" size=2>F-6&nbsp; </FONT></TD>
  </TR>
  <TR valign="bottom">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
  </TR>
  <TR valign="bottom">
    <TD width=144>&nbsp;</TD>
    <TD><a href="#b6"><FONT face="Times New Roman, Times, Serif" size=2>Notes to Consolidated Financial Statements</FONT></a></TD>
    <TD align="right"><FONT face="Times New Roman, Times, Serif" size=2> F-8&nbsp;</FONT></TD>
  </TR>
  <TR valign="bottom">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
  </TR>
</TABLE>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top width=90>&nbsp;</TD>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U></U><U>Financial Statement Schedules</U></FONT></TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font face="Times New Roman, Times, Serif" size=2>The following schedule is filed as part of this Form 10-K:</font></TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>

<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top width=144>&nbsp;</TD>
    <TD vAlign=top><a href="#b7"><FONT face="Times New Roman, Times, Serif" size=2>Schedule II- Valuation and Qualifying Accounts </FONT></a></TD>
    <TD width="45" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top width=144>&nbsp;</TD>
    <TD vAlign=top><a href="#b7"><FONT face="Times New Roman, Times, Serif" size=2>for the years ended April 30, 2004, 2003, and 2002&nbsp;</FONT></a></TD>
    <TD align="right" vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>F-35&nbsp;</FONT></TD>
  </TR>
</TABLE>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
  <TD vAlign=top>&nbsp;</TD>
  <TD vAlign=top>&nbsp;</TD>
</TR>
<TR>
<TD vAlign=top width=36>&nbsp;</TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>All other schedules for which provision is made in the applicable accounting regulations of the Securities
and Exchange Commission are not required under the related instructions or are inapplicable and therefore
have been omitted.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>55</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=96>&nbsp;</TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>(3) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Exhibits</U></FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR></TABLE>
<br>
<TABLE width="100%" border="0" cellPadding="0" cellSpacing="0">
  <TR valign="bottom">
    <TD align="center"><font size="2" face="Times New Roman, Times, serif"><strong>Exhibit<BR>
      Number</strong></font></TD>
    <TD><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD><font size="2" face="Times New Roman, Times, serif"><strong>Description</strong></font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><hr  size=1 color=black></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><hr  size=1 color=black></TD>
  </TR>
  <TR>
    <TD width=8% align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">3.1&nbsp; </font></TD>
    <TD width=2% vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD width=90% vAlign=top><font size="2" face="Times New Roman, Times, serif">Certificate of Incorporation of Techniclone Corporation, a Delaware corporation (Incorporated by reference to Exhibit B to the Company&#146;s 1996 Proxy Statement as filed with the Commission on or about August 20, 1996).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">3.2&nbsp; </font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Amended and Restated Bylaws of Peregrine Pharmaceuticals, Inc. (formerly Techniclone Corporation), a Delaware corporation (Incorporated by reference to Exhibit 3.1 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended October 31, 2003).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">3.3&nbsp; </font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Certificate of Designation of 5% Adjustable Convertible Class C Preferred Stock as filed with the Delaware Secretary of State on April 23, 1997. (Incorporated by reference to Exhibit 3.1 contained in Registrant&#146;s Current Report on Form 8-K as filed with the Commission on or about May 12, 1997).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">3.4&nbsp; </font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Certificate of Amendment to Certificate of Incorporation of Techniclone Corporation to effect the name change to Peregrine Pharmaceuticals, Inc., a Delaware corporation. </font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">3.5&nbsp; </font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">
    Certificate of Amendment to Certificate of Incorporation of Peregrine
    Pharmaceuticals, Inc. to increase the number of authorized shares of the
    Company&#146;s common stock to two hundred million shares (Incorporated by reference to Exhibit 3.5 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended October 31, 2003). </font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">4.1&nbsp; </font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of Certificate for Common Stock (Incorporated by reference to the exhibit of the same number contained in Registrant&#146;s Annual Report on Form 10-K for the year end April 30, 1988).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">4.7&nbsp; </font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">5% Preferred Stock Investment Agreement between Registrant and the Investors (Incorporated by reference to Exhibit 4.1 contained in Registrant&#146;s Current Report on Form 8-K as filed with the Commission on or about May 12, 1997).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">4.8&nbsp; </font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Registration Rights Agreement between the Registrant and the holders of the Class C Preferred Stock (Incorporated by reference to Exhibit 4.2 contained in Registrant&#146;s Current Report on Form 8-K as filed with the Commission on or about May 12, 1997).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">4.9&nbsp; </font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of Stock Purchase Warrant to be issued to the holders of the Class C Preferred Stock upon conversion of the Class C Preferred Stock (Incorporated by reference to Exhibit 4.3 contained in Registrant&#146;s Current Report on Form 8-K as filed with the Commission on or about May 12, 1997).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">4.10 </font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Regulation D Common Equity Line Subscription Agreement dated June 16, 1998 between the Registrant and the Equity Line Subscribers named therein (Incorporated by&nbsp;reference to Exhibit 4.4 contained in Registrant&#146;s Current Report on Form 8-K dated as filed with the Commission on or about June 29, 1998).</font></TD>
  </TR>
  <TR>
    <TD vAlign=top width=91></TD>
    <TD vAlign=top width=534></TD>
    <TD vAlign=top width=534></TD>
  </TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>56</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<TABLE width="100%" border="0" cellPadding="0" cellSpacing="0">
  <TR align="center" valign="bottom">
    <TD><font size="2" face="Times New Roman, Times, serif"><strong>Exhibit<BR>
      Number</strong></font></TD>
    <TD><font size="2" face="Times New Roman, Times, serif"><strong></strong></font></TD>
    <TD align="left"><font size="2" face="Times New Roman, Times, serif"><strong>Description&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><hr  size=1 color=black></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><hr  size=1 color=black></TD>
  </TR>
  <TR>
    <TD width=8% align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">4.11&nbsp; </font></TD>
    <TD width=2% vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD width=90% vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of Amendment to Regulation D Common Stock Equity Line Subscription Agreement (Incorporated by reference to Exhibit 4.5 contained in Registrant&#146;s Current Report on Form 8-K filed with the Commission on or about June 29, 1998).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">4.12&nbsp; </font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Registration Rights Agreement between the Registrant and the Subscribers (Incorporated by reference to Exhibit 4.6 contained in Registrant&#146;s Current Report on Form 8-K as filed with the Commission on or about June 29, 1998).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">4.13&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of Stock Purchase Warrant to be issued to the Equity Line Subscribers pursuant to the Regulation D Common Stock Equity Subscription Agreement (Incorporated by reference to Exhibit 4.7 contained in Registrant&#146;s Current Report on Form 8-K as filed with the Commission on or about June 29, 1998).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">4.14&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Placement Agent Agreement dated as of June 16, 1998, by and between the Registrant and Swartz Investments LLC, a Georgia limited liability company d/b/a Swartz Institutional Finance (Incorporated by reference to the exhibit contained in Registration&#146;s Registration Statement on Form S-3 (File No. 333-63773)).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">4.15&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Second Amendment to Regulation D Common Stock Equity Line Subscription Agreement dated as of September 16, 1998, by and among the Registrant, The Tail Wind Fund, Ltd. and Resonance Limited (Incorporated by reference to the exhibit contained in Registration&#146;s Registration Statement on Form S-3 (File No. 333-63773)).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">4.16&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of Non-qualified Stock Option Agreement by and between Registrant, Director and certain consultants dated December 22, 1999 (Incorporated by reference to the exhibit contained in Registrant&#146;s Registration Statement on Form S-3 (File No. 333-40716)).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">4.17&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Peregrine Pharmaceuticals, Inc. 2002 Non-Qualified Stock Option Plan (Incorporated by reference to the exhibit contained in Registrant&#146;s Registration Statement in Form S-8 (File No. 333-106385)).*</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">4.18&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of 2002 Non-Qualified Stock Option Agreement (Incorporated by reference to the exhibit contained in Registrant&#146;s Registration Statement in Form S-8 (File No. 333-106385)).*</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.31</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Agreement dated February 5, 1996, between Cambridge Antibody Technology, Ltd. and Registrant (Incorporated by reference to Exhibit 10.1 contained in Registrant&#146;s Current Report on Form 8-K dated February 5, 1996, as filed with the Commission on or about February 8, 1996).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.32</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Distribution Agreement dated February 29, 1996, between Biotechnology Development, Ltd. and Registrant (Incorporated by reference to Exhibit 10.1 contained in Registrant&#146;s Current Report on Form 8-K dated February 29, 1996, as filed with the Commission on or about March 7, 1996).</font></TD>
  </TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>57</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<TABLE width="100%" border="0" cellPadding="0" cellSpacing="0">
  <TR align="left" valign="bottom">
    <TD align="center"><font size="2" face="Times New Roman, Times, serif"><B>Exhibit<BR>
      Number</B></font></TD>
    <TD><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD><font size="2" face="Times New Roman, Times, serif"><B>Description&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></font></TD>
  </TR>
  <TR>
    <TD vAlign=top><hr  size=1 color=black></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><hr  size=1 color=black></TD>
  </TR>
  <TR>
    <TD width=8% align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.33</font></TD>
    <TD width=2% vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD width=90% vAlign=top><font size="2" face="Times New Roman, Times, serif">Option Agreement dated February 29, 1996, by and between Biotechnology Development, Ltd. and Registrant (Incorporated by reference to Exhibit 10.2 contained in Registrant&#146;s Current Report on Form 8-K dated February 29, 1996, as filed with the Commission on or about March 7, 1996).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.40</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">1996 Stock Incentive Plan (Incorporated by reference to the exhibit contained in Registrant&#146;s Registration Statement in form S-8 (File No. 333-17513)).*</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.41</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Stock Exchange Agreement dated as of January 15, 1997 among the stockholders of Peregrine Pharmaceuticals, Inc. and Registrant (Incorporated by reference to Exhibit 2.1 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 1997).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.42</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">First Amendment to Stock Exchange Agreement among the Stockholders of Peregrine Pharmaceuticals, Inc. and Registrant (Incorporated by reference to Exhibit 2.1 contained in Registrant&#146;s Current Report on Form 8-K as filed with the Commission on or about May 12, 1997).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.43</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Termination and Transfer Agreement dated as of November&nbsp;14, 1997 by and between Registrant and Alpha Therapeutic Corporation&nbsp;(Incorporated by reference to Exhibit 10.1 contained in Registrant&#146;s Current Report on Form 8-K as filed with the commission on or about November 24, 1997).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.46</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Option Agreement dated October 23, 1998 between Biotechnology Development Ltd. and the Registrant (Incorporated by reference to the exhibit contained in Registrant&#146;s Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 1998, as filed with the SEC on or about December 15, 1998).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.47</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Real Estate Purchase Agreement by and between Techniclone Corporation and 14282 Franklin Avenue Associates, LLC dated December 24, 1998 (Incorporated by reference to Exhibit 10.47 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 1999).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.48</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Lease and Agreement of Lease between TNCA, LLC, as Landlord, and Techniclone Corporation, as Tenant, dated as of December 24, 1998 (Incorporated by reference to Exhibit 10.48 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 1999).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.49</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Promissory Note dated as of December 24, 1998 between&nbsp;Techniclone Corporation (Payee) and TNCA Holding, LLC (Maker) for $1,925,000 (Incorporated by reference to Exhibit 10.49 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 1999).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.50</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Pledge and Security Agreement dated as of December 24, 1998 for $1,925,000 Promissory Note between Grantors and Techniclone Corporation (Secured Party) (Incorporated by reference to Exhibit 10.50 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 1999).</font></TD>
  </TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>58</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<TABLE width="100%" border="0" cellPadding="0" cellSpacing="0">
  <TR>
    <TD vAlign=top width=91></TD>
    <TD vAlign=top width=534></TD>
    <TD vAlign=top width=534></TD>
  </TR>
  <TR valign="bottom">
    <TD align="center"><font size="2" face="Times New Roman, Times, serif"><B>Exhibit<BR>
      Number</B></font></TD>
    <TD><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD><font size="2" face="Times New Roman, Times, serif"><B>Description</B></font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><hr  size=1 color=black></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><hr  size=1 color=black></TD>
  </TR>
  <TR>
    <TD width=8% align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.51</font></TD>
    <TD width=2% vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD width=90% vAlign=top><font size="2" face="Times New Roman, Times, serif">Final fully-executed copy of the Regulation D Common Stock Equity Line Subscription Agreement dated as of June 16, 1998 between the Registrant and the Subscribers named therein (Incorporated by reference to exhibit 10.51 contained in the Registrant&#146;s Registration Statement on Form S-3/A as filed with the Commission on April 30, 1999). </font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.53</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Termination Agreement dated as of March 8, 1999 by and between Registrant and Biotechnology Development Ltd. (Incorporated by reference to Exhibit 10.53 to Registrant&#146;s Annual Report on Form 10-K for the year ended April 30, 1999).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.54</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Secured Promissory Note for $3,300,000 dated March 8, 1999 between Registrant and Biotechnology Development Ltd. (Incorporated by reference to Exhibit 10.54 to Registrant&#146;s Annual Report on Form 10-K for the year ended April 30, 1999).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.55</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Security Agreement dated March 8, 1999 between Registrant and Biotechnology Development Ltd. (Incorporated by reference to Exhibit 10.52 to Registrant&#146;s Annual Report on Form 10-K for the year ended April 30, 1999).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.56</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">License Agreement dated as of March 8, 1999 by and between Registrant and Schering A.G. (Incorporated by reference to Exhibit 10.56 to Registrant&#146;s Annual Report on Form 10-K for the year ended April 30, 1999).**</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.57</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Patent License Agreement dated October 8, 1998 between Registrant and the Board of Regents of the University of Texas System for patents related to Targeting the Vasculature of Solid Tumors (Vascular Targeting Agent patents) (Incorporated by reference to Exhibit 10.57 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 1999).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.58</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Patent License Agreement dated October 8, 1998 between Registrant and the Board of Regents of the University of Texas System for patents related to the Coagulation of the Tumor Vasculature (Vascular Targeting Agent patents) (Incorporated by reference to Exhibit 10.58 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 1999).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.59</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">License Agreement between Northwestern University and Registrant dated August 4, 1999 covering the LYM-1 and LYM-2 antibodies (Oncolym) (Incorporated by reference to Exhibit 10.59 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 1999).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.64</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Regulation D Subscription Agreement dated January 6, 2000 between Registrant and Subscribers, Swartz Investments, LLC and Biotechnology Development, LTD. (Incorporated by reference to Exhibit 10.64 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 2000).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.65</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Registration Right Agreement dated January 6, 2000 between Registrant and Subscribers of the Regulation D Subscription Agreement dated January 6, 2000 (Incorporated by reference to Exhibit 10.65 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 2000).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.66</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of Warrant to be issued to Subscribers pursuant to the Regulation D Subscription Agreement dated January 6, 2000 (Incorporated by reference to Exhibit 10.66 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 2000).</font></TD>
  </TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>59</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<TABLE width="100%" border="0" cellPadding="0" cellSpacing="0">
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif"><B>Exhibit<BR>
      Number</B></font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=bottom><font size="2" face="Times New Roman, Times, serif"><B>Description</B></font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><hr  size=1 color=black>      <font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><hr  size=1 color=black></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.67</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Warrant to purchase 750,000 shares of Common Stock of Registrant issued to Swartz Private Equity, LLC dated November 19, 1999 (Incorporated by reference to Exhibit 10.67 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 2000).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD width=8% align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.68</font></TD>
    <TD width=2% vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD width=90% vAlign=top><font size="2" face="Times New Roman, Times, serif">Amendment Agreement dated June 14, 2000 to the License Agreement dated March 8, 1999 by and between Registrant and Schering A.G. (Incorporated by reference to Exhibit 10.68 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-40716).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.69</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Waiver Agreement effective December 29, 1999 by and between Registrant and Biotechnology Development Ltd. (Incorporated by reference to Exhibit 10.69 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-40716).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.70</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Joint Venture Agreement dated May 11, 2000 by and between Registrant and Oxigene, Inc. (Incorporated by reference to Exhibit 10.70 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-40716).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.71</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Third Amendment to Regulation D Common Stock Equity Line Subscription Agreement dated June 2, 2000 by and among the Registrant, the Tail Wind Fund, Ltd. and Resonance Limited (Incorporated by reference to Exhibit 10.71 contained in Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 2000).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.73</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement to purchase up to 6,000,000 shares of Common Stock of Registrant issued to ZLP Master Fund, LTD, ZLP Master Technology Fund, LTD, Eric Swartz, Michael C. Kendrick, Vertical Ventures LLC and Triton West Group, Inc. dated November 16, 2001 (Incorporated by reference to Exhibit 10.73 to Registrant&#146;s Current Report on Form 8-K dated November 19, 2001, as filed with the Commission on November 19, 2001).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.74</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of Warrant to be issued to Investors pursuant to the Common Stock Purchase Agreement dated November 16, 2001 (Incorporated by reference to Exhibit 10.74 to Registrant&#146;s Current Report on Form 8-K dated November 19, 2001, as filed with the Commission on November 19, 2001).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.75</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement to purchase 1,100,000 shares of Common Stock of Registrant issued to ZLP Master Fund, LTD and Vertical Capital Holdings, Ltd. dated January 28, 2002 (Incorporated by reference to Exhibit 10.75 to Registrant&#146;s Current Report on Form 8-K dated January 31, 2002, as filed with the Commission on February 5, 2002).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.76</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of Warrant to be issued to Investors pursuant to the Common Stock Purchase Agreement dated January 28, 2002 (Incorporated by reference to Exhibit 10.76 to Registrant&#146;s Current Report on Form 8-K dated January 31, 2002, as filed with the Commission on February 5, 2002).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.77</font></TD>
    <TD vAlign=top width=534><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Securities Purchase Agreement dated as of August 9, 2002 between Registrant and Purchasers (Incorporated by reference to Exhibit 10.77 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</font></TD>
  </TR>
  <TR>
    <TD vAlign=top width=91></TD>
    <TD vAlign=top width=534></TD>
    <TD vAlign=top width=534></TD>
  </TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>60</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<TABLE cellSpacing="0" cellPadding="0" border="0">
  <TR>
    <TD vAlign=top width=91></TD>
    <TD vAlign=top width=534></TD>
    <TD vAlign=top width=534></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif"><B>Exhibit<BR>
      Number</B></font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=bottom><font size="2" face="Times New Roman, Times, serif"><B>Description</B></font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><hr  size=1 color=black></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><hr  size=1 color=black></TD>
  </TR>
  <TR>
    <TD width=8% align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.78</font></TD>
    <TD width=2% vAlign=top>&nbsp;</TD>
    <TD width=90% vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of Convertible Debentures issued to Purchasers pursuant to Securities Purchase Agreement dated August 9, 2002 (Incorporated by reference to Exhibit 10.78 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.79</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Registration Rights Agreement dated August 9, 2002 between Registrant and Purchasers of Securities Purchase Agreements dated August 9, 2002 (Incorporated by reference to Exhibit 10.79 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.80</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of Warrant to be issued to Purchasers pursuant to Securities Purchase Agreement dated August 9, 2002 (Incorporated by reference to Exhibit 10.80 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.81</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of Warrant issued to Debenture holders pursuant to Securities Purchase Agreement dated August 9, 2002 (Incorporated by reference to Exhibit 10.81 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.82</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of Adjustment Warrant issued to Investors pursuant to Securities Purchase Agreement dated August 9, 2002 (Incorporated by reference to Exhibit 10.82 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.83</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Securities Purchase Agreement dated as of August 9, 2002 between Registrant and ZLP Master Fund, Ltd. (Incorporated by reference to Exhibit 10.83 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.84</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Registration Rights Agreement dated August 9, 2002 between Registrant and ZLP Master Fund, Ltd. (Incorporated by reference to Exhibit 10.84 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.85</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of Warrant to be issued to ZLP Master Fund, Ltd. pursuant to Securities Purchase Agreement dated August 9, 2002 (Incorporated by reference to Exhibit 10.85 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.86</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Form of Adjustment Warrant issued to ZLP Master Fund, Ltd. pursuant to Securities Purchase Agreement dated August 9, 2002 (Incorporated by reference to Exhibit 10.86 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.87</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated June 6, 2003 between Registrant and eight institutional investors (Incorporated by reference to Exhibit 10.87 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 2003).</font></TD>
  </TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>61</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<TABLE width="100%" border="0" cellPadding="0" cellSpacing="0">
  <TR>
    <TD align="center" vAlign=middle><font size="2" face="Times New Roman, Times, serif"><B>Exhibit<BR>
      Number</B></font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=bottom><font size="2" face="Times New Roman, Times, serif"><B>Description</B></font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><hr  size=1 color=black></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><hr  size=1 color=black></TD>
  </TR>
  <TR>
    <TD width=8% align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.88</font></TD>
    <TD width=2% vAlign=top>&nbsp;</TD>
    <TD width=90% vAlign=top><font size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated June 6, 2003 between Registrant and one institutional investor (Incorporated by reference to Exhibit 10.88 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 2003).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.89</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated June 26, 2003 between Registrant and seven institutional investors (Incorporated by reference to Exhibit 10.89 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 2003).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.90</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated July 24, 2003 between Registrant and one institutional investor (Incorporated by reference to Exhibit 10.90 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 2003).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.91</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated September 18, 2003 between Registrant and one institutional investor (Incorporated by reference to Exhibit 10.91 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended October 31, 2003).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.92</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated January 22, 2004 between Registrant and one institutional investor (Incorporated by reference to Exhibit 10.92 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 2004).</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">10.93</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated March 31, 2004 between Registrant and one institutional investor***</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">21&nbsp;&nbsp;&nbsp; &nbsp;</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Subsidiaries of Registrant ***</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">23.1&nbsp;</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Consent of Independent Registered Public Accounting Firm ***</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">31.1 &nbsp;</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.***</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">31.2&nbsp;</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.***</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">32&nbsp;&nbsp;&nbsp;&nbsp;</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.***</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD colspan="3" align="center" vAlign=top><hr align="left" width="200" size="1" color="black"></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;*</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">This Exhibit is a management contract or a compensation plan or arrangement.</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">** </font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Portions omitted pursuant to a request of confidentiality filed separately with the Commission.</font></TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD align="center" vAlign=top><font size="2" face="Times New Roman, Times, serif">***</font></TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top><font size="2" face="Times New Roman, Times, serif">Filed herewith.</font></TD>
  </TR>
  <TR>
    <TD width=8%></TD>
    <TD width=2%></TD>
    <TD width=90%></TD>
  </TR>
</TABLE>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
  <TD vAlign=top></TD>
  <TD vAlign=top>&nbsp;</TD>
  <TD vAlign=top>&nbsp;</TD>
</TR>
<TR>
<TD vAlign=top width=35></TD>
<TD vAlign=top width=48><FONT face="Times New Roman, Times, Serif" size=2>(b)<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Reports on Form 8-K:&nbsp;&nbsp; </FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR></TABLE>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=83></TD>
<TD width="1149" vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>None.</FONT></TD></TR></TABLE>
<B><U></U></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>62</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><U><a name="a18"></a>SIGNATURES</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant
has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.<br>
</FONT></P>
<TABLE width="100%" align="center" CELLPADDING="0" CELLSPACING="0">
  <TR VALIGN="TOP">
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
  </TR>
  <TR VALIGN="TOP">
    <TD>&nbsp;</TD>
    <TD colspan="2"><FONT face="Times New Roman, Times, Serif" size=2>PEREGRINE PHARMACEUTICALS, INC.</FONT></TD>
  </TR>
  <TR VALIGN="TOP">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR VALIGN="TOP">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR VALIGN="TOP">
    <TD WIDTH="50%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
    <TD WIDTH="2%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN="TOP">
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Dated:&nbsp;&nbsp;July 12, 2004</FONT></TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">By:</FONT></TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;/s/ &nbsp;Steven W. King</FONT></TD>
  </TR>
  <TR VALIGN="TOP">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><hr align="left" width="250" size="1" color="black"></TD>
  </TR>
  <TR VALIGN="TOP">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Steven W. King, President and CEO</FONT></TD>
  </TR>
</TABLE>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below
by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.<br>
</FONT></P>
<TABLE WIDTH=100% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><strong><FONT face="Times New Roman, Times, Serif" size=2>Signature &nbsp;</FONT></strong></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD width="47%" ALIGN=LEFT valign="top"><strong><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;Capacity</FONT></strong></TD>
    <TD width="16%" ALIGN=LEFT><strong><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;Date</FONT></strong></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><hr align="left" width="100" size="1" color="black"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT valign="top"><hr align="left" width="100" size="1" color="black"></TD>
    <TD ALIGN=LEFT><hr align="left" width="100" size="1" color="black"></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT valign="top">&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD WIDTH=29% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>/s/ </FONT><FONT face="Times New Roman, Times, Serif" size=2>Steven W. King&nbsp;</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT valign="top"><FONT face="Times New Roman, Times, Serif" size=2>President &amp; Chief Executive </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>July 12, 2004</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><hr size="1" color="black"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT valign="top"><FONT face="Times New Roman, Times, Serif" size=2>Officer (Principal Executive</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Steven W. King</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT valign="top"><FONT face="Times New Roman, Times, Serif" size=2>Officer) </FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT valign="top">&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>/s/ Paul J. Lytle</FONT><BR>
    </TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT valign="top"><FONT face="Times New Roman, Times, Serif" size=2>Chief Financial Officer</FONT></TD>
    <TD ALIGN=LEFT valign="top"><FONT face="Times New Roman, Times, Serif" size=2>July 12, 2004</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><hr size="1" color="black"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT valign="top"><FONT face="Times New Roman, Times, Serif" size=2>(Principal Financial and </FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Paul J. Lytle</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT valign="top"><FONT face="Times New Roman, Times, Serif" size=2>Principal Accounting Officer)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT valign="top">&nbsp;</TD>
    <TD ALIGN=LEFT valign="top">&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>/s/ </FONT><FONT face="Times New Roman, Times, Serif" size=2>Carlton M. Johnson</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT valign="top"><FONT face="Times New Roman, Times, Serif" size=2>Director</FONT></TD>
    <TD ALIGN=LEFT valign="top"><FONT face="Times New Roman, Times, Serif" size=2>July 12, 2004</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><hr size="1" color="black"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT valign="top">&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Carlton M. Johnson</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT valign="top">&nbsp;</TD>
  </TR>

  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT valign="top">&nbsp;</TD>
    <TD ALIGN=LEFT valign="top">&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>/s/ Eric S. Swartz</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT valign="top"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Director</FONT></TD>
    <TD ALIGN=LEFT valign="top"><FONT face="Times New Roman, Times, Serif" size=2>July 12, 2004</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><hr size="1" color="black"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Eric S. Swartz</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT valign="top">&nbsp;</TD>
    <TD ALIGN=LEFT valign="top">&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>/s/ Clive R. Taylor, M.D., Ph.D.</FONT>    </TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT valign="top"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Director</FONT></TD>
    <TD ALIGN=LEFT valign="top"><FONT face="Times New Roman, Times, Serif" size=2>July 12, 2004</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><hr size="1" color="black"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Clive R. Taylor, M.D., Ph.D.</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
</TABLE>

<P align=center><FONT face="Times New Roman, Times, serif" size=2>63</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><a name="b1"></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>The Board of Directors and Stockholders<br>
</FONT><FONT face="Times New Roman, Times, Serif" size=2>Peregrine Pharmaceuticals, Inc.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>We have audited the accompanying consolidated balance sheets of Peregrine Pharmaceuticals, Inc. as
of April 30, 2004 and 2003, and the related consolidated statements of operations, stockholders&#146;
equity, and cash flows for each of the three years in the period ended April 30, 2004. Our audits
also included the financial statement schedule listed in the Index at Item&nbsp;15&nbsp;(a)(2). These
financial statements and schedule are the responsibility of the Company&#146;s management. Our responsibility
is to express an opinion on these financial statements and schedule based on our audits. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>We conducted our audits in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.
An audit also includes assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>In our opinion, the financial statements referred to above present fairly, in all material respects,
the consolidated financial position of Peregrine Pharmaceuticals, Inc. at April&nbsp;30, 2004 and
2003, and the consolidated results of its operations and its cash flows for each of the three years
in the period ended April 30, 2004, in conformity with U.S. generally accepted accounting principles.
Also, in our opinion, the related financial statement schedule, when considered in relation to the
basic financial statements taken as a whole, presents fairly in all material respects the information
set forth therein.<br>
</FONT></P>
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td width="50%">&nbsp;</td>
    <td width="50%"><FONT face="Times New Roman, Times, Serif" size=2><B>/s/ ERNST &amp; YOUNG LLP</B></FONT></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Orange County, California<br>
</FONT><FONT face="Times New Roman, Times, Serif" size=2>June 30, 2004,<B>&nbsp; <br>
</B></FONT><FONT face="Times New Roman, Times, Serif" size=2>except for Note 17, as to which the date is<br>
</FONT><FONT face="Times New Roman, Times, Serif" size=2>July 6, 2004</FONT></P>
<B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 1</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">

<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td>
      <P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B><a name="b2"></a>CONSOLIDATED BALANCE SHEETS<br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>AS OF APRIL 30, 2004 AND 2003</B></FONT></td>
  </tr>
  <tr>
    <td><hr  size=1 color=black></td>
  </tr>
</table>

<br>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT></strong></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2><strong>ASSETS</strong></FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CURRENT ASSETS:</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cash and cash equivalents</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 14,884,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3,137,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>


  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Trade and other receivables, net of allowance for doubtful accounts of $64,000 (2004) and $59,000 (2003)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,520,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>245,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Short-term investments</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>242,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Inventories</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,240,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>376,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Prepaid expenses and other current assets</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>240,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>257,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>17,884,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,257,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT colspan=7><FONT FACE="Times New Roman, Times, Serif" SIZE=2>PROPERTY:</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Leasehold improvements</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>389,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>291,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Laboratory equipment</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,211,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,936,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Furniture, fixtures and computer equipment</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>646,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>724,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,246,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,951,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Less accumulated depreciation and amortization</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2,373,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2,115,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property, net</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>873,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>836,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>OTHER ASSETS:</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Note receivable, net of allowance of $1,581,000 (2004) and $1,645,000 (2003)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>

  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Debt issuance costs, net</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>176,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>380,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>130,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other assets</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>380,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>306,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>TOTAL ASSETS</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 19,137,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5,399,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
  </TR>
</TABLE>

<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 2</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B>CONSOLIDATED BALANCE SHEETS<br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>AS OF APRIL 30, 2004 AND 2003  (continued)</B></FONT></td>
  </tr>
  <tr>
    <td><hr  size=1 color=black></td>
  </tr>
</table>

<br>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT></strong></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><hr  size=1 color=black></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><strong>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</strong></FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif " SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CURRENT LIABILITIES:</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Accounts payable</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,331,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 560,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Accrued clinical trial site fees</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>54,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>260,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Accrued legal and accounting fees</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>407,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>194,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Accrued royalties and license fees</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>149,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>149,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Accrued payroll and related costs</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>503,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>314,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other current liabilities</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>285,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>300,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Deferred revenue</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,524,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>531,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,253,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,308,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CONVERTIBLE DEBT, net of discount</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>760,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>DEFERRED LICENSE REVENUE</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>125,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>200,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT colspan=7><FONT FACE="Times New Roman, Times, Serif" SIZE=2>COMMITMENTS AND CONTINGENCIES</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>STOCKHOLDERS&#146; EQUITY:</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT colspan=7><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Common stock-$.001 par value; authorized 200,000,000 shares;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>outstanding &#150; 141,268,182 (2004); 119,600,501 (2003) </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>141,000 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>120,000 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Additional paid-in-capital</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>168,969,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>142,274,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Deferred stock compensation</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(257,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Accumulated deficit</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(154,351,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(140,006,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders&#146; equity</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>14,759,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,131,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>TOTAL LIABILITIES AND STOCKHOLDERS&#146; EQUITY</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 19,137,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5,399,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
  </TR>
</TABLE>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">See accompanying notes to consolidated financial statements.</font> </p>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 3</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B><a name="b3"></a>CONSOLIDATED STATEMENTS OF OPERATIONS<br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004</B></FONT></td>
  </tr>
  <tr>
    <td><hr  size=1 color=black></td>
  </tr>
</table>

<br>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2002</FONT></strong></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>REVENUES:</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Contract manufacturing revenue</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3,039,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3,346,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 46,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>License revenue</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>275,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>575,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,720,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total revenues</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,314,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,921,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,766,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT colspan=10>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT colspan=10><FONT FACE="Times New Roman, Times, Serif" SIZE=2>COSTS AND EXPENSES:</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cost of contract manufacturing &nbsp; </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,212,000 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,860,000 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12,000 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Research and development</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9,673,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8,744,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11,494,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Selling, general and administrative</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,225,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,987,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,478,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Purchased in-process research and development</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,000,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>

  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total costs and expenses</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>16,110,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>14,591,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15,984,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>LOSS FROM OPERATIONS</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(12,796,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(10,670,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(12,218,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>OTHER INCOME (EXPENSE):</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Interest and other income</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>291,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>291,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>512,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Interest and other expense</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,840,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,180,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(12,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>NET LOSS</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (14,345,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (11,559,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (11,718,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>WEIGHTED AVERAGE SHARES OUTSTANDING</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>134,299,407</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>116,468,353</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>104,540,204</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>BASIC AND DILUTED LOSS PER COMMON SHARE</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.11</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.10</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.11</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
  </TR>
</TABLE>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">See accompanying notes to consolidated financial statements.</font> </p>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 4</FONT></P>

<hr noshade size=5>
<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B><a name="b4"></a>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY<br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004</B></FONT></td>
  </tr>
  <tr>
    <td><hr  size=1 color=black></td>
  </tr>
</table>

<br>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=bottom>
    <TD align="CENTER">&nbsp;</TD>
    <TD align="CENTER" colSpan=6>&nbsp;</TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD colSpan=2 rowspan="3" align="CENTER"><FONT face="Times New Roman, Times, Serif" size=1><B>Additional<br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=1><B>Paid-In<br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=1><B>Capital</B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD colSpan=2 rowspan="3" align="CENTER"><FONT face="Times New Roman, Times, Serif" size=1><B>Deferred<br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=1><B>Stock<br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=1><B>Compensation</B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align="CENTER" colSpan=2></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD colSpan=2 rowspan="3" align="CENTER"><FONT face="Times New Roman, Times, Serif" size=1><B>Total <br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=1><B>Stockholders&#146; <br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=1><B>Equity</B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
  </TR>
  <TR vAlign=bottom>
    <TD align="CENTER">&nbsp;</TD>
    <TD align="CENTER" colSpan=6><FONT face="Times New Roman, Times, Serif" size=1><B>Common Stock</B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD colSpan=2 rowspan="2" align="CENTER"><FONT face="Times New Roman, Times, Serif" size=1><B>Accumulated<br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=1><B>(Deficit)</B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
  </TR>
  <TR vAlign=bottom>
    <TD align="CENTER">&nbsp;</TD>
    <TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>Shares</B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>Amount</B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD><FONT face="Times New Roman, Times, Serif" size=2><B>BALANCES, May 1, 2001</B></FONT></TD>
    <TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD width="3%" align=right><FONT face="Times New Roman, Times, Serif" size=2><B>97,288,934</B></FONT></TD>
    <TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2><B>$</B></FONT></TD>
    <TD width="2%" align=right><FONT face="Times New Roman, Times, Serif" size=2><B>97,000</B></FONT></TD>
    <TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2><B>$</B></FONT></TD>
    <TD width="5%" align=right><FONT face="Times New Roman, Times, Serif" size=2><B>120,253,000</B></FONT></TD>
    <TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2><B>$</B></FONT></TD>
    <TD width="5%" align=right><FONT face="Times New Roman, Times, Serif" size=2><B>(935,000</B></FONT></TD>
    <TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2><B>)</B></FONT></TD>
    <TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2><B>$</B></FONT></TD>
    <TD width="5%" align=right><FONT face="Times New Roman, Times, Serif" size=2><B>(116,729,000</B></FONT></TD>
    <TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2><B>)</B></FONT></TD>
    <TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2><B>$</B></FONT></TD>
    <TD width="4%" align=right><FONT face="Times New Roman, Times, Serif" size=2><B>2,686,000</B></FONT></TD>
    <TD width="2%" align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
  </TR>
  <TR vAlign=bottom>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued for cash under Equity Line, net of cash offering  costs of $478,000</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>5,039,203</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>5,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>5,031,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>5,036,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued for cash upon exercise of options and warrants</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>847,072</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>468,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>469,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued for cash under Shelf File No. 333-71086, net of  cash offering costs of $87,000</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>7,100,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>7,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>7,856,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>7,863,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Deferred stock compensation</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>613,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(613,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
  </TR>
  <TR vAlign=bottom>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Stock-based compensation</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>747,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>747,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Net loss</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(11,718,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(11,718,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
  </TR>
  <TR vAlign=bottom>
    <TD><FONT face="Times New Roman, Times, Serif" size=2><B>BALANCES, April 30, 2002</B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>110,275,209</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>110,000</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>134,221,000</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>(801,000</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B>)</B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>(128,447,000</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B>)</B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>5,083,000</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued for cash under Securities Purchase Agreement,&nbsp;net of issuance costs of $341,000</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>5,221,540</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>5,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,858,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,863,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued for cash under Shelf File No. 333-71086, net of issuance costs of $190,000<BR>
 </FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,900,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,853,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,856,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued upon conversion of convertible debt, net of issuance cost of $17,000
&nbsp;&nbsp; </FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,594,119</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,336,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,338,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued for cash upon exercise of options</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>109,633</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>38,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>38,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Rescind prior sale of common stock to related party</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(500,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(500,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(500,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
  </TR>
  <TR vAlign=bottom>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Intrinsic value of embedded conversion feature related to convertible debt</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,143,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>

    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,143,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Fair market value of detachable warrants issued with convertible debt</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,321,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,321,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Deferred stock compensation</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>4,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(4,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Stock-based compensation</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>548,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>548,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Net loss</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(11,559,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(11,559,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD><FONT face="Times New Roman, Times, Serif" size=2><B>BALANCES, April 30, 2003</B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>119,600,501</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>120,000</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>142,274,000</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>(257,000</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B>)</B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>(140,006,000</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B>)</B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>2,131,000</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
  </TR>
  <TR vAlign=bottom>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued for cash under June 6, 2003 Financing, net of issuance costs of $104,000
&nbsp;&nbsp; </FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,412,448</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,969,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,971,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued for cash under June 26, 2003 Financing, net of issuance costs of $101,000
&nbsp;&nbsp; </FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,599,997</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,737,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,739,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued for cash under option granted under June 26, 2003 Financing, net of
    issuance costs of $54,000&nbsp;&nbsp; </FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,599,997</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,784,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,786,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued for cash under July 24, 2003 Financing, net of issuance costs of $13,000
&nbsp;&nbsp; </FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,000,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,885,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,887,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued for cash under September 18, 2003 Financing, net of issuance costs of $19,000
&nbsp;&nbsp; </FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,800,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>5,271,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>5,273,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued for cash under November 17, 2003 Financing, net of issuance costs of $1,000
&nbsp;&nbsp; </FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,000,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>4,254,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>4,256,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued for cash under January 22, 2004 Financing, net of issuance costs of $1,000
&nbsp;&nbsp; </FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,000,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,274,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,275,000</FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
  </TR>
  <TR vAlign=bottom>
    <TD bordercolor="#EAF9E8" bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>
    Common stock issued to Aeres Biomedical Ltd for research services under
a research collaboration agreement, net of issuance costs of under $1,000</FONT></TD>
    <TD align=right bordercolor="#EAF9E8" bgcolor="#EAF9E8">&nbsp;</TD>
    <TD align=right bordercolor="#EAF9E8" bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>243,101</FONT></TD>
    <TD align=left bordercolor="#EAF9E8" bgcolor="#EAF9E8">&nbsp;</TD>
    <TD bordercolor="#EAF9E8" bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bordercolor="#EAF9E8" bgcolor="#EAF9E8"></TD>
    <TD align=right bordercolor="#EAF9E8" bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bordercolor="#EAF9E8" bgcolor="#EAF9E8"></TD>
    <TD bordercolor="#EAF9E8" bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bordercolor="#EAF9E8" bgcolor="#EAF9E8">&nbsp;</TD>
    <TD align=right bordercolor="#EAF9E8" bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>648,000</FONT></TD>
    <TD align=left bordercolor="#EAF9E8" bgcolor="#EAF9E8">&nbsp;</TD>
    <TD bordercolor="#EAF9E8" bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bordercolor="#EAF9E8" bgcolor="#EAF9E8"></TD>
    <TD align=right bordercolor="#EAF9E8" bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bordercolor="#EAF9E8" bgcolor="#EAF9E8"></TD>
    <TD bordercolor="#EAF9E8" bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bordercolor="#EAF9E8" bgcolor="#EAF9E8"></TD>
    <TD align=right bordercolor="#EAF9E8" bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bordercolor="#EAF9E8" bgcolor="#EAF9E8"></TD>
    <TD bordercolor="#EAF9E8" bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bordercolor="#EAF9E8" bgcolor="#EAF9E8">&nbsp;</TD>
    <TD align=right bordercolor="#EAF9E8" bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>648,000</FONT></TD>
    <TD align=left bordercolor="#EAF9E8" bgcolor="#EAF9E8">&nbsp;</TD>
  </TR>

  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued upon conversion of convertible debt</FONT></TD>
    <TD align=right bgcolor="#FFFFFF">&nbsp;</TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>2,817,645</FONT></TD>
    <TD align=left bgcolor="#FFFFFF">&nbsp;</TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF">&nbsp;</TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>3,000</FONT></TD>
    <TD align=left bgcolor="#FFFFFF">&nbsp;</TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF">&nbsp;</TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>2,392,000</FONT></TD>
    <TD align=left bgcolor="#FFFFFF">&nbsp;</TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF"></TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#FFFFFF"></TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF"></TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#FFFFFF"></TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF">&nbsp;</TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>2,395,000</FONT></TD>
    <TD align=left bgcolor="#FFFFFF">&nbsp;</TD>
  </TR>
  <TR vAlign=bottom>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>Common stock issued upon exercise of options and warrants, net of  issuance costs of $134,000
&nbsp;&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8">&nbsp;</TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>5,194,493</FONT></TD>
    <TD align=left bgcolor="#EAF9E8">&nbsp;</TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8">&nbsp;</TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>5,000</FONT></TD>
    <TD align=left bgcolor="#EAF9E8">&nbsp;</TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8">&nbsp;</TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>3,467,000</FONT></TD>
    <TD align=left bgcolor="#EAF9E8">&nbsp;</TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8"></TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#EAF9E8"></TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8"></TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#EAF9E8"></TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8">&nbsp;</TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>3,472,000</FONT></TD>
    <TD align=left bgcolor="#EAF9E8">&nbsp;</TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>Reversal of deferred stock compensation associated with the cancellation of unvested options
&nbsp;&nbsp; </FONT></TD>
    <TD align=right bgcolor="#FFFFFF"></TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#FFFFFF"></TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF"></TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#FFFFFF"></TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF">&nbsp;</TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>(52,000</FONT></TD>
    <TD align=left bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF">&nbsp;</TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>28,000</FONT></TD>
    <TD align=left bgcolor="#FFFFFF">&nbsp;</TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF"></TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#FFFFFF"></TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF">&nbsp;</TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>(24,000</FONT></TD>
    <TD align=left bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
  </TR>
  <TR vAlign=bottom>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>Deferred stock compensation</FONT></TD>
    <TD align=right bgcolor="#EAF9E8"></TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#EAF9E8"></TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8"></TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#EAF9E8"></TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8">&nbsp;</TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>66,000</FONT></TD>
    <TD align=left bgcolor="#EAF9E8">&nbsp;</TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8">&nbsp;</TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>(66,000</FONT></TD>
    <TD align=left bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8"></TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#EAF9E8"></TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8"></TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#EAF9E8"></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>Stock-based compensation</FONT></TD>
    <TD align=right bgcolor="#FFFFFF"></TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#FFFFFF"></TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF"></TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#FFFFFF"></TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF"></TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#FFFFFF"></TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF">&nbsp;</TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>295,000</FONT></TD>
    <TD align=left bgcolor="#FFFFFF">&nbsp;</TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF"></TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#FFFFFF"></TD>
    <TD bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#FFFFFF">&nbsp;</TD>
    <TD align=right bgcolor="#FFFFFF"><FONT face="Times New Roman, Times, Serif" size=2>295,000</FONT></TD>
    <TD align=left bgcolor="#FFFFFF">&nbsp;</TD>
  </TR>
  <TR vAlign=bottom>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>Net loss</FONT></TD>
    <TD align=right bgcolor="#EAF9E8"></TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#EAF9E8"></TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8"></TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#EAF9E8"></TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8"></TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#EAF9E8"></TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8"></TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
    <TD align=left bgcolor="#EAF9E8"></TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8">&nbsp;</TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>(14,345,000</FONT></TD>
    <TD align=left bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
    <TD bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right bgcolor="#EAF9E8">&nbsp;</TD>
    <TD align=right bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>(14,345,000</FONT></TD>
    <TD align=left bgcolor="#EAF9E8"><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=1 color=black>
    </TD>
    <TD></TD>
  </TR>
  <TR vAlign=bottom bgcolor="#eaf9e8">
    <TD><FONT face="Times New Roman, Times, Serif" size=2><B>BALANCES, April 30, 2004</B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>141,268,182</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>$</B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>141,000</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>$</B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>168,969,000</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>$</B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>&#151;</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>$</B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>(154,351,000</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B>)</B></FONT></TD>
    <TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>$</B></FONT></TD>
    <TD align=right><FONT face="Times New Roman, Times, Serif" size=2><B>14,759,000</B></FONT></TD>
    <TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B></B></FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD colSpan=2><HR SIZE=2 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=2 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=2 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=2 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=2 color=black>
    </TD>
    <TD></TD>
    <TD></TD>
    <TD colSpan=2><HR SIZE=2 color=black>
    </TD>
    <TD></TD>
  </TR>
</TABLE>
<B></B>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">See accompanying notes to consolidated financial statements.</font> </p>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 5</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B><a name="b5"></a>CONSOLIDATED STATEMENTS OF CASH FLOWS<br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004</B></FONT></td>
  </tr>
  <tr>
    <td><hr  size=1 color=black></td>
  </tr>
</table>

<br>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2002</FONT></strong></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CASH FLOWS FROM OPERATING ACTIVITIES:</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net loss</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (14,345,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (11,559,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (11,718,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT colspan=11><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Allowance for bad debts</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>25,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Depreciation</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>374,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>364,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>424,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Gain on disposal of property</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(73,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Stock-based compensation expense</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>271,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>548,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>747,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Amortization of discount on convertible debt and debt issuance costs</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,811,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,017,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Stock issued for services under research collaboration</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>616,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Trade and other receivables</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,275,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>83,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(307,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Short-term investments</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>242,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(242,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Inventories</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(864,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(370,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(6,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>49,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>127,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(100,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Accounts payable</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>771,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(510,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>394,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Accrued clinical trial site fees</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(206,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(347,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>339,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Deferred revenue</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>918,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>701,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(3,491,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Other accrued expenses and current liabilities</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>387,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(117,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>413,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(11,251,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(10,305,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(13,353,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CASH FLOWS FROM INVESTING ACTIVITIES:</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Proceeds from sale of property</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>131,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Property acquisitions</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(411,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(184,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(280,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Increase in other assets</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(250,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(35,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(661,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(173,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(184,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT colspan=11><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CASH FLOWS FROM FINANCING ACTIVITIES:</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock, net of issuance costs of $428,000 (2004), $548,000 (2003), and $565,000 (2002)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>23,659,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,740,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13,368,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>

  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Rescind prior sale of common stock to related party</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(500,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Proceeds from issuance of convertible debt, net of issuance costs of $363,000 (2003)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,387,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>

  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;Principal payments on notes payable</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(84,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(86,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>23,659,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7,543,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13,282,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
</TABLE>

<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 6</FONT></P>
<hr noshade size=5>
<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B>CONSOLIDATED STATEMENTS OF CASH FLOWS<br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued)</B></FONT></td>
  </tr>
  <tr>
    <td><hr  size=1 color=black></td>
  </tr>
</table>

<br>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2002</FONT></strong></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 11,747,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (2,935,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (255,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CASH AND CASH EQUIVALENTS, Beginning of year</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,137,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6,072,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6,327,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CASH AND CASH EQUIVALENTS, End of year</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 14,884,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3,137,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 6,072,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SUPPLEMENTAL INFORMATION:</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Interest paid</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 78,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 104,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 5,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>

    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Property acquired in exchange for note payable</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 82,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Conversion of Convertible Debt into common stock</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,395,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,355,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Common stock issued for services under research collaboration</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 648,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
  </TR>
</TABLE>
<br>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
supplemental information relating to conversion of convertible debentures into common stock, common
stock issued in exchange for services, provision for note receivable, and property acquired in exchange
for note payable, see Notes&nbsp;4, 6, 8, and 9.</FONT></TD>
</TR></TABLE>

<p align="center"> <font size="2" face="Times New Roman, Times, serif">See accompanying notes to consolidated financial statements.</font> </p>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 7</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B> <strong> <a name="b6"></a>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong> <br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 </B></FONT></td>
  </tr>
  <tr>
    <td><hr  size=1 color=black></td>
  </tr>
</table>
<P><FONT face="Times New Roman, Times, Serif" size=2>1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ORGANIZATION AND BUSINESS DESCRIPTION</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Organization</I> &nbsp;&#150; In this Annual Report, &#147;Peregrine,&#148; &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148;
and &#147;our,&#148; refer to Peregrine Pharmaceuticals, Inc. We were incorporated in the state of
Delaware on September 25, 1996. We were originally incorporated in California in June 1981 under
the name Techniclone International Corporation and subsequently merged into Techniclone Corporation
in March 1997. We changed our name to Peregrine Pharmaceuticals, Inc. in October 2000 from Techniclone
Corporation. In conjunction with our name change to Peregrine Pharmaceuticals, Inc., we changed the
name of our wholly-owned subsidiary acquired in April 1997 to Vascular Targeting Technologies, Inc.
(formally known as Peregrine Pharmaceuticals, Inc.). In January 2002, we commenced operations of
our wholly-owned subsidiary, Avid Bioservices, Inc. (&#147;Avid&#148;), which was formed from the
facilities and expertise of Peregrine. Avid provides contract manufacturing services for biopharmaceutical
and biotechnology businesses, including the manufacture of biologics under current Good Manufacturing
Practices, cell culture, process development, and testing of biologics.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Business Description &#150;</I> &nbsp;We are a biotechnology company engaged in the research, development and manufacturing of biotechnology
products. We are organized into two reportable operating segments: (i) Peregrine, the parent company,
is engaged in the research and development of novel therapeutics and (ii) Avid, our wholly-owned
subsidiary, is engaged in providing contract manufacturing and development of biologics for biopharmaceutical
and biotechnology companies.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT face="Times New Roman, Times, Serif" size=2>We are primarily focused on developing therapeutic agents that effect blood vessels and blood flow
in cancer and other diseases. Our vascular research programs fall under several different proprietary
platforms including Anti-Phospholipid Therapy (&quot;APT&quot;), Vascular Targeting Agents (&quot;VTAs&quot;), anti-Angiogenesis
and Vasopermeation Enhancement Agents (&quot;VEAs&quot;). Our first APT agent is scheduled to enter into clinical
trials during calendar year 2004. These therapeutic agents may have applications in the treatment
of cancer and other diseases such as viral infections, diabetes, arthritis, skin disorders and eye
diseases. Our most clinically advanced therapeutic program is based on a targeting platform outside
vascular biology. This technology platform is known as Tumor Necrosis Therapy (&quot;TNT&quot;) and targets dead
or dying tumor cells to deliver therapeutic reagents that are common to the majority of different tumor types.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>As
of April 30, 2004, we had $14,884,000 in cash and cash equivalents on hand. We have expended substantial
funds on the development of our product candidates and for clinical trials and we have incurred negative
cash flows from operations for the majority of our years since inception. We expect negative cash
flows from operations to continue until we are able to generate sufficient revenue from the contract
manufacturing services provided by Avid and/or from the sale and/or licensing of our products under
development. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT face="Times New Roman, Times, Serif" size=2>Revenues earned by Avid during fiscal years ended April 30, 2004, 2003 and 2002 amounted to $3,039,000,
$3,346,000 and $46,000, respectively. We expect that Avid will continue to generate revenues which
should lower consolidated cash flows used in operations, although we expect those near term revenues
will be insufficient to cover consolidated cash flows used in operations. As such, we will continue
to need to raise additional capital to provide for our operations, including the anticipated development
and clinical trial costs of Tarvacin&#153; and Cotara&#153;, the anticipated research and development
costs associated with Anti-Phospholipid Therapy (APT), Vasopermeation Enhancement Agents (&#147;VEA&#146;s&#148;)
and Vascular Targeting Agents (&#147;VTA&#146;s&#148;), and the potential expansion of our manufacturing
capabilities.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 8</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B> <strong> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong> <br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004  (continued)</B></FONT></td>
  </tr>
  <tr>
    <td><hr  size=1 color=black></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2></FONT><FONT face="Times New Roman, Times, Serif" size=2>We plan to raise additional capital through the offer and sale of shares of our common stock in a public
offering pursuant to our current shelf registration statement on Form S-3, File No. 333-109982. As
of June 30, 2004, we had approximately 8,757,000 shares available for possible future transactions
under the shelf registration statement. However, given uncertain market conditions and the volatility
of our stock price, we may not be able to sell our securities in public offerings at prices and on
terms that are favorable to us, if at all. We believe we have sufficient cash on hand to meet our
obligations on a timely basis through fiscal year 2005. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition to equity financing, we are always actively exploring various other non-dilutive sources
of cash by utilizing our many assets. Our broad intellectual property portfolio allows us to develop
products in-house while at the same time we are able to out-license certain areas of the technology.
In addition, for the products that we develop internally, we may seek a licensing or development
partner after we have generated clinical proof of efficacy, which we believe will generate the most
value to the Company. We are also seeking to out-license or partner products we do not have sufficient
financial resources to develop internally, such as the registration trial using Cotara&#153; for
the treatment of brain cancer, which final stage trial would require significant financial resources
to complete. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2></FONT><FONT face="Times New Roman, Times, Serif" size=2>We also have the facilities of Avid that we may utilize for non-dilutive financing. During the past
fiscal year, we have had discussions with several parties interested in either partnering or acquiring
Avid. If the right opportunity and financial terms are presented to us and if the manufacturing needs
of our customers and Peregrine are not jeopardized, we would be open to a possible strategic transaction
related to Avid. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>There can be no assurances that we will be successful in raising sufficient capital on terms acceptable
to us, or at all (from either debt, equity or the licensing, partnering or sale of technology assets
and/or the sale of all or a portion of Avid), or that sufficient additional revenues will be generated
from Avid or under potential licensing agreements to complete the research, development, and clinical
testing of our product candidates beyond fiscal year 2005. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>2. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basis
of Presentation - </I>The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned
subsidiaries, Avid Bioservices, Inc. and Vascular Targeting Technologies, Inc. All intercompany balances
and transactions have been eliminated.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash
and Cash Equivalents</I> &nbsp;<I>-</I> We consider all highly liquid, short-term investments with an initial maturity of three months or
less to be cash equivalents. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allowance
for Doubtful Receivables -</I> &nbsp;We continually monitor our allowance for all receivables. A considerable amount of judgment
is required in assessing the ultimate realization of these receivables and we estimate an allowance
for doubtful accounts based on factors that appear reasonable under the circumstances.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Short-term
Investments</I> <I>-</I> We classify our short-term investments as trading securities under the requirements of Statement of
Financial Accounting Standards No. 115 (&#147;SFAS No. 115&#148;), <I>Accounting for Certain Investments in Debt and Equity Securities</I>. SFAS No. 115 considers trading securities as securities that are bought with the intention of being
sold in the near term for the general purpose of realizing profits. Trading securities are recorded
at fair market value and unrealized holding gains and losses on trading securities are included in
other income in the accompanying consolidated financial statements.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 9</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B> <strong> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong> <br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued)</B></FONT></td>
  </tr>
  <tr>
    <td><hr  size=1 color=black></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories</I> &nbsp;<I>-</I> Inventories are stated at the lower of cost or market and primarily includes raw materials, direct
labor, and overhead costs associated with our wholly-owned subsidiary, Avid. Inventories consist
of the following at April 30, 2004 and April 30, 2003:</FONT></P>
<TABLE WIDTH=60% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT></strong></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Raw materials</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 411,000</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 205,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Work-in-process</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>829,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>171,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total inventories</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,240,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 376,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
  </TR>
</TABLE>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></B> <I>Concentrations of Credit Risk</I> &nbsp;- The majority of trade and other receivables are from customers in the United States and Israel.
Most contracts require up-front payments and installment payments as the project progresses. We perform
periodic credit evaluations of our ongoing customers and generally do not require collateral, but
we can terminate any contract if a material default occurs. Reserves are maintained for potential
credit losses, and such losses have been minimal and within our estimates. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></B> <I>Comprehensive Loss</I> &nbsp;- Comprehensive loss is equal to net loss for all periods presented.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property</I> &nbsp;- Property is recorded at cost. Depreciation and amortization are computed using the straight-line
method over the estimated useful lives of the related asset, generally ranging from three to seven
years. Amortization of leasehold improvements is calculated using the straight-line method over the
shorter of the estimated useful life of the asset or the remaining lease term.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment</I> &nbsp;&#150; We assess recoverability of our long-term assets by comparing the remaining carrying
value to the value of the underlying collateral or the fair market value of the related long-term
asset based on undiscounted cash flows. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
Revenue </I>- Deferred revenue primarily consists of up-front contract fees and installment payments received prior
to the recognition of revenues under contract manufacturing and development agreements and up-front
license fees received under technology licensing agreements. Deferred revenue is generally recognized
once the service has been provided, all obligations have been met and/or upon shipment of the product
to the customer.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Revenue Recognition </I>- We currently derive revenues primarily from licensing agreements associated with Peregrine&#146;s
technologies under development and from contract manufacturing services provided by Avid.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> We recognize revenues pursuant to Staff Accounting Bulletin No. 101 (&#147;SAB No. 101&#148;), <I>Revenue Recognition in Financial Statements </I>and Staff Accounting Bulletin No. 104 (&#147;SAB No. 104&#148;), <I>Revenue Recognition</I>. These bulletins draw on existing accounting rules and provide specific guidance on how those accounting
rules should be applied. Revenue is generally realized or realizable and earned when (i) persuasive
evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii)

the seller&#146;s price to the buyer is fixed or determinable, and (iv) collectibility is reasonably
assured. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 10</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B> <strong> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong> <br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued)</B></FONT></td>
  </tr>
  <tr>
    <td><hr  size=1 color=black></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenues
associated with licensing agreements primarily consist of nonrefundable up-front license fees and
milestones payments. Revenues under licensing agreements are recognized based on the performance
requirements of the agreement. Nonrefundable up-front license fees received under license agreements,
whereby continued performance or future obligations are considered inconsequential to the relevant
licensed technology, are generally recognized as revenue upon delivery of the technology. Nonrefundable
up-front license fees, whereby ongoing involvement or performance obligations exist, are generally
recorded as deferred revenue and generally recognized as revenue over the term of the performance
obligation or relevant agreement. Under a license agreement with Schering A.G. (Note 9), the obligation
period was not contractually defined in relation to a $300,000 upfront fee. Under this circumstance,
we exercised judgment in estimating the period of time over which certain deliverables will be provided
to enable the licensee to practice the license, which was determined to be 48 months. The estimated
period of 48 months was primarily determined based on the historical experience with Schering A.G.
under a separate license agreement. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract
manufacturing revenues are generally recognized once the service has been provided and/or upon shipment
of the product to the customer. We also record a provision for estimated contract losses, if any,
in the period in which they are determined. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
July 2000, the Emerging Issues Task Force (&#147;EITF&#148;) released Issue 99-19 (&#147;EITF 99-19&#148;),
<I>Reporting Revenue Gross as a Principal versus Net as an Agent</I>. EITF 99-19 summarized the EITF&#146;s views on when revenue should be recorded at the gross amount

billed to a customer because it has earned revenue from the sale of goods or services, or the net

amount retained (the amount billed to the customer less the amount paid to a supplier) because
it
has earned a fee or commission. In addition, the EITF released Issue 00-10 (&#147;EITF 00-10&#148;),
<I>Accounting for Shipping and Handling Fees and Costs</I>, and Issue 01-14 (&#147;EITF 01-14&#148;), <I>Income Statement Characterization of Reimbursements Received for &#147;Out-of-Pocket&#148; Expenses

Incurred</I>. EITF 00-10 summarized the EITF&#146;s views on how the seller of goods should classify in the income
statement amounts billed to a customer for shipping and handling and the costs associated with shipping
and handling. EITF 01-14 summarized the EITF&#146;s views on when the reimbursement of out-of-pocket
expenses should be characterized as revenue or as a reduction of expenses incurred. Our revenue recognition
policies are in compliance with EITF 99-19, EITF 00-10 and EITF 01-14 whereby we recorded revenue
for the gross amount billed to customers (the cost of raw materials, supplies, and shipping, plus
the related handling mark-up fee) and we recorded the cost of the amounts billed as cost of sales
as we act as a principal in these transactions. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Fair Value of Financial Instruments </I>- Our financial instruments consist principally of cash and cash equivalents, receivables, inventories,
accounts payable, and accrued liabilities. We believe all of the financial instruments&#146; recorded
values approximate current values due to the short-term nature of these instruments.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Use of Estimates</I> &nbsp;- The preparation of our financial statements in conformity with accounting principles generally
accepted in the United States requires management to make estimates and assumptions that affect the
amounts reported in the consolidated financial statements and accompanying notes. Actual results
could differ from these estimates. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 11</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B> <strong> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong> <br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued)</B></FONT></td>
  </tr>
  <tr>
    <td><hr  size=1 color=black></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Basic and Diluted Net Loss Per Common Share</I> &nbsp;- Basic and diluted net loss per common share is calculated in accordance with Statement of
Financial Accounting Standards No. 128, <I>Earnings per Share</I>. Basic net loss per common share is computed by dividing the net loss by the weighted average number
of common shares outstanding during the period and excludes the dilutive effects of options, warrants
and convertible instruments. Diluted net loss per common share is computed by dividing the net loss
by the sum of the weighted average number of common shares outstanding during the period plus the
potential dilutive effects of options, warrants, and convertible debt outstanding during the period.
Potentially dilutive common shares consist of stock options and warrants calculated in accordance
with the treasury stock method, but are excluded if their effect is antidilutive. The potential dilutive
effect of convertible debt was calculated using the if-converted method assuming the conversion of
the convertible debt as of the earliest period reported or at the date of issuance, if later. Because
the impact of options, warrants, and other convertible instruments are antidilutive, there is no
difference between basic and diluted loss per share amounts for the three years ended April 30, 2004.
We excluded the dilutive effect of the following shares issuable upon the exercise of options, warrants,
and convertible debt outstanding during the period because their effect is antidilutive as we reported
a net loss in the periods presented:</FONT></P>
<TABLE WIDTH=80% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2002</FONT></strong></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD WIDTH=59% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Common stock equivalent shares assuming issuance of</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;shares represented by outstanding stock options</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;and warrants utilizing the treasury stock method </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11,462,682</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,354,442 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7,141,459 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Common stock equivalent shares assuming issuance of</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;shares upon conversion of convertible</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;debt utilizing the if-converted method</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>563,054</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12,025,736</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,354,442</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7,141,459</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Weighted outstanding options and warrants to purchase up to
8,393,083, 13,845,742 and 6,160,275 shares
of common stock for the fiscal years ended April 30, 2004, 2003 and 2002, respectively, were also
excluded from the calculation of diluted earnings per common share because their exercise prices
were greater than the average market price during the period. In addition, weighted average shares
of 2,581,547, assuming issuance of shares upon conversion of convertible debt for fiscal year 2003,
were also excluded from the calculation of diluted earnings per common share because the conversion
price was greater than the average market price during the period.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Income Taxes</I> &#150; We utilize the liability method of accounting for income taxes as set forth in Statement of
Financial Accounting Standards No. 109, <I>Accounting for Income Taxes</I>. Under the liability method, deferred taxes are determined based on the differences between the consolidated
financial statements and tax basis of assets and liabilities using enacted tax rates. A valuation
allowance is provided when it is more likely than not that some portion or the entire deferred tax
asset will not be realized.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
and Development</I> &nbsp;- Research and development costs are charged to expense when incurred in accordance with Statement
of Financial Accounting Standards No. 2, <I>Accounting for Research and Development Costs</I>. Research and development expenses primarily include (i) payroll and related costs associated with
research and development personnel, (ii) costs related to clinical and pre-clinical testing of our
technologies under development, (iii) the costs to manufacture the product candidates, including
raw materials and supplies, (iv) patent filing and maintenance fees, (v) expenses for research and
services rendered under outside contracts, including sponsored research funding, and (vi) facility
expenses. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 12</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B> <strong> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong> <br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued)</B></FONT></td>
  </tr>
  <tr>
    <td><hr  size=1 color=black></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Stock-based Compensation</I> &#150; In December 2002, the FASB issued Statement of Financial Accounting Standards No. 148 (&#147;SFAS
No. 148&#148;), Accounting for Stock-Based Compensation-Transition and Disclosure, which we adopted
on February 1, 2003. SFAS No. 148 amends SFAS No. 123 (&#147;SFAS No. 123&#148;), <I>Accounting for Stock-Based Compensation, </I>and provides alternative methods of transition for a voluntary change to the fair value based method
of accounting for stock-based employee compensation. In addition, SFAS No. 148 amends the disclosure
requirements of SFAS No. 123 to require prominent disclosures in both annual and interim financial
statements about the method of accounting for stock-based employee compensation and the effect of
the method used on reported results.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not adopted a method under SFAS No. 148 to expense stock options but rather we continue to apply
the provisions of SFAS No. 123; however, we have adopted the additional disclosure provisions of
the statement. As SFAS No. 123 permits, we elected to continue accounting for our employee stock
options in accordance with Accounting Principles Board Opinion No. 25 (&#147;APB No. 25&#148;), <I>Accounting for Stock Issued to Employees</I> <I>and related interpretations</I>. APB No. 25 requires compensation expense to be recognized for stock options when the market price
of the underlying stock exceeds the exercise price of the stock option on the date of the grant.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
utilize the guidelines in APB No. 25 for measurement of stock-based transactions for employees and,
accordingly no compensation expense has been recognized for the options in the accompanying consolidated
financial statements for the three years ended April 30, 2004. Had we used a fair value model for
measurement of stock-based transactions for employees under SFAS No. 123 and amortized the expense
over the vesting period, pro forma information would be as follows:</FONT></P>
<TABLE WIDTH=90% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT></strong></TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><strong><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2002</FONT></strong></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr  size=1 color=black></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net loss, as reported</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=11% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (14,345,000</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=11% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (11,559,000</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=11% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (11,718,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Stock-based employee compensation cost that</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT colspan=11><FONT FACE="Times New Roman, Times, Serif" SIZE=2>would have been included in the determination</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>of net loss if the fair value based method had</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>been applied to all awards </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2,541,000 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2,003,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,883,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=1 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pro forma net loss as if the fair value based</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>method had been applied to all awards</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (16,886,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (13,562,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (13,601,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>

  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Basic and diluted net loss per share, as reported</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.11</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.10</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.11</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Basic and diluted net loss per share, pro forma</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.13</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.12</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (0.13</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>

  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR SIZE=2 color=black></TD>
    <TD></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair value of stock options on the date of grant and the assumptions used to estimate the fair value
of the stock options using the Black-Scholes option valuation model, were as follows:</FONT></P>
<TABLE WIDTH=80% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Weighted average fair value of stock options granted</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.59</FONT></TD>
    <TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.64</FONT></TD>
    <TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.53</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Risk-free interest rate</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.31</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.31</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4.19</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Expected life (in years)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Expected volatility factor</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>124</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>122</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>162</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Expected dividend yield</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Black-Scholes option valuation model was developed for use in estimating the fair value of traded
options that have no vesting restrictions and are fully transferable. Option valuation models require
the input of highly subjective assumptions, including the expected stock volatility. Because our
options have characteristics significantly different from those of traded options and because changes
in the subjective input assumptions can materially affect the fair values estimated, in the opinion
of management, the existing models do not necessarily provide a reliable measure of the fair value
of our options. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 13</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B> <strong> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong> <br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued)</B></FONT></td>
  </tr>
  <tr>
    <td><hr  size=1 color=black></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Stock-based compensation expense recorded during each of the three years in the periods ended April
30, 2004 primarily relates to stock option grants made to consultants and has been measured utilizing
the Black-Scholes option valuation model. Stock-based compensation expense recorded during fiscal
years 2004, 2003 and 2002 amounted to $271,000, $548,000, and $747,000, respectively, and is being
amortized over the estimated period of service or related vesting period. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition, during August 2003, a member of our Board of Directors voluntarily cancelled an option
to purchase shares of our common stock due to an insufficient number of stock options available in
our stock option plans for new employee grants. During October 2003, we received stockholder approval
for our 2003 Stock Incentive Plan (&#147;2003 Plan&#148;) and the director was re-granted options
to purchase shares under the 2003 Plan. In accordance with FASB Interpretation No. 44 (&#147;FIN
No. 44&#148;), <I>Accounting for Certain Transactions Involving Stock Compensation</I>, the option granted to the director under the 2003 Plan is subject to variable accounting, which could
result in increases or decreases to compensation expense in subsequent periods based on movements
in the intrinsic value of the option until the date the option is exercised, forfeited or expires
unexercised. Decreases in compensation expense are limited to the net expense previously reported.
During the fiscal year ended April 30, 2004, as a result of movements in the intrinsic value of the
option, we did not record compensation expense with respect to such option in accordance with FIN No. 44.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recent
Accounting Pronouncements</I> &nbsp;- In August 2001, the FASB issued Statement of Financial Accounting Standards No. 143 (&#147;SFAS
No. 143&#148;), <I>Asset Retirement Obligations</I>. SFAS No. 143 requires entities to record the fair value of a liability for an asset retirement obligation
in the period in which it is incurred. When the liability is initially recorded, the entity capitalizes
the cost by increasing the carrying amount of the related long-lived asset. Over time, the liability
is accreted to its present value each period, and the capitalized cost is depreciated over the useful
life of the related asset. Upon settlement of the liability, an entity either settles the obligation
for its recorded amount or incurs a gain or loss upon settlement. The standard is effective for fiscal
years beginning after June 15, 2002. We adopted SFAS No. 143 on May 1, 2003, which had no material
impact on our consolidated financial position and results of operations. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January&nbsp;2003, the FASB issued Interpretation No. 46 (&#147;FIN No. 46&#148;), <I>Consolidation of Variable Interest Entities</I>, as amended, an interpretation of Accounting Research Bulletin No. 51, issued in January 2003. FIN
No. 46 requires a variable interest entity (or VIE) to be consolidated by a company if that company
absorbs a majority of the VIE&#146;s expected losses, receives a majority of the entity&#146;s expected
residual returns, or both, as a result of ownership, contractual or other financial interest in the
VIE. Prior to the adoption of FIN 46, VIE&#146;s were generally consolidated by companies owning
a majority voting interest in the VIE. FIN No. 46 is effective for all new variable interest entities
created or acquired after January&nbsp;31, 2003. For VIE&#146;s created or acquired prior to February&nbsp;1,
2003, the provisions of FIN No. 46 are required to be adopted in periods ending after December 15,
2003. We adopted FIN No. 46 during the quarter ended January 31, 2004, which had no material impact
on our consolidated financial position and results of operations.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 14</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B> <strong> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong> <br>
    </B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued)</B></FONT></td>
  </tr>
  <tr>
    <td><hr  size=1 color=black></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2003, the FASB issued Statement of Financial Accounting Standards No. 150, (&#147;SFAS No. 150&#148;),
<I>Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</I>. SFAS No. 150 establishes standards for how an issuer classifies and measures certain financial instruments
with characteristics of both liabilities and equity. SFAS No. 150 is effective for financial instruments
entered into or modified after May 31, 2003, and otherwise is effective at the beginning of the first
interim period beginning after June 15, 2003. We adopted SFAS No. 150 on August 1, 2003, which had
no material impact on our financial position and results of operations.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2003, the SEC issued Staff Accounting Bulletin No. 104, (&#147;SAB No. 104&#148;), <I>Revenue Recognition</I>. SAB No. 104 revises or rescinds portions of the SAB No. 101, <I>Revenue Recognition in Financial Statements</I> and included in Topic 13 of the Codification of Staff Accounting Bulletins. SAB No. 104 deletes interpretative
guidance no longer necessary, and conforms the interpretive material retained, because of pronouncements
issued by the FASB&#146;s EITF on various revenue recognition topics, including EITF 00-21, <I>Revenue Arrangements with Multiple Deliverables</I>. SAB No. 104 also rescinds the SEC staff&#146;s <I>Revenue Recognition in Financial Statements &#150; Frequently Asked Questions and Answers</I> (the &#147;FAQ&#148;) issued in conjunction with SAB No. 101 and selected portions of the FAQ have
been incorporated into SAB No. 104. We adopted SAB No. 104 during December 2003, which had no material
impact on our consolidated financial position and results of operations.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SHORT-TERM INVESTMENTS</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
March 2003, we received 61,653 shares of SuperGen, Inc. common stock under a license agreement dated
February 13, 2001 (Note 9). We account for our short-term investments at fair value as trading securities
in accordance with SFAS No. 115. The cost basis of the common stock was $200,000. During the quarter
ended July 31, 2003, we sold all 61,653 shares of common stock of SuperGen, Inc. for gross proceeds
of $271,000. The realized gain of $71,000 relating to the short-term investment is included in interest
and other income in the accompanying consolidated financial statements for the year ended April 30, 2004.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES RECEIVABLE</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
December 1998, we completed the sale and subsequent leaseback of our two facilities (Note 5) and
recorded an initial note receivable from the buyer of $1,925,000. In accordance with the related
lease agreement, if we default under the lease agreement, including but not limited to, filing a
petition for bankruptcy or failure to pay the basic rent, the note receivable shall be deemed to
be immediately satisfied in full and the buyer shall have no further obligation to us for such note
receivable. Although we have made all payments under the lease agreement and we have not filed for
protection under the laws of bankruptcy, during the quarter ended October 31, 1999, we did not have
sufficient cash on hand to meet our obligations on a timely basis and we were operating at significantly
reduced levels. In addition, at that time, if we could not raise additional cash by December 31,
1999, we may have had to file for protection under the laws of bankruptcy. Due to the uncertainty
of the our ability to pay our lease obligations on a timely basis, we established a 100% reserve
for the note receivable in the amount of $1,887,000 as of October 31, 1999. We reduce the reserve
as payments are received and we record the reduction as interest and other income in the accompanying
consolidated statement of operations. Due to the uncertainty of our ability to fund our operations
beyond the next twelve months, the carrying value of the note receivable approximates its fair value
at April 30, 2004. We have received all payments to date under the note receivable. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 15</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">

<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
  following represents a rollforward of the allowance of the note receivable for the two years ended
April 30, 2004:</FONT></P>

<TABLE width=60% border=0 align="center" cellPadding=0 cellSpacing=0>
<TR vAlign=bottom>
<TD align="CENTER"></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>2004</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>2003</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=1>
</TD>
<TD></TD>
<TD></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>Allowance balance, beginning </FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="18%" align=right><FONT face="Times New Roman, Times, Serif" size=2>1,705,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="18%" align=right><FONT face="Times New Roman, Times, Serif" size=2>1,760,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>Principal payments received</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(60,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(55,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>Allowance balance, ending</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,645,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,705,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>5. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PROPERTY</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December 24, 1998, we completed the sale and subsequent leaseback of our two facilities with an unrelated
entity. The aggregate sales price of the two facilities was $6,100,000, comprised of $4,175,000 in
cash and a note receivable of $1,925,000 (Note 4). In accordance with SFAS No. 98, we accounted for
the sale and subsequent leaseback transaction as a sale and removed the net book value of land, buildings
and building improvements of $7,014,000 from the consolidated financial statements and recorded a
loss on sale of $1,171,000, which included selling expenses of $257,000.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>6. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES PAYABLE</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
May 2002, we entered into two separate note payable agreements with an aggregate original amount
due of $134,000 to finance laboratory equipment. The notes, which were unsecured, bore interest at
10% per annum and were paid in full during March 2003. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>7. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; COMMITMENTS AND CONTINGENCIES</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating
Lease</I> &nbsp;- In December 1998, we sold and subsequently leased back our two facilities in Tustin, California.
The lease has an original lease term of 12 years with two 5-year renewal options and includes scheduled
rental increases of 3.35% every two years. Annual rent expense under the lease agreement totaled
$735,000 during fiscal year 2004, 2003 and 2002. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
fiscal year 2004, we entered into an operating lease agreement to lease certain office equipment.
The lease has a 5 year term and annual minimum lease payments are $29,000. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
April 30, 2004, future minimum lease payments and sublease income under all non-cancelable operating
leases are as follows: </FONT></P>

<TABLE width=80% border=0 align="center" cellPadding=0 cellSpacing=0>
<TR vAlign=bottom>
<TD align="left"> <b><font size="1" face="Times New Roman, Times, serif">Year ending<br>
April 30: </font></b></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>Minimum Lease<br>
  Payments</B> </FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>Sublease Income</B> </FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>Net Lease Payments</B> </FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD>
<HR align="left" color=black width="100" SIZE=1>
</TD>
<TD colspan="2">  <HR color="#000000"size=1></TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; 2005 </FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="15%" align=right bgcolor="#eaf9e8"><FONT face="Times New Roman, Times, Serif" size=2>760,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="15%" align=right><FONT face="Times New Roman, Times, Serif" size=2>(58,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="18%" align=right><FONT face="Times New Roman, Times, Serif" size=2>702,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; 2006</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>774,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(59,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>715,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; 2007</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>784,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(40,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>744,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; 2008</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>799,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>799,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; 2009</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>793,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>793,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp; Thereafter</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,326,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,326,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>5,236,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(157,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>5,079,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 16</FONT></P>
<HR noshade SIZE=5>
<br>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Rental Income</I> &nbsp;&#150; We&nbsp;currently sublease portions of our unused space. Sublease rental income totaled
$179,000, $216,000 and $326,000 for fiscal years 2004, 2003 and 2002, respectively.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>8. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONVERTIBLE DEBT</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
August 9, 2002, we entered into a private placement with four investors under a Debenture Securities
Purchase Agreement (&#147;Debt SPA&#148;), whereby we issued Convertible Debentures (&#147;Convertible
Debt&#148;) for gross proceeds of $3,750,000. The Debenture earns interest at a rate of 6% per annum
payable in cash semi-annually each June 30th and December 31st, and mature in August 2005. Under
the terms of the Debenture, the principal amount is convertible, at the option of the holder, into
a number of shares of our common stock calculated by dividing the unpaid principal amount of the
Convertible Debt by the initial conversion price of $0.85 per share (&#147;Conversion Price&#148;). </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> In accordance with EITF 00-27, <I>Application of Issue No. 98-5 to Certain Convertible Instruments</I>, we initially recorded the convertible debt net of discount of (i) the relative fair value of the
warrants issued in the amount of $1,321,000 and (ii) the intrinsic value of the embedded conversion
feature in the amount of $1,143,000. The relative fair value of the warrants was determined in accordance
with the Black-Scholes valuation model based on the warrant terms. The debt discount associated with
unconverted Convertible Debt and warrants are amortized as non-cash interest expense on a straight-line
basis over the term of the Convertible Debt, which approximates the effective interest method, and
the amortization is recorded as interest expense in the accompanying consolidated statements of operations.
Upon conversion of any Convertible Debt, the entire unamortized debt discount remaining at the date
of conversion that is attributed to the converted Convertible Debt is immediately recognized as interest
expense in the accompanying consolidated statements of operations. During fiscal years 2004 and 2003,
we recognized $1,635,000 and $829,000, respectively, in non-cash interest expense associated with
the Convertible Debt, which amount was included in interest and other expense in the accompanying
consolidated statements of operations.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> As of April 30, 2004, all outstanding
Convertible Debt was converted into common stock and the associated
discount was fully amortized as non-cash interest expense in the accompanying financial statements
as follows:</FONT></P>

<TABLE width=80% border=0 align="center" cellPadding=0 cellSpacing=0>
<TR vAlign=bottom>
<TD align="CENTER"></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>2004</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>2003</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2><B><U>Principal Balance of Convertible Debt</U></B></FONT></TD>
<TD width="1%" align=right></TD>
<TD width="17%" align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="1%" align=left></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right></TD>
<TD width="16%" align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="1%" align=left></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;Convertible
Debt, beginning</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,395,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;Convertible
Debt issued</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3,750,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;Convertible
Debt conversions</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(2,395,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(1,355,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible
Debt, ending</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,395,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2><B><U>Discount on Convertible Debt</U></B></FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;Convertible debt discount, beginning</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,635,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,464,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;Amount amortized as non-cash interest expense</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(1,635,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(829,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible debt discount, ending</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,635,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
</TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;Convertible
Debt, net of discount</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>760,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD></TR></TABLE>
<B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 17</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> Under the Debt SPA, each Debenture holder was granted a detachable warrant equal to 75% of the quotient
obtained by dividing the principal amount of the Convertible Debt by the Conversion Price or an aggregate
of 3,308,827 warrants. The detachable warrants have a 4-year term with an exercise price of $0.75
per share. During fiscal year 2004, Debenture holders exercised 2,244,120 warrants under the Debt
SPA for gross proceeds of $1,683,000 at the exercise price of $0.75 per share. As of April 30, 2004,
1,064,707 warrants were outstanding under the Debt SPA (Note 11).</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> In connection with the Convertible Debt issued on August 9, 2002, we incurred approximately $363,000
in debt issuance costs, including placement agent fees of $318,000, which are being amortized on
a straight-line basis over the life of the Convertible Debt, which approximates the effective interest
method. Upon conversion of any Convertible Debt, the unamortized debt issuance costs remaining at
the date of conversion which were allocated to the Convertible Debt is immediately recognized as
non-cash interest expense. During fiscal years 2004 and 2003, we expensed $175,000 and $188,000,
respectively, in debt issuance costs included in interest and other expense in the accompanying consolidated
statements of operations. As of April 30, 2004, the debt issuance costs were completely amortized. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>9. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LICENSE, RESEARCH AND DEVELOPMENT
AGREEMENTS</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The following represents our significant licensing arrangements for the development and commercialization
of our technologies. We do not perform any research and development activities for any unrelated
entities. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Tumor Necrosis Therapy (Cotara <i>&#153;</i>)</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We acquired the rights to the TNT technology in July 1994 after the merger between Peregrine and Cancer
Biologics, Inc. was approved by our stockholders. The assets acquired from Cancer Biologics, Inc.
primarily consisted of patent rights to the TNT technology. To date, no product revenues have been
generated from our TNT technology.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During October 2000, we entered into a licensing agreement with Merck KGaA to license a segment of
our TNT technology for use in the application of cytokine fusion proteins. During January 2003, we
entered into an amendment to the license agreement, whereby we received an extension to the royalty
period from six years to ten years from the date of the first commercial sale. Under the terms of
the amendment, we received the remaining up-front fee of $350,000 which is included in license revenue
in the accompanying consolidated statements of operations for the year ended April 30, 2003 in accordance
with SAB No. 101 and SAB No. 104. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In February 1996, we entered into a joint venture agreement with Cambridge Antibody Technology, Inc.
(&#147;CAT&#148;), which provided for the co-sponsorship of development and clinical testing of the
TNT antibodies. In May 1998, we mutually elected to discontinue the joint venture of the TNT antibodies
and we assumed full responsibility to fund development and clinical trials of the TNT antibody. During
January 2003, we entered into an assignment agreement whereby CAT assigned us the worldwide rights
to the human TNT antibody. In exchange, we agreed to pay a royalty on net sales to CAT, as defined
in the agreement, and agreed to forgive any amounts owed to us under the joint venture. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During September 1995, we entered into an agreement with Cancer Therapeutics, Inc. whereby we granted
to Cancer Therapeutics, Inc. the exclusive right to sublicense TNT to a major pharmaceutical company
solely in the People&#146;s Republic of China (Note 14).</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 18</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We are negotiating with certain third parties to acquire licenses needed to produce and commercialize
certain antibodies, including our TNT antibody. We believe the terms of the licenses will not significantly
impact the cost structure or marketability of the antibody based products.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Anti-Phospholipid Therapy (&#147;APT&#148;)</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In August 2001, we exclusively licensed a new platform technology from the University of Texas Southwestern
Medical Center at Dallas which we named Anti-Phospholipid Therapy (&#147;APT&#148;). Under the license
agreement, we paid an up-front license fee, annual maintenance fees, and are obligated to pay future
milestone payments based on development progress, plus a royalty on net sales or a percentage of
sublease income. Tarvacin&#153; is planned to be our first APT compound to enter clinical trials
later this calendar year. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During November 2003, we entered into a non-exclusive license agreement with an unrelated entity to
license the methods and processes for producing antibodies used in connection the development of
our APT program. Under the terms of the non-exclusive license agreement, we are required to pay a
non-refundable license grant fee, future development milestone fees and royalties on net sales. During
fiscal year 2004, we have expensed $100,000 under this agreement which is included in research and
development expense in the accompanying consolidated financial statements. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
December 2003, we entered into a research collaboration agreement with Aeres Biomedical Ltd. (&#147;Aeres&#148;)
regarding the humanization of one of our Tarvacin&#153; antibody&#146;s to be used as a possible
future generation clinical candidate. Under the terms of the research collaboration agreement, we
are required to pay Aeres a non-refundable up-front payment, future project milestone payments and
royalties on net sales. During January 2004, we issued and sold 243,101 shares of our common stock
to Aeres valued at $648,000 based on the more readily determinable value of the services received
or the fair value of the common stock issued, of which, $616,000 was recorded as research and development
expensed during fiscal year 2004. The remaining balance will be amortized as research and development
expense during fiscal year 2005 in accordance with the terms of the agreement.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Vascular Targeting Agents
(&#147;VTAs&#148;)</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During December 2002, we granted the exclusive rights for the development of diagnostic and imaging
agents in the field of oncology to Schering A.G. under our Vascular Targeting Agent (&#147;VTA&#148;)
technology. Under the terms of the agreement, we received an up-front payment of $300,000, of which,
$200,000 is included in deferred license revenue in accordance with SAB No. 101 and SAB No. 104 in
the accompanying consolidated financial statements at April 30, 2004 and will be amortized over an
estimated period of 48 months. Under this license agreement, the obligation period was not contractually
defined and we exercised judgment in estimating the period of time over which certain deliverables
will be provided to enable the licensee to practice the license. The estimated period of 48 months
was primarily determined based on the historical experience with Schering A.G. under a separate license
agreement. In addition, we could also receive future milestone payments and a royalty on net sales,
as defined in the agreement. Under the same agreement, we granted Schering A.G. an option to obtain
certain non-exclusive rights to the VTA technology with predetermined up-front fees and milestone
payments as defined in the agreement. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 19</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During February 2001, we completed a licensing deal with SuperGen, Inc. (&#147;SuperGen&#148;) to license
a segment of our VTA technology, specifically related to Vascular Endothelial Growth Factor (&#147;VEGF&#148;).
Under the terms of the licensing agreement, SuperGen purchased 150,000 shares of our common stock
at $4.00 per share for total proceeds of $600,000. We also received an annual license fee of $200,000
in cash or SuperGen common stock until SuperGen files an Investigational New Drug Application in
the United States utilizing the VEGF technology. As of April 30, 2004, SuperGen has not filed an
Investigational New Drug Application in the United States utilizing the VEGF technology. The $200,000
annual license fee is included in license revenue in the accompanying consolidated financial statements
for the years ended April 30, 2004, 2003 and 2002 in accordance with SAB No. 101 and SAB No. 104.
In addition, we could receive additional milestone payments based on the development success, plus
receive a royalty on net sales of all drugs commercialized by SuperGen utilizing the VEGF technology.
We could also receive additional consideration for each clinical candidate that enters a Phase III
clinical trial by SuperGen.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During May 2000, we entered into a joint venture with Oxigene, Inc. (&#147;Oxigene&#148;). Under the
terms of the joint venture agreement, we had agreed to supply our VTA intellectual property to the
joint venture while Oxigene paid us a non-refundable $1,000,000 license fee, which was received in
May 2000 and amortized as license revenue over the term of the agreement. In addition, Oxigene purchased
$2,000,000 of our common stock and agreed to (i) provide its next generation tubulin-binding compounds
(ii) spend up to $20,000,000 to fund the development expenses of the joint venture based on its development
success and (iii) pay us a $1,000,000 up-front license fee and subscribe to an additional $1,000,000
in Peregrine&#146;s common stock upon filing an Investigational New Drug Application (&#147;IND&#148;)
for the first clinical candidate developed. During February 2002, we entered into a Plan and Agreement
of Liquidation with Oxigene to dissolve the joint venture. Under the terms of the Plan and Agreement
of Liquidation, we paid Oxigene $2,000,000 in cash, which we charged to operations as purchased in-process
research and development in the accompanying consolidated financial statements during the year ended
April 30, 2002, as the related technology had not reached technological feasibility. In exchange,
we reacquired full rights and interest to the Vascular Targeting Agent platform we contributed to
the joint venture, as well as any new discoveries to our contributed technology. During February
2002, we recognized the remaining unamortized up-front license fee, which is included in license
revenue in the accompanying consolidated financial statements at April 30, 2002.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In April 1997, in conjunction with the acquisition of Vascular Targeting Technologies, Inc. (formerly
known as Peregrine Pharmaceuticals, Inc.), we gained access to certain exclusive licenses for Vascular
Targeting Agents (&#147;VTAs&#148;) technologies. In conjunction with obtaining these exclusive licenses,
we will be required to pay annual patent maintenance fees plus milestone payments and future royalties
on net sales to various universities. No product revenues have been generated from our VTA technology. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Anti-Angiogenesis</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During August 2001, we entered into an exclusive worldwide license for a new preclinical compound from
the University of Texas Southwestern Medical Center. This new compound, named 2C3, added to our anti-cancer
platform technologies in the anti-angiogenesis field. Under this license agreement, we paid an up-front
license fee, annual maintenance fees, and are obligated to pay future milestone payments based on
development progress, plus a royalty on net sales.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During June 2003, we entered into a research collaboration agreement with an unrelated entity regarding
the production of human antibodies for our VTA and anti-angiogenesis programs to be used as possible
future clinical candidates. Under the terms of the research collaboration agreement, we
will pay a non-refundable technology access fee and we may either develop
identified antibodies as part of a joint development program with the unrelated
entity or pay future milestone payments and royalties on net sales.
During fiscal year 2004, we expensed $200,000 in non-refundable technology access fees under two
separate research projects which amount is included in research and development expense in the accompanying
consolidated financial statements.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 20</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Vasopermeation Enhancement Agents and Other Licenses</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During February 2000, we entered into an exclusive worldwide licensing transaction with the University
of Southern California for its Permeability Enhancing Protein (&#147;PEP&#148;) in exchange for an
up-front payment plus future milestone payments and a royalty on net sales based on development success.
The PEP technology is classified under our Vasopermeation Enhancing Agent (&#147;VEA&#148;) technology,
which is designed to increase the uptake of chemotherapeutic agents into tumors. PEP is designed
to be used in conjunction with the VEA technology platform.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Prior to fiscal year 1996, we entered into several license and research and development agreements
with a university for the exclusive, worldwide licensing rights to use certain patents and technologies
in exchange for fixed and contingent payments and royalties on net sales of the related products.
Minimum future royalties under these agreements are $84,500 annually. Royalties related to these
agreements amounted to $84,500 for fiscal years 2004, 2003 and 2002. No product revenues have been
generated from our VEA technology.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Lymphoma Therapy</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Oncolym is the name for our most advanced LYM-1 antibody. In 1985, we entered into a research and development
agreement, as amended in August 1999, with Northwestern University and its researchers to develop
the LYM-1 antibodies. We hold an exclusive world-wide license to manufacture and market products
using the Oncolym antibodies. In exchange for the world-wide license to manufacture and market the
products, we will pay Northwestern University a royalty on net sales. To date, no product revenues
have been generated from our Oncolym technology.</FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On March 8, 1999, we entered into a License Agreement with Schering A.G. whereby Schering A.G. was
granted the exclusive, worldwide right to market and distribute Oncolym products, in exchange for
an initial payment of $3,000,000 and future milestone payments plus a royalty on net sales. During
June 2000, we entered into an amendment to the License Agreement (&#147;the Amendment&#148;) with
Schering A.G. whereby Schering A.G. agreed to pay for 100% of the Oncolym clinical development expenses,
excluding drug related costs, for the Phase I/II clinical trial. In exchange for this commitment,
we agreed to transfer $1,300,000 of our common stock to Schering A.G. as defined in the Amendment.
During June 2001, we assumed the rights previously licensed to Schering A.G. and recognized deferred
license revenue of $3,000,000 upon termination of the agreement, which is included in license revenue
in the accompanying consolidated financial statements for the year ended April 30, 2002. </FONT></TD>
</TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In November 1997, we entered into a Termination and Transfer Agreement with Alpha Therapeutic Corporation,
whereby we reacquired the rights for the development, commercialization and marketing of Oncolym
in the United States and certain other countries, previously granted to Alpha in October 1992. We
have contingent obligations due upon filing of a Biologics License Application and upon FDA approval
by the Food and Drug Administration plus a royalty on net sales for product sold in certain countries
for five (5) years after commercialization of the product. No amounts were due or payable at April
30, 2004 under the Termination and Transfer Agreement.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 21</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On March 8, 1999, we entered into a Termination Agreement with Biotechnology Development Ltd. (&#147;BTD&#148;),
pursuant to which we terminated all previous agreements with BTD and thereby reacquired the marketing
rights to Oncolym products in Europe and certain other designated foreign countries. In exchange
for these rights, we expensed $4,500,000 as a license fee in fiscal year 1999, which was comprised
of a secured promissory note payable in the amount of $3,300,000, which was paid in full during fiscal
year 2001, and issued 1,523,809 shares of our common stock calculated in accordance with the Termination
Agreement. In addition, we issued warrants to purchase up to 3,700,000 shares of common stock at
an exercise price of $3.00 per share and issued warrants to purchase up to 1,000,000 shares of common
stock at an exercise price of $5.00 per share. The warrants were measured utilizing the Black-Scholes
option valuation model. During fiscal year 2000, we defaulted under the Termination Agreement and
extended the expiration date of 4,700,000 warrants to December 1, 2005 and only in the case of a
merger, acquisition, or reverse stock split, agreed to re-price the outstanding warrants to an exercise
price of $0.34 per share. BTD is a limited partnership controlled by Mr. Edward J. Legere, a former
member of the our Board of Directors and our former President and Chief Executive Officer. The warrants
under the Termination Agreement were outstanding as of April 30, 2004.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On October 28, 1992, we entered into an agreement with an unrelated corporation (licensee) to terminate
a previous license agreement relating to Oncolym. The termination agreement provides for aggregate
maximum payments of $1,100,000 to be paid by us based on achievement of certain milestones, including
a royalty on net sales. As of April 30, 2004, we had accrued $100,000 for milestones incurred as
of April 30, 2004, which is included in accrued royalties and license fees in the accompanying consolidated
financial statements.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>10. &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; STOCKHOLDERS&#146; EQUITY</FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Common Stock Equity Line Agreement</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During June 1998, we secured access to a Common Stock Equity Line (&#147;Equity Line&#148;) with two
institutional investors, as amended on June 2, 2000 (the &#147;Amendment&#148;). Under the Amendment,
we may, in our sole discretion, and subject to certain restrictions, periodically sell (&#147;Put&#148;)
shares of our common stock until all common shares previously registered under the Equity Line have
been exhausted. During September 2001, we issued all available shares under the Equity Line and therefore,
the Equity Line was immediately terminated. In addition, at the time of each Put, the investors were
issued warrants, which are immediately exercisable on a cashless basis only and expire through December
31, 2005, to purchase up to 15% of the amount of common stock issued to the investors at the same
price as the shares of common stock sold in the Put.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In accordance with Emerging Issues Task Force Issue No. 96-13 (&#147;EITF No. 96-13&#148;), <I>Accounting for Derivative Financial Instruments</I>, contracts that require a company to deliver shares as part of a physical settlement should be measured
at the estimated fair value on the date of the initial Put. The Equity Line solely requires settlement
to be made with shares of our common stock. As such, we had an independent appraisal performed to
determine the estimated fair market value of the various financial instruments included in the Equity
Line and recorded the related financial instruments as reclassifications between equity categories.
Reclassifications were made for the estimated fair market value of the warrants issued and estimated
Commitment Warrants to be issued under the Equity Line of $1,140,000 and the estimated fair market
value of the reset provision of the Equity Line of $400,000 as additional consideration and have
been included in the accompanying consolidated financial statements. The above recorded amounts were
offset by $700,000 related to the restrictive nature of the common stock issued under the initial
Put in June 1998 and the estimated fair market value of the Equity Line Put option of $840,000. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 22</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During January 2001, the Emerging Issues Task Force issued EITF No. 00-19 (&#147;EITF No. 00-19&#148;),
<I>Accounting for Derivative Financial Instruments Indexed To, and Potentially Settled In, The Company&#146;s
Own Stock</I>, which reached a consensus on the application of EITF No. 96-13. In accordance with EITF No. 00-19,
the Equity Line contract remains recorded as permanent equity and recorded at fair value as of the
date of the transaction. EITF No. 00-19 is effective for all transactions entered into after September
20, 2000. As of April 30, 2004, EITF No. 00-19 had no impact on our consolidated financial position
and results of operations.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During fiscal year 2002, we received gross proceeds of $5,526,000 in exchange for 5,039,203 shares
of common stock under the Equity Line including commission shares. On April 15, 1999 and July 15,
1999, we issued an additional 881,481 and 179,485 shares of common stock covering the initial three
and six month adjustment dates as defined in the agreement, respectively. There are no future reset
provisions under the Equity Line.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>At the time of each Put, the investors were issued warrants, exercisable only on a cashless basis to
purchase up to 10%, (increased to 15% under the Amendment) of the amount of common stock issued to
the investor at the same price as the purchase of the shares sold in the Put. During fiscal year
2002, we issued 732,970 warrants under the Equity Line including commission warrants. During fiscal
years 2004 and 2002, we issued 14,124 and 216,435 shares of common stock upon the cashless exercise
of 16,854 and 79,512 Equity Line warrants, respectively. As of April 30, 2004, we had outstanding
warrants to purchase up to 1,380,683 shares of common stock under the Equity Line (Note 11).</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Placement agent fees under each draw of the Equity Line are issued to Dunwoody Brokerage Services,
Inc., which are equal to 10% of the common shares (commission shares) and warrants (commission warrants)
issued to the institutional investors plus an overall cash commission equal to 7% of the gross draw
amount. Mr. Eric Swartz, a member of our Board of Directors, maintains a contractual right to 50%
of the shares and warrants issued under the Equity Line. During the fiscal years ended April 2002,
Dunwoody Brokerage Services, Inc. was issued 458,109 shares of common stock and was paid cash commissions
of $387,000. The Equity Line was consummated in June 1998 when Mr. Swartz had no Board affiliation
with the Company.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Financing Under Shelf Registration Statement on Form S-3, File Number 333-71086</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On November 14, 2001, we filed a registration statement on Form S-3, File Number 333-71086 (the &#147;November
2001 Shelf&#148;) which was declared effective by the Securities and Exchange Commission, allowing
us to issue, from time to time, in one or more offerings, (i) up to 10,000,000 shares of our common
stock, and (ii) warrants to purchase up to 2,000,000 shares of our common stock. As of April 30,
2004, 9,912,445 shares of&nbsp;common stock and warrants to purchase up to 2,000,000 shares of our
common stock were issued under the November 2001 Shelf under the following transactions:</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 23</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During November 2001, we received $5,750,000 under a Common Stock Purchase Agreement in exchange for
5,750,000 shares of our common stock and warrants to purchase up to 1,725,000 shares of common stock
at an exercise price of $1.00 per share. The warrants can be exercised on a cash basis only. Mr.
Eric Swartz, a member of our Board of Directors, invested $500,000 of the total amount in exchange
for 500,000 shares of our common stock and warrants to purchase up to 150,000 shares of common stock
at an exercise price of $1.00, which transaction was subsequently rescinded due to the lack of stockholder
approval (Note 14). The fair value of the warrants were recorded as a cost of equity based on a Black-Scholes
valuation model after considering terms in the related warrant agreements. In connection with the
offering, we paid a fee to the placement agent equal to five percent (5%) of the number of shares
issued to certain investors, or 200,000 shares. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During October 2002, we were required to rescind the prior sale of shares to Mr. Swartz under the November
2001 Common Stock Purchase Agreement in accordance with Nasdaq Market Rule 4350 and to return the
sum of $500,000 to Mr. Swartz in exchange for the 500,000 shares of our common stock and the cancellation
of a warrant to purchase up to 150,000 shares of our common stock. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During January 2002, we received $2,200,000 under a Common Stock Purchase Agreement in exchange for
1,100,000 shares of our common stock and warrants to purchase up to 275,000 shares of our common
stock at an exercise price of $2.00 per share. The warrants have a five year term and are exercisable
at an exercise price of $2.00 per share on a cash basis only. The fair value of the warrants were
recorded as a cost of equity based on a Black-Scholes valuation model after considering terms in
the related warrant agreements. In connection with the offering, we paid a fee to the placement agent
equal to five percent (5%) of the number of shares issued to certain of the investors, or 50,000 shares.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During August 2002, we received gross proceeds of $1,856,000 under a Common Stock Purchase Agreement
in exchange for 2,900,000 shares of our common stock. There were no warrants issued in connection
with this transaction. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On June 6, 2003, we received gross proceeds of $355,000 under a Common Stock Purchase Agreement in
exchange for 412,445 shares of our common stock. In connection with the offering, we paid a fee to
the placement agent equal to five percent (5%) of the gross proceeds, or $18,000. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>As of April 30, 2004, we had outstanding warrants to purchase up to 1,703,612 shares of common stock
under the November 2001 Shelf (Note 11).</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>As of April 30, 2004, 87,555 shares of common stock were available for issuance under the November
2001 Shelf. All warrants have been issued under the November 2001 Shelf as of April 30, 2004. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Financing Under Shelf Registration Statement on Form S-3, File Number 333-103965</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On March 21, 2003, we filed a registration statement on Form S-3, File Number 333-103965 which was
declared effective by the Securities and Exchange Commission, allowing us to issue, from time to
time, in one or more offerings, up to 10,000,000 shares of our common stock (&#147;March 2003 Shelf&#148;).
During fiscal year 2004, 9,999,997 shares of our common stock were issued under the March 2003 Shelf
under the following transactions:</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On June 6, 2003, we received gross proceeds of $1,720,000 under a Common Stock Purchase Agreement in
exchange for 2,000,003 shares of our common stock and warrants to purchase up to 150,000 shares of
our common stock at an exercise price of $0.86 per share (&#147;June 6, 2003 Financing&#148;). The
warrants have a four year term and are exercisable at an exercise price of $0.86 per share. The fair
value of the warrants were recorded as a cost of equity based on a Black-Scholes valuation model
after considering the terms in the related warrant agreement. The warrants were issued under the
November 2001 Shelf. In connection with the offering, we paid a fee to the placement agent equal
to five percent (5%) of the gross proceeds, or $86,000.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 24</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On June 26, 2003, we received gross proceeds of $1,840,000 under a Common Stock Purchase Agreement
in exchange for 1,599,997 shares of our common stock (&#147;June 26, 2003 Financing&#148;). Under
the same arrangement, we granted the investors a six-month option to purchase up to 1,599,997 additional
shares of our common stock under the same terms as this offering. The fair value of the option was
recorded as a cost of equity based on a Black-Scholes valuation model after considering terms in
the related agreement. In connection with the offering, we paid issuance cost of $9,000 and a fee
to the placement agent equal to five percent (5%) of the gross proceeds, or $92,000.
The investors elected to purchase all 1,599,997 shares of our common stock under the six-month
option in exchange for gross proceeds of $1,840,000. We paid issuance costs and commissions of $54,000
related to the exercise of the six-month option.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On July 24, 2003, we entered into a Common Stock Purchase Agreement with one institutional investor
whereby we agreed to sell from time to time, at our option, up to an aggregate of 2,000,000 shares
of our common stock at the per share price of $1.45 (&#147;July 24, 2003 Financing&#148;). As of
April 30, 2004, we sold and issued all 2,000,000 shares of our common stock under the July 24, 2003
Financing to the institutional investor in exchange for gross proceeds of $2,900,000. We paid issuance
costs of $13,000 and no commissions in connection with this offering.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On September 18, 2003, we entered into a Common Stock Purchase Agreement with one institutional investor
whereby we agreed to sell from time to time, at our option, up to an aggregate of 2,800,000 shares
of our common stock at predetermined per share prices based upon the average closing price of our
common stock for the prior three trading days (&#147;September 18, 2003 Financing&#148;). As of April
30, 2004, we sold and issued all 2,800,000 shares of our common stock under the September 18, 2003
Financing to the institutional investor in exchange for gross proceeds of $5,292,000. We paid issuance
costs of $19,000 and no commissions in connection with this offering.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Financing Under Shelf Registration Statement on Form S-3, File Number 333-109982</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On October 24, 2003, we filed a registration statement on Form S-3, File Number 333-109982 which was
declared effective by the Securities and Exchange Commission, allowing us to issue, from time to
time, in one or more offerings, up to 12,000,000 shares of our common stock (&#147;October 2003 Shelf&#148;).
</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On November 17, 2003, we entered into a Common Stock Purchase Agreement with one institutional investor
whereby we agreed to sell from time to time, at our option, up to an aggregate of 2,000,000 shares
of our common stock at predetermined per share prices based upon the average closing price of our
common stock for the prior three trading days (&#147;November 17, 2003 Financing&#148;). During fiscal
year 2004, we sold and issued all 2,000,000 shares of our common stock under the November 17, 2003
Financing to the institutional investor in exchange for gross proceeds of $4,257,000. We paid issuance
costs of $1,000 and no commissions in connection with this offering.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 25</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On January 22, 2004, we entered into a Common Stock Purchase Agreement with one institutional investor
whereby we agreed to sell from time to time, at our option, up to an aggregate of 3,000,000 shares
of our common stock at a price per share prices based upon a discount to the average volume weighted
average price of our common stock for the three trading days prior to the date of the put, which
per share prices can be adjusted upon mutual agreement (&#147;January 22, 2004 Financing&#148;).
As of April 30, 2004, we sold and issued 1,000,000 shares of our common stock under the January 22,
2004 Financing to the institutional investor in exchange for gross proceeds of $2,275,000. We paid
no commissions in connection with this offering. As of April 30, 2004, 2,000,000 shares of our common
stock were available for issuance under the January 22, 2004 Financing. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During January 2004, we issued and sold 243,101 shares of our common stock to Aeres Biomedical Ltd.
as payment for certain amounts due under a research collaboration agreement dated December 9, 2003
for the humanization of one of our Tarvacin&#153; antibodies to be used as a possible future generation
clinical candidate (Note 9). The value of the shares issued of $648,000 was recorded based on the
more readily determinable value of the services received or the fair value of our common stock issued.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>As of April 30, 2004, 8,756,899 shares of our common stock were available for issuance under the October
2003 Shelf.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Financing Under Securities Purchase Agreement</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On August 9, 2002, we entered into a private placement with two investors under a Securities Purchase
Agreement (&#147;SPA&#148;) and issued an aggregate of 1,923,078 shares of our common stock in exchange
for gross proceeds of $1,250,000. In conjunction with the private placement, we issued warrants to
purchase up to an aggregate of 1,442,309 shares of our common stock. The warrants have a four year
term and are exercisable six months after the date of issuance at an exercise price of $0.71 per
share. During fiscal year 2004, the two investors exercised all 1,442,309 warrants in exchange for
gross proceeds of $1,024,000 at the exercise price of $0.71 per share.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Also on August 9, 2002, we agreed to sell 3,298,462 shares of our common stock at a negotiated price
of $0.65 per share in exchange for gross proceeds of $2,144,000 to one investor. In conjunction with
this offering, we issued a warrant to purchase up to 4,648,846 shares of our common stock. The warrant
has a four year term and is exercisable six months after the date of issuance at an exercise price
of $0.71 per share. As of April 30, 2004, warrants to purchase up to 4,648,846 shares our common
stock were outstanding under the SPA.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Under all equity financing agreements entered into during August 2002, we paid combined placement agent
fees of $445,000.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Other Equity Transactions</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On November 19, 1999, in consideration of a commitment by Swartz Private Equity, LLC (&#147;SPE&#148;)
to fund a $35,000,000 equity line financing over a three year term, we issued SPE a five-year warrant
to purchase up to 750,000 shares of our common stock at an initial exercise price of $0.46875 per
share (&#147;Commitment Warrant&#148;) subject to reset provisions as defined in the agreement. This
agreement was entered into and approved by the previous Board of Directors. Mr. Eric Swartz, a member
of our Board of Directors, maintains a 50% ownership in SPE. We utilized the Black-Scholes valuation
model to calculate the fair value of the warrant, which was recorded as stock-based compensation
in the accompanying consolidated financial statements. As of April 30, 2004, warrants to purchase
up to 699,000 shares of our common stock were outstanding under the Commitment Warrant.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 26</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In accordance with our option plans and warrant agreements, we have reserved 27,716,053 shares of our
common stock at April 30, 2004 for future issuance, calculated as follows:&nbsp;</FONT></P>

<TABLE width=70% border=0 align="center" cellPadding=0 cellSpacing=0>
<TR vAlign=bottom>
  <TD align="CENTER"></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>Number of <BR>&nbsp;shares reserved</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
  <TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD></TR>
<TR vAlign=bottom>
  <TD bgcolor="#eaf9e8"><FONT face="Times New Roman, Times, Serif" size=2>Options issued and outstanding</FONT></TD>
<TD width="1%" align=right bgcolor="#eaf9e8"><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="17%" align=right bgcolor="#eaf9e8"><FONT face="Times New Roman, Times, Serif" size=2>11,704,205</FONT></TD>
<TD width="1%" align=left bgcolor="#eaf9e8"><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%" bgcolor="#eaf9e8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
  <TD><FONT face="Times New Roman, Times, Serif" size=2>Warrants issued and outstanding</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>16,011,848</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
  <TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD></TR>
<TR vAlign=bottom>
  <TD bgcolor="#eaf9e8"><FONT face="Times New Roman, Times, Serif" size=2>Total shares reserved</FONT></TD>
<TD align=right bgcolor="#eaf9e8"><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right bgcolor="#eaf9e8"><FONT face="Times New Roman, Times, Serif" size=2>27,716,053</FONT></TD>
<TD align=left bgcolor="#eaf9e8"><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD bgcolor="#eaf9e8"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
  <TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>11. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STOCK OPTIONS AND WARRANTS</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We maintain three equity compensation plans, the 1996 Plan, the 2002 Plan, and the 2003 Plan. The 1996
and 2003 Plans were approved by our stockholders while the 2002 Plan was not submitted for stockholder
approval. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Equity Compensation Plan Approved by Stockholders</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have two incentive stock option plans with outstanding options as of April 30, 2004:&nbsp;the
1996 Plan and the 2003 Plan. The plans provide for the granting of options to purchase shares of
our common stock at prices not less than the fair market value of our common stock at the date of
grant and generally expire ten years after the date of grant. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The 1996 Plan originally provided for the issuance of options to purchase up to 4,000,000 shares of
our common stock. The number of shares for which options may be granted under the 1996 Plan automatically
increases for all subsequent common stock issuances by us in an amount equal to 20% of such subsequent
issuances up to a maximum of 10,000,000 options as long as the total shares allocated to the 1996
Plan do not exceed 20% of our authorized stock. As a result of issuances of our common stock subsequent
to the adoption of the 1996 Plan, the number of shares for which options may be granted has increased
to 10,000,000. Options granted generally vest over a period of four years with a maximum term of
ten years. As of April 30 2004, options to purchase 4,833,328 shares of our common stock were outstanding
under the 1996 Plan and 285,742 options were available for grant under the 1996 Plan. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During October 2003, our stockholders approved the 2003 Stock Incentive Plan (&#147;2003 Plan&#148;)
for the issuance of up to 5,000,000 options. The 2003 Plan provides for the granting of options to
purchase shares of the our common stock at prices not less than the fair market value of the stock
at the date of grant and generally expire ten years after the date of grant. As of April 30 2004,
options to purchase 3,263,464 shares of our common stock were outstanding under the 2003 Plan and
1,736,536 options were available for grant under 2003 Plan. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Equity Compensation Plans Not Approved by Stockholders</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During June 2002, we adopted a broad-based non-qualified stock option plan (&#147;2002 Plan&#148;)
for the issuance of up to 3,000,000 options. The 2002 Plan provides for the granting of options to
purchase shares of our common stock at prices not less than the fair market value of the stock at
the date of grant and generally expire ten years after the date of grant. As of April 30 2004, options
to purchase 2,685,749 shares of our common stock were outstanding under the 2002 Plan and 231,202
options were available for grant under the 2002 Plan. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 27</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition to the 2002 Plan, during 1999, we granted non-qualified options, which are not part of
any compensation plan, to purchase up to an aggregate of 1,500,000 shares of our common stock. As
of April 30, 2004, options to purchase 921,664 shares of our common stock were outstanding and no
options were available for grant as of April 30, 2004. The resale of the underlying shares of common
stock is registered on a registration statement on Form S-3.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Option activity for all option plans for each of the three years ended April 30, 2004 is as follows:</FONT></P>

<TABLE WIDTH=80% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
     <TH colspan="5"><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></TH>
     <TH width="2%">&nbsp;</TH>
     <TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT></TH>
     <TH width="2%">&nbsp;</TH>
     <TH COLSPAN=5><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2002</FONT></TH>
     <TH width="2%">&nbsp;</TH>
</TR>
<TR VALIGN=Bottom>
  <TH>&nbsp;</TH>
  <TH colspan="5"><HR color="#000000"SIZE=1></TH>
  <TH>&nbsp;</TH>
  <TH colspan="5"><HR color="#000000"SIZE=1></TH>
  <TH>&nbsp;</TH>
  <TH COLSPAN=5><HR color="#000000"SIZE=1></TH>
  <TH>&nbsp;</TH>
</TR>
<TR VALIGN=Bottom>
     <TH>&nbsp;</TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Shares</FONT></TH>
     <TH>&nbsp;</TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1> Weighted<br>
Average<br>
Exercise Price</FONT></TH>
     <TH>&nbsp;</TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Shares</FONT></TH>
     <TH>&nbsp;</TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Weighted<br>
Average<br>
Exercise<br>
Price </FONT></TH>
     <TH>&nbsp;</TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Shares</FONT></TH>
     <TH>&nbsp;</TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Weighted<br>
Average<br>
Exercise Price</FONT></TH>
     <TH>&nbsp;</TH>
</TR>
<TR VALIGN=Bottom>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD width="3%" ALIGN=RIGHT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD width="3%" ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD width="3%" ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
</TR>
<TR VALIGN=Bottom bgcolor="#eaf9e8">
     <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> BALANCE,&nbsp;Beginning  of year</FONT></TD>
     <TD width="1%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD width="9%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9,580,458</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD width="1%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
     <TD width="9%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.16</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD width="1%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD width="9%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10,055,527</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD width="1%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
     <TD width="9%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.20</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD width="1%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD width="9%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7,795,402</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD width="1%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
     <TD width="9%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.03</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Granted</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,187,947</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2.09</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,517,800</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.94</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,853,440</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.58</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom bgcolor="#eaf9e8">
     <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exercised</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,131,242</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.61</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(109,633</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.34</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(535,760</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.66</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Forfeited or Expired</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(932,958</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.99</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,883,236</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.25</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(57,555</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.43</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD></TR>
<TR>
     <TD></TD>
     <TD COLSPAN=3></TD>
     <TD COLSPAN=3></TD>
     <TD COLSPAN=3></TD>
     <TD COLSPAN=3></TD>
     <TD COLSPAN=3></TD>
     <TD COLSPAN=3></TD></TR>
<TR VALIGN=Bottom>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
</TR>
<TR VALIGN=Bottom bgcolor="#eaf9e8">
     <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> BALANCE, End of year</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11,704,205</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.48</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9,580,458</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.16</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10,055,527</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.20</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR>
     <TD></TD>
     <TD colspan="2"><HR color="black" SIZE=2></TD>
     <TD></TD>
     <TD></TD>
     <TD></TD>
     <TD></TD>
     <TD colspan="2"><HR color="black" SIZE=2></TD>
     <TD></TD>
     <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD><TD></TD>
     <TD COLSPAN=2 ALIGN=RIGHT><HR color="black" SIZE=2></TD><TD></TD>
     <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD><TD></TD></TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
information regarding options outstanding as of April 30, 2004 is as follows:</FONT></P>

<TABLE width="90%" border=0 align="center" cellPadding=0 cellSpacing=0>
<TR vAlign=bottom>
<TD colspan="2" align="CENTER"><FONT face="Times New Roman, Times, Serif" size=1><B>&nbsp;</B></FONT></TD>
<TD align="CENTER" colSpan=2></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align="CENTER" colSpan=6><FONT face="Times New Roman, Times, Serif" size=1><B>Options&nbsp;&nbsp; Outstanding</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align="CENTER" colSpan=6><FONT face="Times New Roman, Times, Serif" size=1><B>Options&nbsp;&nbsp; Exercisable</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
  <td align="center">&nbsp;</td>
  <td align="center"></td>
  <td colspan="2" align="center">&nbsp;</td>
  <TD align="CENTER">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD colspan="6" align="center"><HR color="#000000"SIZE=1></TD>
  <TD align="CENTER">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD colspan="6" align="center"><HR color="#000000"SIZE=1></TD>
  </TR>
<TR vAlign=bottom>
  <td align="center"><font face="Times New Roman, Times, serif" size=1><b>Range of Per<br>
    Share Exercise<br>
    Prices</b></font></td>
  <td align="center"></td>
  <td colspan="2" align="center"><font face="Times New Roman, Times, serif" size=1><b>Number of Shares<br>
    Outstanding</b></font></td>
  <TD align="CENTER"><font face="Times New Roman, Times, serif">&nbsp;</font></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>&nbsp;</FONT></TD>
<TD colspan="2" align="center"><font face="Times New Roman, Times, serif" size=1><b>Weighted Average <br>
  Remaining <br>
  Contractual Life <br>
  (years)</b></font></TD>
<TD align="CENTER"></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>&nbsp;</FONT></TD>
<TD colspan="2" align="center"><font face="Times New Roman, Times, serif" size=1><b>Weighted Average<br>
  Per Share<br>
  Exercise Price</b></font></TD>
<TD align="CENTER"><font face="Times New Roman, Times, serif">&nbsp;</font></TD>
<TD>&nbsp;</TD>
<TD colspan="2" align="center"><font face="Times New Roman, Times, serif" size=1><b>Number of <br>
  Shares<br>
  Exercisable</b></font></TD>
<TD align="CENTER"><font face="Times New Roman, Times, serif">&nbsp;</font></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>&nbsp;</FONT></TD>
<TD colspan="2" align="center"><font face="Times New Roman, Times, serif" size=1><b>Weighted Average<br>
  Per Share<br>
  Exercise Price</b></font></TD>
</TR>
<TR>
<TD>
<HR color="#000000"SIZE=1>
</TD>
<TD>&nbsp;</TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2>$ 0.34 - $ 0.60</FONT></TD>
<TD align=left>&nbsp;</TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="13%" align=right><FONT face="Times New Roman, Times, Serif" size=2>2,679,787</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="13%" align=right><FONT face="Times New Roman, Times, Serif" size=2>5.59</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="13%" align=right><FONT face="Times New Roman, Times, Serif" size=2>0.41</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="13%" align=right><FONT face="Times New Roman, Times, Serif" size=2>2,404,521</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="13%" align=right><FONT face="Times New Roman, Times, Serif" size=2>0.39</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
</TR>
<TR vAlign=bottom>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2>$ 0.72 - $ 1.28</FONT></TD>
<TD align=left>&nbsp;</TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3,179,314</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>6.70</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1.08</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2,856,279</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1.10</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2>$ 1.38 - $ 2.19</FONT></TD>
<TD align=left>&nbsp;</TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,834,793</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>6.62</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1.65</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,120,275</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1.56</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
</TR>
<TR vAlign=bottom>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 2.20 - $ 2.20</FONT></TD>
<TD align=left>&nbsp;</TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3,034,231</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>9.48</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2.20</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>566,668</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2.20</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2>$ 2.48 - $ 5.28</FONT></TD>
<TD align=left>&nbsp;</TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>976,080</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>7.46</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3.17</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>849,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3.23</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
</TR>
<TR>
<TD align="center"></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2>$ 0.34 - $ 5.28</FONT></TD>
<TD align=left>&nbsp;</TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>11,704,205</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>7.22</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1.48</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>7,796,743</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1.26</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
</TR>
<TR>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
</TR></TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 28</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> As of April&nbsp;30, 2004, warrants to purchase an aggregate of 16,011,848 shares of our common stock
were outstanding under the following arrangements:</FONT></P>

<TABLE width=100% border=0 align="center" cellPadding=0 cellSpacing=0>
<TR vAlign=bottom>
<TD align="left"><FONT face="Times New Roman, Times, Serif" size=1><B>Description of Arrangement</B></FONT></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>Warrants <br>
  Outstanding</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>Weighted Average Per<br>
  Share Exercise Price</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD>
<HR align="left" width="150" SIZE=1 color=black>
</TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>

</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>Warrants issued under Regulation D Subscription Agreement (Note 14)</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="14%" align=right><FONT face="Times New Roman, Times, Serif" size=2>1,680,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="18%" align=right><FONT face="Times New Roman, Times, Serif" size=2>0.25</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>Commitment Warrant (Note 10)</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>699,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>0.47</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>Financing Under Securities Purchase Agreement (Note 10)</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>4,648,846</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>0.71</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2>Convertible Debt (Note 8)</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,064,707</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>0.75</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>Financing Under November 2001 Shelf (Note 10)</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,703,612</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1.15</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2>Common Stock Equity Line Agreement (Note 10)</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,380,683</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1.70</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>Other Transactions</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>135,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>2.96</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2>Warrant issued to BTD under Termination Agreement (Note 9)</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>4,700,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3.43</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=2>
  <HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
  <HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp; Total</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>16,011,848</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1.60</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During fiscal year 2004, warrants to purchase 4,087,871 shares of our common stock were exercised on
a combined cash and cashless basis for net proceeds of $2,786,000 and the issuance of 4,063,251 shares
of our common stock. No warrants were exercised during fiscal year 2003. During fiscal year 2002,
warrants to purchase 448,235 shares of our common stock were exercised on a combined cash and cashless
basis for net proceeds of $114,000 and the issuance of 311,312 shares of our common stock. The warrants
outstanding at April 30, 2004 are exercisable at prices ranging between $0.24 and $5.00 per share
with an average exercise price of $1.60 per share and expire at various dates through March 25, 2008.
The value of the warrants was based on a Black-Scholes formula after considering terms in the related
warrant agreements.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>12. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SEGMENT REPORTING </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Our business is organized into two reportable operating segments. Peregrine is engaged in the research
and development of cancer therapeutics and cancer diagnostics through a series of proprietary platform
technologies using monoclonal antibodies. Avid is engaged in providing contract manufacturing and
development of biologics to biopharmaceutical and biotechnology businesses. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The accounting policies of the operating segments are the same as those described in Note 2. We primarily
evaluate the performance of our segments based on net revenues, gross profit or loss and long-lived
assets. Our segment net revenues shown below are derived from transactions with external customers.
Our segment gross profit or loss represents net revenues less the cost of sales. Our long-lived assets
consist of leasehold improvements, laboratory equipment, and furniture, fixtures and computer equipment
and are net of accumulated depreciation.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 29</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Segment information for fiscal years 2004, 2003 and 2002 is summarized as follows:</FONT></P>

<TABLE width=80% border=0 align="center" cellPadding=0 cellSpacing=0>
<TR vAlign=bottom>
<TD align="CENTER"></TD>
<TD align="CENTER" colSpan=10><FONT face="Times New Roman, Times, Serif" size=1><B>Fiscal Year Ended April 30,</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right width="1%"><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=center width="12%"><b><FONT face="Times New Roman, Times, serif" size=1>2004</FONT></b></TD>
<TD align=center width="1%">&nbsp;</TD>
<TD width="2%" align="center">&nbsp;</TD>
<TD align=center width="1%">&nbsp;</TD>
<TD align=center width="11%"><b><FONT face="Times New Roman, Times, serif" size=1>2003</FONT></b></TD>
<TD align=center width="1%">&nbsp;</TD>
<TD width="2%" align="center">&nbsp;</TD>
<TD align=center width="1%">&nbsp;</TD>
<TD align=center width="11%"><b><FONT face="Times New Roman, Times, serif" size=1>2002</FONT></b></TD>
<TD align=left width="1%"><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2>
  <HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
  <HR color="#000000"SIZE=1>
</TD>
<TD></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2><B>Net Revenues:</B></FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;Contract manufacturing and development of biologics</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3,039,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3,346,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>46,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;Research and development of cancer therapeutics</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>275,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>575,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3,720,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>Total net revenues</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3,314,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3,921,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3,766,000</FONT></TD>
<TD align=left bgcolor="#eaf9e8"><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD bgcolor="#eaf9e8"><FONT face="Times New Roman, Times, Serif" size=2><B>Gross Profit:</B></FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;Contract manufacturing and development of biologics</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>827,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>486,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>34,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;Research and development of cancer therapeutics</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>275,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>575,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3,720,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
</TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>Total gross profit</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,102,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,061,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3,754,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
</TR></TABLE>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> Long-lived assets consist of the following at April 30, 2004 and April 30, 2003:</FONT></P>

<TABLE width=80% border=0 align="center" cellPadding=0 cellSpacing=0>
<TR vAlign=bottom>
<TD align="CENTER"></TD>
<TD align="CENTER" colSpan=6><FONT face="Times New Roman, Times, Serif" size=1><B>Fiscal Year Ended April 30,</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align="CENTER"></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>2004</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>2003</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2><B>Long-lived Assets, net:</B></FONT></TD>
<TD width="1%" align=right></TD>
<TD width="15%" align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="1%" align=left></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right></TD>
<TD width="14%" align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="1%" align=left></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;Contract manufacturing and development of biologics</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>633,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>556,000</FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;Research and development of cancer therapeutics</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>240,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>280,000</FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
</TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>Total long-lived assets, net</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>873,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>836,000</FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Net revenues generated from Peregrine during fiscal years 2004, 2003 and 2002 were primarily from up-front
license fees under various license agreements discussed in Note 9.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Net revenues generated from Avid during fiscal years 2004, 2003 and 2002 were primarily from one customer
headquartered in Israel, one customer located in Germany and one customer located in the U.S as follows:</FONT></P>

<TABLE width=50% border=0 align="center" cellPadding=0 cellSpacing=0>
<TR vAlign=bottom>
<TD align="CENTER"></TD>
<TD align="CENTER" colSpan=10><FONT face="Times New Roman, Times, Serif" size=1><B>Fiscal Year Ended April 30,</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align="CENTER"></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>2004</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>2003</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>2002</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2><B>Customer revenues as a % of net revenues:</B></FONT></TD>
<TD width="1%" align=right></TD>
<TD width="12%" align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="1%" align=left></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right></TD>
<TD width="11%" align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="1%" align=left></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right></TD>
<TD width="11%" align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="1%" align=left></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;United States (one customer)</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>24%&nbsp;&nbsp;</FONT></TD>
<TD align=left>&nbsp;</TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>34%&nbsp;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>37%&nbsp;</FONT></TD>
<TD align=left>&nbsp;</TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;Germany (one customer)</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3%&nbsp;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>65%&nbsp;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>60%&nbsp;</FONT></TD>
<TD align=left>&nbsp;</TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;Israel (one customer)</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>67%&nbsp;</FONT></TD>
<TD align=left>&nbsp;</TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>0%&nbsp;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>0%&nbsp;</FONT></TD>
<TD align=left>&nbsp;</TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;Other customers primarily in the United States</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>6%&nbsp;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1%&nbsp;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3%&nbsp;</FONT></TD>
<TD align=left>&nbsp;</TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
</TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>Total customer revenues as a % of net revenues</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>100%&nbsp;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>100%&nbsp;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>100%&nbsp;</FONT></TD>
<TD align=left>&nbsp;</TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 30</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>13. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; INCOME TAXES </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The provision for income taxes consists of the following for the three years ended April 30, 2004:</FONT></P>

<TABLE width=100% border=0 align="center" cellPadding=0 cellSpacing=0>
<TR vAlign=bottom>
<TD align="CENTER"></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>2004</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>2003</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>2002</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>Provision for federal income taxes at statutory rate</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="12%" align=right><FONT face="Times New Roman, Times, Serif" size=2>(4,877,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="12%" align=right><FONT face="Times New Roman, Times, Serif" size=2>(3,930,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="12%" align=right bgcolor="#eaf9e8"><FONT face="Times New Roman, Times, Serif" size=2>(3,984,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>Other</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>18,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>12,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>Stock based compensation</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(108,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>Increase of effective tax rate for net state deferred tax asset</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(1,941,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>State income taxes, net of federal benefit</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(837,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(347,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(352,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>Expiration of tax credits and carryforwards</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>891,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>876,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>350,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>Change in valuation allowance</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>6,746,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>3,398,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>4,082,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
</TR>
<TR vAlign=bottom>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>Provision</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
income taxes reflect the net effects of temporary differences between the carrying amounts of assets
and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant
components of our deferred tax assets at April 30, 2004 and 2003 are as follows:</FONT></P>

<TABLE width=50% border=0 align="center" cellPadding=0 cellSpacing=0>
<TR vAlign=bottom>
<TD align="CENTER"></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>2004</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align="CENTER" colSpan=2><FONT face="Times New Roman, Times, Serif" size=1><B>2003</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>Net operating loss carryforwards</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="15%" align=right><FONT face="Times New Roman, Times, Serif" size=2>39,355,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="14%" align=right><FONT face="Times New Roman, Times, Serif" size=2>33,071,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2>Stock-based compensation</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,813,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,971,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>General business and research and development credits</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>118,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>118,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2>Deferred revenue</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>657,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>74,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>Accrued liabilities</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,681,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,644,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>43,624,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>36,878,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>Less valuation allowance</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(43,624,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(36,878,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2><HR color="#000000"SIZE=1>
</TD>
<TD></TD>
<TD></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2>Net deferred taxes</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="black" SIZE=2>
</TD>
<TD></TD>
<TD></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>At April 30, 2004, we had federal net operating loss carryforwards and tax credit carryforwards of
approximately $105,439,000 and $118,000, respectively. During fiscal year 2004 and 2003, net operating
loss carryforwards of approximately $1,633,000 and $463,000 expired, respectively, with the remaining
net operating losses expiring in fiscal year 2005 through fiscal year 2024. The net operating losses
of $2,986,000 applicable to Vascular Targeting Technologies, our wholly-owned subsidiary, can only
be offset against future income of that subsidiary. The tax credit carryforwards begin to expire
in 2008 and are available to offset our future taxes or our subsidiary.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also have state net operating loss carryforwards of approximately $66,578,000, which begin to expire
in fiscal year 2004. On September 11, 2002, the Governor of California signed into law new legislation
that suspends the use of net operating loss carryforwards into tax years beginning on or after January
1, 2002 and 2003. Unless extended by law, this suspension will not apply to tax years beginning in
2004 and beyond.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 31</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Due
to ownership changes in our common stock, there will be limitations on our ability to utilize our
net operating loss carryforwards in the future. The impact of the restricted amount has not been
calculated as of April 30, 2004.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>14. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RELATED PARTY TRANSACTIONS</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the fiscal year 2004 and 2003, we paid Equiplace Securities, LLC (&#147;Equiplace&#148;) $72,000
and $15,000, respectively, for Avid business development services provided by employees of Equiplace
under a Finder&#146;s Agreement. Under the Finder&#146;s Fee Agreement, Equiplace was given a call
list of potential customers which was provided by Avid. Equiplace employees then call each contact
and present Avid&#146;s manufacturing services. All contacts that show an interest in Avid&#146;s
services are then turned over to Avid&#146;s in-house Business Development Department for continued
discussions. In addition, Equiplace may receive a commission ranging from 2% to 4% of revenues generated
by Avid Bioservices, Inc. on new customers referred to Avid by Equiplace. The commissions due Equiplace
can be reduced in half if another third-party finder is jointly responsible for new customer contracts.
Mr. Swartz, a member of our Board of Directors, owns fifty percent (50%) of Equiplace. The Finder
Fee Agreement was canceled on June 30, 2004. To date, we have not paid any commissions under the
agreement. Mr. Swartz has referred one of Avid&#146;s largest customers to date without receiving
any commission or fee.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
November 19, 2001, we received $5,750,000 under a Common Stock Purchase Agreement in exchange for
the issuance of 5,750,000 shares of our common stock and warrants to purchase up to 1,725,000 shares
of our common stock at an exercise price of $1.00 per share. Mr. Eric Swartz, a member of our Board
of Directors, invested $500,000 of the total amount in exchange for 500,000 shares of our common
stock and warrants to purchase up to 150,000 shares of our common stock at an exercise price of $1.00
(Note 10). Subsequent to the sale, we were informed by The Nasdaq Stock Market that the sale of shares
to a member of our Board of Directors at a discount to the market price of our common stock required
stockholder approval in order for us to be in compliance with Nasdaq Market Rule 4350. On October
22, 2002, our prior sale of common stock to Mr. Eric Swartz did not receive stockholder approval
due to insufficient stockholder votes. As such, we were required to rescind the transaction and to
return the sum of $500,000 to Mr. Swartz in exchange for the return of 500,000 shares of our common
stock and the cancellation of a warrant to purchase up to 150,000 shares of our common stock. During
December 2002, we paid Mr. Swartz $508,000, which included interest calculated at our money market rates. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>On December 29, 1999, Swartz Investments, LLC and BTD agreed to provide interim funding to us for up
to $500,000 to continue our operations and to avoid us from filing for protection from our creditors.
During this period of time, the closing stock price was $0.41 per share, we had a minimal amount
of cash on hand, significant payables to vendors and patent attorneys, and we were near a time of
being delisted from The NASDAQ Stock Market. During January 2000, we entered into the final agreement,
a Regulation D Subscription Agreement, whereby we received $500,000 in exchange for an aggregate
of 2,000,000 shares of our common stock and issued warrants to purchase up to 2,000,000 shares of
our common stock at $0.25 per share. Mr. Eric Swartz, a member of our Board of Directors, maintains
a 50% ownership in Swartz Investments, LLC. BTD is controlled by Mr. Edward J. Legere, our former
CEO and a former member of our Board of Directors. As of April 30, 2004, warrants to purchase up
to 1,680,000 shares of our common stock were outstanding.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 32</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During September 1995, we entered into an agreement with Cancer Therapeutics, Inc. whereby we granted
to Cancer Therapeutics, Inc. the exclusive right to sublicense TNT to a major pharmaceutical company
solely in the People&#146;s Republic of China for a period of 10 years, subject to the major pharmaceutical
company obtaining product approval within 36 months. In exchange for this right, the major pharmaceutical
company would be required to fund not less than $3,000,000 for research and development expenses
of Cancer Therapeutics related to Tumor Necrosis Therapy (&#147;TNT&#148;) and we would retain exclusive
rights to all research, product development and data outside of the People&#146;s Republic of China.
The technology was then sublicensed to Shanghai Brilliance Pharmaceuticals, Inc. (&#147;Brilliance&#148;)
and later assigned to Medipharm Biotech. In addition, we are entitled to receive 50% of all revenues
received by Cancer Therapeutics with respect to our sublicensing of TNT to Brilliance/Medipharm Biotech.
Cancer Therapeutics has the right to 20% of the distributed profits from Brilliance/Medipharm Biotech.
During March 2001, we extended the exclusive licensing period granted to Cancer Therapeutics, which
now expires on December 31, 2016. In exchange for this extension, Cancer Therapeutics, Inc. agreed
to pay us ten percent (10%) of all other consideration received by Cancer Therapeutics, Inc., excluding
research funding. Dr. Clive Taylor, a member of our Board of Directors, owns 26% of Cancer Therapeutics
and is an officer and director of Cancer Therapeutics. Dr. Taylor has abstained from voting at meetings
of our Board of Directors on any matters relating to Cancer Therapeutics or Brilliance/Medipharm
Biotech. Through fiscal year ended April 30, 2004, Cancer Therapeutics has not derived any revenues
from its agreement with Brilliance/Medipharm Biotech. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>15. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BENEFIT PLAN</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During fiscal year 1997, we adopted a 401(k) benefit plan (the &#147;Plan&#148;) for all employees
who are over age 21, work at least 25 hours per week and have three or more months of continuous
service. The Plan provides for employee contributions of up to 100% of their compensation or a maximum
of $13,000. We made no matching contributions to the Plan since its inception. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>16. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=48>&nbsp;</TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Selected quarterly financial information for each of the two most recent fiscal years is as follows:</FONT></TD></TR>
<TR>
<TD vAlign=top></TD>
<TD vAlign=top>&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
  <TH>&nbsp;</TH>
  <TH COLSPAN=23 align="center"><font size="1" face="Times New Roman, Times, serif">Quarter Ended </font></TH>
  <TH>&nbsp;</TH>
</TR>
<TR VALIGN=Bottom>
  <TH>&nbsp;</TH>
  <TH COLSPAN=23><HR color="#000000"SIZE=1></TH>
  <TH>&nbsp;</TH>
</TR>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>April<br>
      30,<br>
2004</FONT></TH>
     <TH>&nbsp;</TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>January <br>
      31,<br>
2004 </FONT></TH>
     <TH>&nbsp;</TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>October <br>
      31,<br>
2003 </FONT></TH>
     <TH>&nbsp;</TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>July <br>
      31,<br>
       2003 </FONT></TH>
     <TH>&nbsp;</TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>April<br>
      30,<br>
2003 </FONT></TH>
     <TH>&nbsp;</TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>January<br>
      31,<br>
2003 </FONT></TH>
     <TH>&nbsp;</TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>October <br>
      31,<br>
2002 </FONT></TH>
     <TH>&nbsp;</TH>
     <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>July
         <br>
      31, <br>
       2002</FONT></TH>
     <TH>&nbsp;</TH>
</TR>
<TR VALIGN=Bottom>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD colspan="2" ALIGN=RIGHT><HR color="#000000"SIZE=1></TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
</TR>
<TR VALIGN=Bottom bgcolor="#eaf9e8">
     <TD WIDTH=26% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net  revenues</FONT></TD>
     <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>  1,855,000</FONT></TD>
        <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    229,000</FONT></TD>
        <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    858,000</FONT></TD>
        <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    372,000</FONT></TD>
        <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>  2,314,000</FONT></TD>
        <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    512,000</FONT></TD>
        <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    621,000</FONT></TD>
        <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    474,000</FONT></TD>
        <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
</TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cost of sales</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>  1,005,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    223,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    666,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    318,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>  1,559,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    270,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    711,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    320,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
</TR>
<TR VALIGN=Bottom bgcolor="#eaf9e8">
     <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Gross profit (loss)</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    850,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>      6,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    192,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>     54,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    755,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    242,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(90,000 </FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>    154,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
</TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Operating expenses</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,104,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,819,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,084,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,891,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,401,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,357,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,910,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,063,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
</TR>
<TR VALIGN=Bottom bgcolor="#eaf9e8">
     <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Net loss</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (3,182,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (4,137,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (2,915,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (4,111,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (1,868,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (2,650,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (3,190,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (3,851,000</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>

<TR VALIGN=Bottom>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=RIGHT>&nbsp;</TD>
  <TD ALIGN=LEFT>&nbsp;</TD>
</TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Basic and diluted net loss per common share</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.03</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.03</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.02</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.03</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.02</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.02</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.03</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(0.03</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD></TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 33</FONT></P>

<HR noshade SIZE=5>
<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
      FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004 (continued) </b></font></td>
  </tr>
  <tr>
    <td><HR color="black" SIZE=1></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>17. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SUBSEQUENT EVENTS</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> On July 6, 2004, we announced that we signed a worldwide exclusive licensing agreement for intellectual
property related to anti-phosphatidylserine (anti-PS) antibodies from The University of Texas M.
D. Anderson Cancer Center for use in mammalian therapeutics. Under the terms of the agreement, we
will pay The University of Texas M. D. Anderson Cancer Center an upfront fee, milestone fees based
on the future success of drugs that fall under the licensed intellectual property and a royalty on
net sales as defined in the agreement. Products that may fall under this
licensing agreement are currently in discovery or preclinical development.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 34</FONT></P>
<HR noshade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="50%"><font size="2" face="Times New Roman, Times, serif"><b><a name="b7" id="b7"></a>PEREGRINE PHARMACEUTICALS, INC. </b></font></td>
    <td align="right"><b><font size="2" face="Times New Roman, Times, serif">SCHEDULE II </font></b></td>
  </tr>
  <tr>
    <td colspan="2">&nbsp;</td>
  </tr>
  <tr>
    <td colspan="2"><font size="2" face="Times New Roman, Times, serif"><b>VALUATION OF QUALIFYING ACCOUNTS<br>
    FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2004</b></font></td>
  </tr>
  <tr>
    <td colspan="2"><HR color="black" SIZE=1></td>
  </tr>
</table>
<br>
<TABLE width=90% border=0 align="center" cellPadding=0 cellSpacing=0>
<TR vAlign=bottom>
<TD align="CENTER"></TD>
<TD colSpan=2 rowspan="3" align="CENTER"><FONT face="Times New Roman, Times, Serif" size=1><B>Balance at<br>
</B></FONT><FONT face="Times New Roman, Times, Serif" size=1><B>Beginning</B></FONT><FONT face="Times New Roman, Times, Serif" size=1><B><br>
of period</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD colSpan=2 rowspan="3" align="CENTER"><FONT face="Times New Roman, Times, Serif" size=1><B>Charged</B></FONT><FONT face="Times New Roman, Times, Serif" size=1><B><br>
  to costs and</B></FONT><FONT face="Times New Roman, Times, Serif" size=1><B><br>
  expenses </B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD colSpan=2 rowspan="3" align="CENTER"><FONT face="Times New Roman, Times, Serif" size=1><B>Deductions</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD colSpan=2 rowspan="3" align="CENTER"><FONT face="Times New Roman, Times, Serif" size=1><B>Balance</B></FONT><FONT face="Times New Roman, Times, Serif" size=1><B><br>
  at end</B></FONT><FONT face="Times New Roman, Times, Serif" size=1><B><br>
  of period</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align="CENTER"></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD align="left"><FONT face="Times New Roman, Times, Serif" size=1><B>Description</B></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR>
<TD><HR align="left" width="50" SIZE=1 color="#000000"></TD>
<TD colSpan=2>
<HR color="#000000" SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000" SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000" SIZE=1>
</TD>
<TD></TD>
<TD></TD>
<TD colSpan=2>
<HR color="#000000" SIZE=1>
</TD>
<TD></TD>
<TD></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>Valuation reserve for note and other receivables for the year ended April 30, 2002</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="11%" align=right><FONT face="Times New Roman, Times, Serif" size=2>1,813,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="9%" align=right><FONT face="Times New Roman, Times, Serif" size=2>25,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="9%" align=right><FONT face="Times New Roman, Times, Serif" size=2>(53,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="1%" align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width="11%" align=right><FONT face="Times New Roman, Times, Serif" size=2>1,785,000</FONT></TD>
<TD width="1%" align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width="2%"><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2>Valuation reserve for note and other receivables for the year ended April 30, 2003</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,785,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(81,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,704,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=bottom bgcolor="#eaf9e8">
<TD><FONT face="Times New Roman, Times, Serif" size=2>Valuation reserve for note and other receivables for the year ended April 30, 2004</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1,704,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>(59,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2>1, 645,000</FONT></TD>
<TD align=left><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR vAlign=bottom>
<TD><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=right></TD>
<TD align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=left></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F - 35</FONT></P>
<HR noshade SIZE=5>
<P style="PAGE-BREAK-BEFORE: always">
</body>
</html>

</TEXT>
</DOCUMENT>
